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Cognitive dysfunction syndrome (CDS) is a common age-related condition in 
domestic cats that is characterised by behavioural changes that ultimately lead 
to cognitive decline and dementia. The most common behavioural changes 
displayed by cats affected by CDS have been summarised under the acronym 
VISHDAAL and include excessive Vocalisation, especially at night, alterations 
in their Interaction with their owners (e.g., increased affection), alterations in 
their Sleep-wake cycles, House-soiling, spatial and/or temporal Disorientation, 
alterations in Activity levels, Anxiety, and/or Learning/memory deficits.  
Cats with CDS develop neuropathologies that share many similitudes to those 
seen in the brains of humans with Alzheimer’s disease (AD), which are the 
abnormal accumulation of amyloid- (A) forming senile plaques, and the 
presence of neurofibrillary tangles (NFT) formed by hyperphosphorylated tau 
deposits. In the present study, immunohistochemistry of seven different brain 
regions of cats of various ages, with and without CDS, revealed that cats 
accumulate intra and extracellular A deposits, plus intranuclear and 
intracytoplasmic hyperphosphorylated tau deposits. The intracytoplasmic 
deposits of A were mainly found in younger cats, whereas elderly cats 
accumulated large diffuse extracellular A deposits. While A senile plaques 
in people with AD have a dense core, the diffuse A deposits in cats are 
believed to be an early stage of senile plaques.  
In this study, intranuclear labelling for hyperphosphorylated tau was mainly 
found in the younger cats. In contrast, intranuclear labelling was rarely found 
in elderly cats, especially if pre-tangles were present. Furthermore, 
intracytoplasmic immunolabelling for hyperphosphorylated tau was mainly 
found in the brains of elderly cats. Due to its ultrastructural features, these 
deposits are considered to be pre-tangles, which are an early stage of the 
characteristic NFT seen in the human AD brain.  
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Diagnosing CDS can be challenging, especially as the diagnosis can only be 
achieved by ruling out all other potential causes for the behavioural changes 
displayed by the cats. Veterinarians can only diagnose CDS after performing 
thorough examinations of the cats, which can be a slow, time-consuming, and 
expensive task. Hence, diagnostic tools and/or methods that may facilitate 
prompt diagnosis are urgently needed.  
Imaging techniques, such as magnetic resonance imaging (MRI), have 
recently emerged as potential diagnostic tools for assessing brain changes 
associated with ageing and AD in humans. These imaging techniques also 
have the potential to be effective in vivo diagnostic tools for assessing age-
related brain changes and CDS in cats. In this study, age-related changes 
were assessed in different brain regions of cats of various ages, with and 
without CDS, by using MRI. Elderly cats in this study were shown to develop 
atrophy of the whole brain, the hippocampus, and the occipital lobe, plus 
enlargement of the ventricles. Most of these changes have also been 
described in elderly humans, especially in those with AD.  
While there is currently no treatment available for CDS in cats, interventions 
that can be considered for its management include environmental enrichment, 
dietary supplementations, specific diets, and potentially, medication (licensed 
for the treatment of dogs with CDS). Telmisartan is an angiotensin receptor 
blocker and an activator of PPARγ that has shown to reduce 
neuroinflammation, provide neuroprotection, and to restore cognition in 
humans and rodents. In this study, a three-month double-blinded placebo-
controlled trial was performed in cats with severe CDS. Even though no 
statistically significant differences were found between the treatment groups, 
further studies are needed to determine the true potential of telmisartan for the 
treatment of CDS in cats. 
The present work furthers our understanding about the neuropathology of 
ageing and CDS in cats. Furthermore, it proposes the use of imaging 
techniques, especially of MRI, as a potential in vivo diagnostic tool for age-
related changes that may lead to cognitive decline. Finally, it proposes the use 
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Cognitive dysfunction syndrome (CDS) is a common age-related condition in 
older cats that leads to cognitive impairment and dementia. Cats with CDS 
display certain behavioural changes, including increased vocalisation, 
especially at night, altered interactions with members of the family (e.g., cats 
being more affectionate and demanding more attention), altered sleep-wake 
cycles, toileting mistakes, disorientation, altered activity levels (i.e., aimless 
wandering), anxiety, and learning or memory deficits. 
Cats with CDS develop brain changes that are similar to those seen in humans 
with Alzheimer’s disease (AD). These changes include the abnormal 
accumulation of two proteins: amyloid- (A) and tau. In this study, A and tau 
in cats was found to accumulate in a similar pattern and distribution to that 
seen in humans with AD, with A deposits inside the cells (i.e., within the 
cytoplasm) and in the space around the cells showing a diffuse distribution 
pattern, and tau deposits inside the cells, within the cytoplasm and the nucleus.  
The diagnosis of CDS can be challenging as it can only be made by exclusion, 
ruling out all other potential causes, making it a slow, time-consuming, and 
expensive task. For this reason, diagnostic tools that can help to gain a prompt 
diagnosis are urgently needed. Magnetic resonance imaging (MRI) has been 
shown to be an efficient diagnostic tool when looking for ageing brain changes 
in humans, particularly those with AD. Therefore, MRI also has the potential to 
be an effective diagnostic tool when looking for age-related brain changes in 
cats. Cats in the present study were shown to develop similar age-related brain 
changes to those seen in humans with AD, including shrinkage of the whole 
brain and the hippocampus (an area of the brain involved in making 
memories), plus enlargement of the structures that are filled with cerebrospinal 
fluid, such as the ventricles. 
Even though some interventions can be offered to cats with CDS, such as 
environmental enrichment, specific diets, and supplements, to date, there is 
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no treatment available to help cats with CDS. This study proposed the use of 
the drug Telmisartan to reduce the clinical signs of CDS in cats, because it has 
been shown to have beneficial effects in the cognition of humans and rodents. 
However, the results in cats in the present study were inconclusive, and further 
studies will be needed to determine the true potential of telmisartan for the 
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Feline dementia (also known as cognitive dysfunction syndrome; CDS) is a 
common age-related condition that is becoming increasingly prevalent in 
veterinary practice. The PhD thesis furthers our understanding about this 
condition in cats, its neuropathology, diagnosis and treatment. Moreover, it 
highlights the similarities of this condition to human Alzheimer’s disease (AD).  
 
Thanks to advances in veterinary medicine, improvements in veterinary 
nutrition, and changes in the way we manage our pets (e.g., indoor living), the 
life expectancy of pet cats is increasing, with a reported median longevity of 
14 years1. When classifying cats by age, they are considered to be  ‘mature’ 
at 7 to 10 years of age, ‘senior’ at 12 to 14 years of age, and become ‘geriatric’ 
or ‘super senior’ at 15 years of age2, 3. The most common age-related 
neurological changes include deterioration of cognition (ultimately resulting in 
dementia), motor performance, and visual and auditory decline4-6.  
 
 
1.1 Behavioural changes in elderly cats 
 
Since behavioural changes in aged pets often appear before other signs of 
illness, they can be useful early indicators of a decline in health and welfare. 
There are many potential causes of these behavioural changes, as diverse as 
CDS, hypertension, hyperthyroidism, pain (commonly associated with 
osteoarthritis), and separation anxiety, to name but a few, so it is important 
that our elderly cats get a full clinical examination, to determine the cause of 
their specific behavioural changes (see section on Diagnosis). It is essential to 
identify these behavioural changes early, in order to provide the most effective 
interventions. In a questionnaire-based study, 36% of owners of cats aged 7-
10 years of age reported that their cats had developed age-related behavioural 
problems, including house-soiling and alterations in their activity levels, with 
the percentage of affected cats increasing to 88% in cats aged between 16-19 
years7. Since some of these changes can be subtle or misinterpreted as 
‘normal ageing’, cat owners often need assistance in identifying and reporting 
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them to their veterinary surgeon8. This is made worse when owners are 
reluctant to take their elderly cats to the veterinary clinic. Many owners and 
cats find clinic visits stressful (getting the cat into its basket, driving it to the 
practice, and coping with the consultation)9. In addition, many owners worry 
that little can be done to help improve their cat’s quality of life, so euthanasia 
may be suggested10. Veterinarians need to be aware of these concerns and 
counsel owners about how best to reduce this stress (e.g., giving gabapentin 
or trazadone to the cat 90 minutes before travel is planned)11, 12, and making 
sure that owners know there are many potential interventions that can help 
elderly cats to have a better quality of life. 
 
 
1.2 Behavioural changes in cats with CDS  
 
Cognitive dysfunction syndrome (CDS) describes the age-related decline in 
cognitive abilities, characterised by certain behavioural changes, that cannot 
be attributed to any other medical condition13, 14. Although CDS in cats is a 
well-established condition, much of its pathophysiology has been extrapolated 
from  findings in other species15, mainly dogs with CDS and people with 
Alzheimer’s disease (AD), so our understanding of CDS in cats is less detailed.  
 
The prevalence of the signs of CDS varies by species and age: for pet cats, 
around 28% of cats between 11-14 years of age develop at least one 
behavioural problem related to CDS, with this increasing to 50% in cats over 
15 years of age14, 16.  
 
The major signs of CDS in cats and dogs have previously been summarised 
by the acronym DISHAAL, which stands for: spatial or temporal Disorientation; 
alterations in Interactions between the pet and its owners or other pets; 
alterations in the Sleep-wake cycle; House-soiling; alterations in Activity levels; 
Anxiety; and Learning and memory deficits8, 17. While DISHAAL does 
recognise many of the major behavioural changes reported in cats with CDS, 
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it fails to emphasise the importance of excessive vocalisation, especially at 
night, which is often the most common finding, particularly in the oldest cats. 
In the prevalence study mentioned above14,  altered interactions with the family 
(especially increased attention seeking) was the most common behavioural 
change in cats aged from 11-14 years, while alterations in the activity levels 
and excessive vocalisation were the most common signs in cats aged over 15 
years. A study of 100 cats with behavioural abnormalities (7-11 years old), 
found 36% of them vocalised excessively, especially at night, and 48% 
presented with house-soiling8. In another study of 100 cats, 61% of cats 
between 12-22 years of age vocalised excessively, with 31% vocalising mostly 
at night. In the same study, 27% of cats presented with house-soiling and 22% 
were disorientated15.  Additional studies further emphasise the importance of 
increased vocalisation in cats with CDS, while also trying to determine the 
likely cause. In our most recent study of more than 850 cats of 11 years of age 
or more, almost 60% of cats were reported to vocalise excessively, particularly 
at night, and 50% were more affectionate towards their owners, demanding 
more attention18 (Figure 1.1).  
 
 
Figure 1.1 Behavioural changes associated with cognitive dysfunction syndrome 
(CDS). In response to a questionnaire, cat owners reported whether each of the age-
related behaviours increased, decreased, or remained the same, when compared to 
when their cats were younger. Graph taken from Sordo et. al., 202018 
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In a detailed study of 37 cats with CDS where owners reported increased 
vocalisation, 67% vocalised more at night and 64% vocalised more during the 
day. When asked to suggest the likely main cause of their cats increased 
vocalisation, 41% suggested disorientation, 41% suggested attention seeking 
(i.e., wanting affection and attention from their owner) and 16% that their cat 
was looking for food (Figure 1.2). The owners also reported that 67.5% of cats 
were more affectionate19. These studies show that most of the behaviours 
detailed in the acronym DISHAAL can in themselves cause increased 
vocalisation; ‘alteration in the Interactions between the pet and its owners’, 
‘Anxiety’ (e.g., causing attention seeking),  ‘spatial or temporal Disorientation’ 
and ‘deficits in Learning and memory’ (e.g., causing a cat to forget that they 
have been fed), and ‘alterations in the Sleep-wake cycle’ likely to play a role in 
night crying. However, while these findings clearly support that increased 
vocalisation is part of CDS, the acronym DISHAAL does not recognise the 
importance of increased vocalisation within the acronym itself, with the V of 
Vocalisation being given prime position. 
 
 
Figure 1.2 Main causes of increased vocalisations in cats with cognitive dysfunction 
syndrome (CDS), as reported by their owners. Graph modified from Černá et. al., 
202019 
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Given that cats with CDS present differently to dogs with CDS, for whom the 
DISHAAL acronym was originally developed8, 17, it was proposed that a 
different acronym was needed for cats. Hence, a new feline-focused  acronym 
was created by the authors: VISHDAAL20 describes the behaviours seen in 
cats with CDS, including excessive Vocalisation; alterations in Interactions 
(e.g., increased affection); changes in the Sleep-wake cycle; House-soiling 
(urination and/or defecation); Disorientation; alterations in Activity levels; 
Anxiety; and Learning and memory deficits. The behaviours included in this 
new acronym are more specific to cats and are listed in order of prevalence, 
as supported by the aforementioned studies.  
 
 
1.3 Cognitive decline in cats with CDS 
 
While cognition in humans is composed of multiple features such as learning, 
memory, executive function (the processes to manage resources in order to 
achieve a goal, for example planning, reasoning and problem solving), 
attention, language, psychomotor and spatial abilities, this is less well 
understood in pets, especially cats. There is limited evidence assessing 
cognitive decline in cats with CDS. Since changes in cognition may initially be 
subtle in pets affected by CDS, and their recognition may present a challenge 
for their owners, laboratory-based protocols have been developed to try to 
assess and measure cognitive function in cats8, 14. Testing cognition in cats is 
far more challenging than in dogs; they are motivated by different things, with 
few cats being motivated by food the way many dogs tend to be8, 14.  
 
A neuropsychological test, originally created for dogs to assess cognitive 
function, has been remodelled for use in cats. The cats were divided into three 
groups: 1) young adults aged 3.0-3.8 years; 2) mature cats aged 7.7-9.0 years; 
and 3) senior cats aged 10.5-15 years. The cats were put through a battery of 
cognitive tasks, including a T-maze (i.e., a behavioural test that assesses 
exploratory behaviour in a new environment) and matching tasks (also known 
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as delayed nonmatching to position memory task, which assesses short-term 
visuospatial memory). The results showed an age-dependent decline in both 
discrimination and reversal learning*, as well as significant differences 
between groups during the matching tasks, suggesting that the older the cat, 
the more severe the cognitive decline they may develop21, 22. *(Reversal 
learning is tested when the cat is first trained to remember under which shaped 
pot food is hidden (discrimination learning). Once the cat has learned this, the 
food is then hidden under a different-shaped pot, challenging the cat to reverse 
or inhibit what they previously learned during the discrimination phase).  
 
 
1.4 Causes of CDS 
 
The exact cause of CDS remains unknown; however, several alterations in the 
brain are believed to be involved in its development, including oxidative 
damage, vascular changes (see vascular pathology) and compromised 
cerebrovascular blood flow. 
 
There is normally a balance between the production and removal of free 
radicals within the body such that oxidative damage is limited. However, 
factors such as stress, ageing or disease can alter this balance, reducing their 
elimination and promoting an excess of free radicals which may damage the 
brain13. This oxidative damage is believed to occur in cats, dogs and most, if 
not all other species14, 23. 
 
With age, the blood flow to and within the brain can be compromised by 
changes to the vessels themselves, systemic hypertension, heart disease, 
anaemia, alterations in blood viscosity and/or hypercoagulability, all of which 
exacerbate neuronal hypoxia13, 14.  
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1.5 Changes in the brain with CDS 
 
It is useful to compare changes seen in cats and humans. With ageing, the 
brains of cats and humans suffer several anatomical and physiological 
changes, ultimately associated with the development of dementia24, 25. These 
changes include gradual atrophy of the cerebral cortex and basal ganglia; 
region-specific neuronal loss; increased ventricular size; vascular and 
perivascular changes; lipofuscin accumulation; amyloid- (A) deposition and 
tau hyperphosphorylation, amongst others14, 25, 26. In old cats, brain atrophy, 
neuronal loss, increased ventricular size and widened sulci have all been 
described, although these changes are usually less pronounced than in 
people15, and as yet, these changes have not been directly associated with 
cognitive dysfunction14, 27, 28.  
 
 
1.5.1 Brain atrophy and neuronal loss 
 
Brain atrophy is one of the most important changes associated with ageing; 
the human brain is known to shrink at a rate of 2-5% per decade29, 30. The most 
affected brain region is the frontal lobe31, 32, with more subtle changes affecting 
the temporal and parietal lobes31, 32. In AD, additional age-related brain 
changes have been identified, including enlargement of the ventricles and 
atrophy of the hippocampus31-35. Since these changes are initially subtle and 
can appear decades before a clinical diagnosis of AD can be made, they have 
been proposed to be early predictors of the disease36-39. 
 
Similar age-related brain changes are known to occur in the elderly cat brain, 
including brain atrophy, and enlargement of the ventricles40; however, these 
have not yet been associated to CDS. Further discussion on these changes 
and its similarities to human age-related brain changes and AD can be found 
in Chapter 3. 
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The cerebella of aged cats have a reduced number of Purkinje cells (the 
neurons located in the cortex of the cerebella that are involved in learning and 
play a vital role in controlling motor movement) and other neurons27. In cats, 
this neuronal loss is more evident within the molecular layer of the cerebellum 
in animals of 12-13 years of age, compared with 2-3 year old cats27.   
 
Initial changes in the caudate nucleus, which include neuronal loss and 
reduced numbers of synapses41, 42, appear in cats as young as 6-7 years of 
age5, 42. However, these changes are typically more evident in cats over 10 
years of age, when compared with cats between 1-3 years of age43. They are 
believed to cause impairments in motor function and the inability to habituate 
to repeated stimuli in older cats44-46; hence, elderly cats can be repeatedly 
scared by common noises.  
 
The cholinergic system (which regulates attention and higher-order cognitive 
processing) and the locus coeruleus (which is the main site for 
norepinephrine/noradrenaline synthesis in the brain, and responsible for 
promoting arousal at times of stress) are both affected in humans with AD47-49. 
The loss of cholinergic neurons may directly impair cognition48, 49. Cats aged 
15-18 years of age show myelin disruption, axonal degeneration, and a 
marked reduction in both the size of cholinergic neurons and the dendritic 
length in the locus coeruleus, when compared with cats aged 2-3 years of 
age50. These abnormalities, as well as other neuronal deficits, may cause the 
alterations in the sleep-wake cycle of affected cats50, 51.  
 
The hippocampus (an essential area for learning and memory) is also affected. 
Neuronal loss is seen in cats over 14 years of age, being most severe when 




Chapter 1: Introduction  46 
   
 
1.5.2 Neuropathological changes 
 
In AD, the two main pathognomonic changes are the abnormal accumulation 
of A aggregates forming senile plaques, and the abnormal accumulation of 
hyperphosphorylated tau forming neurofibrillary tangles53.  
 
1.5.2.1 Amyloid- pathology 
 
Amyloid- (A) derives from the amyloid precursor protein (APP), a 
glycoprotein of 695 amino acids, which is highly expressed in different human 
tissues, including the brain53-55. The APP protein is a transmembrane protein, 
which means that part of it is located in the membrane of the cell; however, it 
has a long N-terminus that reaches into the extracellular space, and a shorter 
C-terminus located intracellularly53. The A fragments are derived from parts 
of the extracellular domain, close to the cell membrane, and the 
transmembrane region53. 
 
The APP protein is cleaved, at different sites, by three enzymes: alpha (α), 
beta (), and gamma ()-secretases. Depending on the site it is cleaved, this 
process leads to one of two pathways: the non-amyloidogenic pathway, which 
does not generate A; and the amyloidogenic pathway, in which A is 
generated56 (Figure 1.3). 
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Figure 1.3 Cleavage of the amyloid precursor protein (APP). Normal (non-
amyloidogenic) and abnormal (amyloidogenic) cleavage of APP and formation of 
amyloid- (A). Image from Sordo and Gunn-Moore, 202020 
 
The first cleavage on APP occurs between its extracellular and 
transmembrane portions by either α or  secretases. This cleavage generates 
an N-terminal soluble fragment (i.e., αAPP and APP, respectively) and a C-
terminal fragment (CTF) attached to the membrane forming α-CTF and -CTF; 




In this pathway, α-secretases cleave APP at the amino acid residues 15 to 17, 
breaking the portion of the protein where A is located; hence, the released 




In this pathway, APP is cleaved at two different sites releasing intact A into 
the extracellular space, where it may accumulate54, 58. The first cleavage, by 
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-secretase, occurs between residues 671 and 672 of the APP molecule and 
generates the N-terminus of A (i.e., APP). The second cleavage, by -
secretase, occurs at the C99 fragment, generating the C-terminus of A56. 
 
This second cleavage can occur at one of multiple sites of the C99 fragment, 
resulting in various lengths of the A peptide, ranging from 36 to 43 amino acid 
residues56. However, there are two species that are mostly found in the human 
brain and that are believed to be involved in AD55. These contain 40 amino 
acids (A40) which is the most abundant and accumulates within blood 
vessels54, 56; and a second one with 42 amino acids (A42), which accumulates 
and forms senile plaques54. 
 
After being released into the extracellular space, A fragments form small 
clusters, known as oligomers; if several of these clusters aggregate, they form 
fibrils (assembly of A oligomers that become insoluble and are less likely to 
degrade). Bundles of fibrils form -sheets, which aggregate and form the 
characteristic senile plaques54, 56. 
 
1.5.2.1.1 Types of -amyloid deposits  
 
Different types of A deposits have been identified, such as diffuse deposits 
and senile plaques54. 
 
Diffuse deposits  
 
Immunohistochemical studies have shown that these deposits are areas of 
granular staining containing few to no A fibrils. These deposits are commonly 
seen in the brains of healthy elderly individuals with no signs of cognitive 
impairment53, 54. It has been suggested that these diffuse deposits are an early 
stage of A plaques53, 54. Since they contain few to no A fibrils, diffuse plaques 
cannot be detected with congo red, thioflavin, and silver stains53, 54. 
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Furthermore, diffuse deposits are not associated with dystrophic neurites (see 
senile plaques) and/or reactive glial cells53, 54 (Figure 1.4A and B).   
 
 
Figure 1.4 Amyloid- (A) deposition in the Alzheimer’s disease (AD) brain. In 
humans with AD, A accumulates as a) and b), large diffuse A deposits; and c) well-
defined, dense core, A senile plaques. Image adapted from Murray et. al., 201859. 




Senile or neuritic plaques are A deposits characterised by having a central 
core mainly composed of A fibrils, amongst other proteins such as 
Apolipoprotein E53, 54 (Figure 1.4C).  Unlike diffuse deposits, senile plaques 
are surrounded by reactive microglia and astrocytes, plus abnormal neuronal 
processes (i.e., dendrites and/or axons) called dystrophic neurites53, 54. 
Moreover, dystrophic neurites may contain paired helical filaments (PHF), 
which may later form neurofibrillary tangles (NFT) (see below Tau 
pathology)53. 
 
Another type of senile plaque, called the “end-stage” plaque, has also been 
identified. These plaques share the same characteristics with the senile 
plaques; however, “end-stage” plaques are not surrounded by dystrophic 
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1.5.2.2 Progression of A pathology in AD 
 
Braak and Braak (1991) were the first in identify the progression of A 
pathology in AD and found that A deposits can vary in size and shape 
between individuals60. However, while there is variability at early stages of 
disease, they found that similar patterns of distribution are constant during 
end-stages of disease. Therefore, five stages of A pathology were created60, 
61 (Figure 1.5). 
 
 
Figure 1.5 Progression of amyloid- (A) pathology in Alzheimer’s disease (AD). A 
pathology begins in the cortical regions (stage I); as the disease progresses, A 
pathology spreads to other regions such as the hippocampus, the amygdala, 
thalamus, and hypothalamus (stages II and III), until reaching the medulla oblongata, 
locus coeruleus, and cerebellum in later stages of disease (stages IV and V). Image 
modified from Jouanne et al., 201762 
 
Stage I  
In stage I of A pathology, low densities of A diffuse deposits are mainly found 
in the cortex, particularly in the frontal, temporal, and occipital cortices60, 61. 
 
Stage II  
In stage II, A pathology increases in the cortical regions, and spreads into the 
white matter, A deposits begin to be found in the entorhinal region, the 
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Stage III  
In stage III, all cortex regions and the hippocampus are severely affected by 
A. Furthermore, A deposits aggregate and affect other structures, such as 
the thalamus and the hypothalamus, amongst others60, 61. 
 
Stage IV 
In stage IV, A pathology progresses to other regions, such as the substantia 
nigra and the medulla oblongata, amongst others61. 
 
Stage V 
In stage V, A pathology is found in the same regions affected by stages I-IV; 
however, the locus coeruleus and the cerebellum are also affected61. 
 
Cats over 10 years of age have been shown to have aggregates of A63-67. 
However, these accumulations have a more diffuse distribution than those in 
humans14, 52, 63-65, 67 (Figure 1.6). Similar to humans, A deposits in the brains 
of cats are made predominantly of the peptide A4263, 64 and are almost only 
detectable using certain antibodies e.g., anti-A17-24 (4G8) or anti-A4264. 
However, since anti-A antibodies in cats do not bind to amino acid residues 
1-16 of A (e.g., 6E10)64, it is possible that A in cats is formed by a cleaved 
A protein (i.e., amino acid residues 17-42). The lack of A40 in cats may be 
due to its high solubility and rapid turnover, which impedes its accumulation in 
the brain63, 68, 69. However, A40 deposition has been reported within blood 
vessels in cats, associated with cerebral amyloid angiopathy, as is also seen 
in humans65.  
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Figure 1.6 Amyloid- (A) deposition in the cat brain. Extracellular diffuse A 
immunolabeling (4G8 antibody) in the frontal cortex of a 13-year-old cat. Image taken 
from Gunn-Moore et al., 200667. Scale bars 100 m and 25 m 
 
While there are similarities between the A plaque-like deposits seen in cats 
and those in humans, the A plaque-like deposits in cats are less mature than 
those in humans with AD; the A plaques in AD have dense cores, which are 
rarely seen in the other species14, 63, 65. The pattern and distribution of A in 
aged cats are perhaps more similar to those seen in healthy, non-demented, 
aged human brains, rather than humans with AD14, 63-66. However, cats with 
A deposits can display abnormal behaviours, such as confusion, excessive 
vocalisation and wandering63, 67, although the severity of these behaviours, as 
yet, does not seem to be well correlated with the extent of A deposition64.  
 
1.5.2.3 Tau pathology 
 
The cytoskeleton is a complex network that occupies the cytoplasm of a cell. 
The main function of the cytoskeleton is to maintain the shape, structure and 
integrity of cells70, 71. It is composed of actin filaments, intermediate filaments, 
and microtubules71. Microtubules are composed of tubulin, and are the largest 
filaments in the cytoskeleton71.  
 
Maintenance and stability of microtubules is provided by microtubule-
associated proteins (MAP)70. Tau is a MAP that is mainly located in the cytosol 
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and the axons of the neurons where it regulates tubulin stability70, 72, 
maintaining the structure of the microtubules54. 
 
A total of six tau isoforms have been identified in the adult human brain, they 
result from alternative RNA splicing of exons 2, 3, and 1073, 74. Differences 
between isoforms rely on either the absence, or the presence of one or two 29 
amino acid inserts in the N-terminus, which are encoded by exons 2 and 370, 
74; plus the presence of either three-repeats (3R) or four-repeats (4R) of 31-33 
amino acids in the C-terminus, where the microtubule binding domain (MTBD) 
is located, which are encoded by exon 1070, 74 (Figure 1.7). 
 
 
Figure 1.7 Tau isoforms in the human brain. Tau isoforms result from alternative RNA 
splicing. Splicing of exons 2 and 3 in the N-terminus results in either the absence (0N) 
or presence of one (1N; exon 2) or two inserts (2N; exons 2 and 3). The splicing of exon 
10, within the microtubule binding domain (MTBD) results in 3-repeat or 4-repeat tau 
isoforms. The central region of tau consists in a proline-rich domain (PRD). C-terminus 
remains the same in all six tau isoforms. Image modified from Guo et al., 201775 
 
Tau has a total of 85 phosphorylation sites, which are mainly located in the 
proline-rich domain (PRD) and the C-terminus70, 73. It is believed that tau 
phosphorylation regulates its capacity to bind and stabilise microtubules70; 
hence, abnormal phosphorylation affects its binding ability. While reduced 
phosphorylation or hypophosphorylation facilitates and gives tau a high affinity 
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to bind to microtubules; hyperphosphorylation, on the other hand, reduces its 
binding capacity, jeopardising microtubule stability70.  
 
When abnormally hyperphosphorylated, tau fragments (of one or more 
isoforms) tend to aggregate and form paired, twisted fibrils of approximately 
10nm in diameter, known as paired helical filaments (PHF)53, 54, 70. When PHF 
accumulate in the dendrites and/or axons, they form dense networks of 
filaments called neuropil threads; and when they aggregate within the neuronal 
bodies, they are called neurofibrillary tangles (NFT)53, 54, 70, 73 (Figure 1.8). 
 
 
Figure 1.8 Hyperphosphorylated tau in the human brain. Fragments of 
hyperphosphorylated tau accumulate and form paired helical filaments (PHF). When 
accumulated within the neuronal body, aggregates of PHF are known as 
neurofibrillary tangles (NFT); in contrast, if accumulation occurs in the axons and/or 
dendrites of neurons, they are known as neuropil threads. Image modified from 
Kurihara et al., 202076. Antibody AT8. Scale bars 20 m 
 
Under normal conditions, all tau isoforms are highly expressed in human brain 
tissue73. They have also been found in people with AD; however, they are 
found in the hyperphosphorylated state73.  
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Pre-tangles are considered to be the earliest stage of NFT77. In these, 
hyperphosphorylated tau aggregates occupy the whole cell, including the 
axons77 (Figure 1.9A). During this stage, neither the cell nor the neuronal 
processes show any significant shape alterations77.  
 
 
Figure 1.9 Types of neurofibrillary tangles (NFT) in the human brain. Different types 
of NFT have been identified, including a) pre-tangles; and b) mature NFT. Image 




These are characterised as containing compact aggregates of 
hyperphosphorylated tau within their cytoplasm, which tend to displace the 
nucleus to the periphery of the soma78 (Figure 1.9B).  
 
Unlike the pre-tangles, mature NFT have not been shown to aggregate within 
the axons; however, neuropil threads may still be present77, with the affected 
dendrites becoming shorter, and they may detach from the soma77.  
 
Chapter 1: Introduction  56 
   
 
Depending on their location within the cell, NFT can be classified as globose, 
if they remained within the cell body, occupying most of the soma77; or as flame 
type, if they fill the soma and spread in to the proximal dendrites77 (Figure 
1.10A). 
 
Figure 1.10 Types of neurofibrillary tangles (NFT) in the human brain. Different types 
of NFT have been identified, including a) flame type NFT; and b) ghost tangles. Image 
modified from Braak and Tredici (2010)77. Antibody AT8. Scale bar 100 m 
 
Ghost tangles  
 
These are thought to be the remnants of mature NFT after the host neuron 
dies; however, the NFT stays as a visible extraneuronal aggregate77. As a 
result, ghost tangles do not have a nucleus77 (Figure 1.10B).  
 
1.5.2.4 Progression of tau pathology in AD 
 
Braak and Braak identified the progression of tau pathology in AD and created 
six stages. Stages I and II are known as “Transentorhinal stages”; Stages III 
and IV are known as “Limbic Stages”; and Stages V and VI are known as 
“Cortical stages”60 (Figure 1.11). 
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Figure 1.11 Progression of tau pathology in Alzheimer’s disease (AD). Tau pathology 
begins in the transentorhinal region (stage I); as the disease progresses, tau 
pathology spreads to the entorhinal cortex and hippocampus (stages II and III); then 
to the cortical regions (stages IV-VI) in later stages of disease. Image modified from 
Jouanne et al., 201762 
 
Stage I 
In stage I, a modest number of NFT are confined to the transentorhinal region 




Stage II is an aggravation of stage I. In stage II, several NFT are found in the 
transentorhinal cortex. In addition, moderate tau pathology appears in the 
entorhinal cortex and in the hippocampus60. 
 
Stage III 
In Stage III, tau pathology severely affects both the transentorhinal and the 
entorhinal regions, where ghost tangles can be seen for the first time. 
Moderate number of NFT are found in the hippocampus and a few may start 
to develop in the cortex60. 
 
Stage IV 
In Stage IV, both the transentorhinal and entorhinal regions are severely 
affected, with a large number of ghost tangles. In addition, several NFT are 
found in the hippocampus, and moderate numbers can be found in the cortex 
and the amygdala60. 
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Stage V 
In Stage V, severe pathology and very large numbers of ghost tangles are 
found in both the transentorhinal and entorhinal regions. Severe pathology is 
also observed in the hippocampus, all cortex regions, and the amygdala60.  
 
Stage VI 
In Stage VI, the changes seen in Stage V are even more pronounced60. 
 
Interestingly, severe tau pathology has been correlated with large deposits of 
A pathology; in contrast, severe A pathology does not necessarily correlate 
with a large number of NFT60. Furthermore, the presence and location of NFT, 
plus the progression of tau pathology has been correlated with both the clinical 
symptoms of AD and cognitive decline54, 60, 70, 79. 
 
Finally, tau pathology or “tauopathies” are not exclusive of AD and have been 
linked to other diseases including, but not limited to Down Syndrome, 
Parkinson’s disease and its related dementia, plus other forms of dementia, 
such as frontotemporal dementia54, 70. 
 
Cats produce a number of different tau isoforms similar to those in humans 
with AD52, 64, 67. While some studies found no evidence of neurofibrillary tangles 
(NFT) in the brains of old cats65, 80, others found occasional 
hyperphosphorylated tau deposits, which are an early stage of NFT (i.e., pre-
tangles)52, 64, 67 (Figure 1.12).  As there is only evidence of 
hyperphosphorylated tau in a small number of cats so far, an association 
between NFT and CDS cannot yet be established14, 52, 67. Interestingly, 
intracytoplasmic hyperphosphorylated tau is also found in kittens during early 
postnatal development81 and as a result of ischaemia and seizures64, 67.  
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Figure 1.12 Hyperphosphorylated tau deposits in the cat brain. Positive 
immunolabelling of hyperphosphorylated tau protein (AT8 antibody) in the anterior 
cerebrum of a 14-year-old cat. Image taken from Gunn-Moore et al., 200667. Scale 
bars 100 m and 25 m 
 
Further discussion on the neuropathology of feline ageing and CDS, plus its 
similarities with AD are discussed in Chapter 2 of this thesis. 
 
1.5.2.5 Vascular pathology 
 
Several vascular and perivascular changes have been associated with 
neuropathological ageing and CDS in cats. These include micro-
haemorrhages, infarcts, a non-lipid variety of arteriosclerosis, and the 
accumulation of -amyloid in plaques and sometimes around blood vessels in 
the brain13, 14, 63.  
 
Cerebral amyloid angiopathy occurs when A accumulates around the 
meninges and blood vessels82, 83. It is believed to be a major cause of vascular 
dysfunction and cognitive decline in humans84-86; however, it can also be found 
in the brains of healthy, non-demented people, suggesting that this pathology 
is not specific to AD82. In cats, there is controversy regarding the existence of 
cerebral amyloid angiopathy. Some studies have found this in aged cat brains3, 
63-65, 67, while some have not52.  
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The diagnosis of CDS is challenging, especially as the clinical signs involve 
behavioural changes, which can be nebulous and complicated to investigate. 
Before making a diagnosis of CDS it is necessary to rule out other potential 
causes of the behavioural changes8, 14, 15. These include pain, hypertension, 
chronic, endocrine and infectious diseases (Table 1.1).  
 
Table 1.1 Potential causes for behavioural changes. Diagnosis of cognitive 
dysfunction syndrome (CDS) can only be made by ruling out other potential causes of 
the behavioural changes 
 
Potential causes for behavioural changes 
• Hypertension 
• Pain (e.g., due to osteoarthritis or other musculoskeletal problems, 
gastrointestinal, pancreatic or dental disease, etc.; pain may be a 
more insidious cause of behavioural changes in cats than previously 
considered87-89, for this reason, an analgesia trial may be needed to 
determine whether or not it is playing a role in the behavioural 
alterations) 
• Chronic diseases (e.g., liver or kidney failure) 
• Endocrine disorders (e.g., hyperthyroidism – which can cause many 
of the same behavioural changes as those seen with CDS – or 
diabetes mellitus) 
• Infectious diseases (e.g., toxoplasmosis, feline immunodeficiency 
virus [FIV], feline leukaemia virus [FeLV], urinary tract infections) 
• True behavioural problems (e.g., separation anxiety) 
• Neoplasia (e.g., meningioma) 
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Of note, some of these conditions may exacerbate the clinical signs of CDS, 
such as pain, hyperthyroidism,  hypertension, and chronic kidney disease, and 
since elderly cats are more likely to have a number of concurrent interacting 
conditions, this can complicate both diagnosis and treatment90.  
 
Veterinary surgeons have to conduct a complete evaluation of the cat, 
assessing its history for medical and behavioural problems, performing a full 
physical examination (including determining systemic blood pressure), 
undertaking blood and urine analysis (as needed), and pursuing further 
diagnostics in many cases (Figure 1.13). Only then can the veterinary surgeon 
identify any underlying cause(s) for the behavioural signs. Elderly cats 
frequently have a number of concomitant interacting conditions, so it can be 
difficult to establish exactly what role CDS may be playing. However, it is 
necessary to identify all contributing disorders in order to allow for accurate 
intervention8. Veterinarians need to educate owners on how to recognise and 
monitor changes in their cat’s behaviour, and to report not only any further 
changes in these behaviours, but also any changes in their cat’s body weight, 
food/water consumption, and urine/faeces production90.  
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Figure 1.13 Diagnosis of cognitive dysfunction syndrome (CDS). Veterinarians have 
to undertake a complete examination of the cat and rule out other potential causes 
of behavioural changes. Diagram modified from Černá et al., 202019 
 
It is clear that diagnosing CDS can be a slow and time-consuming task. 
Moreover, making an early diagnosis is critical, especially with elderly patients, 
in order to provide prompt interventions that will improve the quality of life and 
welfare of the affected animals. 
 
Advanced imaging techniques, such as magnetic resonance (MR) imaging and 
computed tomography (CT) have been shown to be effective diagnostic tools 
for age-related brain changes and AD in humans33, 34, especially as some of 
these changes (i.e., enlargement of the ventricles and hippocampal atrophy) 
can be detected decades before making a diagnosis91. Furthermore, MR 
imaging has proven to be an efficient method to assess the progression of 
brain changes in AD92-95. It is therefore possible that imaging techniques could 
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aid in the diagnosis of age-related brain changes and CDS in cats. The use of 
MR imaging for the assessment of brain atrophy and other age-related brain 





Although CDS cannot be cured, appropriate management can reduce its 
clinical impact, and improve the cats’ quality of life. Since it is stressful when a 
loved cat becomes disoriented and confused – and increased vocalisation at 
night (i.e., night-crying) can cause broken nights – improving the cat’s quality 
of life can also help the owner, and preserve the cat-owner bond. Potential 
interventions include environmental enrichment/modification, dietary 
supplementations, specific diets and medication. Interventions need to be 
tailored to each individual cat, and its specific behavioural changes as 
suggested by the authors’ recent study19 (Figures 1.14 and 1.15), as well as 
any concomitant illnesses. Unfortunately, as yet, there is little information to 
indicate which interventions are most likely to help in specific cats, leading to 
trial and error, which is not ideal in cats that are easily frustrated. More work is 
urgently needed in this area. 
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Figure 1.14 Treatment of cognitive dysfunction syndrome (CDS). Treatment of CDS targeting the behavioural changes displayed by the cat. 
Diagram taken from Sordo et. al., 202020 
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Figure 1.15 Treatment of increased vocalisation as per perceived cause. Diagram modified from Černá et. al., 202019 
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1.7.1 Environmental enrichment/modification 
 
Environmental enrichment provides mental stimulation and increases activity 
levels; it enhances the growth and survival of neurons, and improves 
cognition14, 96. Environmental enrichment can be synergistic with antioxidant-
enriched diets.  
 
Poor environmental stimulation increases the risk of developing CDS in later 
life; it can also cause frustration in cats that have already developed CDS, 
aggravating it97. Environmental enrichment is recommended for all young cats, 
especially if they have no access outside. Environmental enrichment includes 
activities and objects that promote play, exploration, hunting, climbing, and 
perching behaviours, and includes novel ways to obtain food or treats8.  
 
However, in older cats with significant to severe CDS, environmental changes 
can potentially have a negative effect, leading to confusion. These animals 
cannot cope with changes (e.g., environment, daily routine, diet) and become 
stressed, thus, exacerbating CDS (e.g., anorexia, hiding, house-soiling)17, 98, 
99. It is the best for these cats to keep changes to a minimum or to reduce the 
size of their environment to minimise stress, while ensuring that their key 
resources are all within easy reach (i.e., food, water, litter box, resting/sleeping 
places, and escape routes and/or a safe place to hide)97. Where changes have 
to be made, for example, where they may improve the cat’s quality of life, they 
need to be made slowly; reassuring the cat frequently, to ensure it does not 
become too stressed20. Since osteoarthritis is very common in older cats87, 
these resources need to be on all floors of the home that the cat can access; 
raised food bowls can help, as can low fronted litterboxes, etc.10. The 
application of synthetic feline pheromone diffusers may help to reduce anxiety 
(Feliway Classic™; Ceva Animal Health Ltd., Zenifel™; Virbac UK) and reduce 
conflict with other cats (Feliway Friends™; Ceva Animal Health Ltd.)100. 
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Environmental needs will differ for each cat. Cats that cry for food may be 
helped by introducing an automatic feeder timed to give many small meals 
throughout the night, scatter feeding, forage feeding, or being given a feeding 
ball at night20. Cats which cry for their owner’s attention may need positive 
affirmation and reassurance (often at night). Anecdotally evidence showed that  
while cuddling an elderly cat at night can be frustrating, it will reduce their 
stress, helping them sleep and so reduce their confusion the following night; 
in contrast, shutting them out or shouting at them will increase their stress, and 
so increase their crying.  Cats which cry when they wake up confused and 
disorientated may be helped by having a night-light, leaving a radio on to play 
soft music or a speech radio station, plugging in synthetic pheromone 
dispensers (e.g., Feliway Classic™), or reducing the area the cat has access 
to so it cannot get lost so easily19. Ultimately, the cat may need to have a room 
of its own to sleep in, with all of its key resources, including a warm comfortable 
bed (e.g., a heat pad under a snuggle bed plus a blanket)90, 101. A strict night-
time routine with a warm meal, warm bedding and a cuddle before shutting the 
door at night may help them to settle. Adding a ‘kitty camera’ can help to 
reduce owner stress as they can then check on the cat, without waking it up20.  
 
 
1.7.2 Dietary supplements 
 
S-adenosyl-L-methionine (SAMe) (NoviSAMe™; generic SAMe) helps to 
maintain the fluidity of cell membranes and enhances the production of the 
antioxidant glutathione102, and when given to elderly cats, there was an 
improvement in cognitive tests, including object discrimination and reversal 
learning; the effects were most evident in cats with mild CDS, suggesting that 
it is more likely to help early in disease103.  
 
While proprietary dietary supplements, such as Senilife™ (CEVA Animal 
Health)8, 104, and Aktivait™ (VetPlus)105,  have been shown to reduce signs of 
CDS in dogs, there is little evidence of their efficacy in cats. Senilife™ contains 
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gingko biloba (a natural ingredient that has been proposed to improve memory 
and cogniton)106, antioxidants such as D-alpha-tocopherol, vitamins B6 and E, 
and resveratrol (a natural compound that has antioxidant, antiinflammatory, 
cardioprotective, and antitumor properties)107, amongst other components. 
Although it is labelled for use in cats, no trials have yet been performed in this 
species. 
 
Aktivait™ contains omega-3, fish oils, and antioxidants such as vitamins E and 
C, L-carnitine, alpha-lipoic acid, and phosphotidylserine, amongst other 
compounds. It is important to highlight that products developed for dogs are 
not always safe for cats, for example, Aktivait™ as it contains alpha-lipoic acid, 
and antioxidant which is toxic in cats108. A feline-safe version of Aktivait™ has 
been commercially released; however, trials still need to determine its efficacy. 
  
Complementary remedies such as melatonin, plug-in pheromones8, 15 (Feliway 
Classic™ and/or Friends™ aka Multicat™ Ceva Animal Health Ltd.), 
suntheanine (Pet Remedy™ and/or Anxitane™ Virbac), milk protein 
hydrolysate (Zylkene™ Intervet Schering Plough)109, essential oils (e.g., 
lavender)8, 15, 17 and amino acid/herbal combinations (e.g., Help My Pet – 
Nerves™, VetPartners Limited), may help in re-establishing the sleep-wake 
cycles and reducing anxiety. 
 
 
1.7.3 Specific diets 
 
Diets high in fruits, vegetables, nuts and whole grains, as well as vitamins C, 
E and B12, may potentially improve cognition and delay the development of 
dementia in humans; deficiency in these vitamins is a risk factor for strokes, 
brain ageing and dementia110.  Diets enriched with antioxidants are known to 
decrease oxidative damage, whilst other compounds, such as alpha-lipoic 
acid, L-carnitine and omega-3 fatty acids, may have a positive effect in the 
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management of dementia as they enhance the health of the cell membranes 
and mitochondrial function111.  
 
Developing diets to reduce the signs of CDS in cats has proven to be 
challenging. Some of the compounds used in diets designed for dogs with 
CDS, for example alpha-lipoic acid, are toxic in cats108, and the effect of diets 
enriched with medium-chain triglycerides (MCTs) is as yet unclear, as MCTs 
are unpalatable to cats97. Nevertheless, it is believed that MTC consumption 
may improve feline metabolism112.  
 
While no specific diet has been designed for cats with CDS, some diets have 
shown positive effects. Commercial diets containing fish oils, antioxidants and 
other supplements (Feline Mature Adult 7+™ Hill’s Pet Nutrition); and others 
containing antioxidants, essential fatty acids and dried chicory root (Nestlé 
Purina Pro Plan Age 7+™ Nestlé Purina Pet Care) have been associated with 
increased longevity compared with non-supplemented diets113, 114. Another 
study by Nestlé Purina showed that the brain function of middle-aged and older 
cats improved significantly when fed a diet supplemented with fish oils, 
antioxidants, arginine, and vitamin B115. A separate study demonstrated that 
activity levels in aged cats increased when fed with a diet containing 
tocopherols, vitamin C, beta-carotene, and L-carnitine, amongst other 
ingredients116. Finally, a two-month long questionnaire-based study showed 
that CDS signs improved in around 70% of the cats that were fed a diet 
containing antioxidants, essential fatty acids, chondroprotectants, L-carnitine, 
and lysine, designed to help osteoarthritis (Prescription Diet Feline j/d™ Hill’s 
Pet Nutrition) (Hill’s Pet Nutrition, data on file, 2008). 
 
Diets supplemented with milk protein hydrolysate and  additional L-tryptophan 
(i.e., α-casozepine) have been shown to reduce anxiety (Royal Canin Calm™ 
Royal Canin; Hill’s Urinary Support™ Hill’s Pet Nutrition)117. 118, 119 
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1.7.4 Drug treatments 
 
Selegiline (Selgian™ Ceva Animal Health Ltd.; Anipryl™ Zoetis) and 
propentofylline (Vivitonin™ MSD Animal Health) are licensed in various 
countries to treat the clinical signs of CDS in dogs120-123. Selegiline has 
undergone many studies, although all in dogs120, 121, 123. It is an inhibitor of 
monoamine oxidase B, which has a neuroprotective effect as it reduces the 
production of free radicals and stimulates the production of enzymes that 
eliminate these free radicals. Propentofylline has neuroprotective properties 
and increases the blood flow to the heart and brain8. Despite these drugs 
having been shown to have positive effects in dogs with CDS124, 125, they are 
not licensed for use in cats; however, positive effects have been anecdotally 
reported. 
 
Anxiety and altered sleeping patterns are common features in pets with CDS. 
Antidepressants/anxiolytics, such as fluoxetine (i.e., Prozac™), have been 
used to treat the signs of CDS in pet cats97. Other anxiolytics, such as 
trazodone,  gabapentin, benzodiazepines (e.g., alprazolam, diazepam, 
clonazepam, and lorazepam), or buspirone can be considered8, 97. However, 
diazepam in tablet form is not recommended as it may cause acute fulminant 
liver failure in cats126, and care should be taken when combining drugs, such 
as selegiline, fluoxetine, gabapentin and others that may affect the 
concentration of serotonin as they could induce serotonin syndrome, seen as 
pyrexia, agitation, increased reflexes, tremor, sweating, dilated pupils, and 
diarrhoea. Melatonin may help to restore the sleep cycles. 
 
Given that cats with CDS have reduced numbers of cholinergic neurons50, 
drugs that enhance cholinergic transmission might improve the signs of CDS, 
such as cholinesterase inhibitor donepezil (Aricept™; Pfizer)127, which is used 
in people with AD128; however, these have not been tested in cats.  
 
Chapter 1: Introduction  71 
 
 
It has been suggested that by blocking the specific receptor AT1, the renin-
angiotensin system (RAS) might be inhibited. Angiotensin receptor blockers 
(e.g., sartans) are drugs that inhibit the RAS and are commonly used for the 
treatment of cardiovascular and metabolic disorders (e.g., diabetes and kidney 
disease)129, 130; furthermore, it has been proposed that the antiinflammatory 
properties of angiotensin receptor blockers may also improve cognition131, 132. 
Telmisartan (Semintra™; Boehringer Ingelheim) blocks the AT1  receptor of 
RAS and partially activates the peroxisome proliferator-activated receptor 
gamma (PPARγ), which regulates neurological disease by preventing 
inflammation and reducing the accumulation of A plaques in the brain133-135. 
In rodents, telmisartan has been shown to: 1) inhibit inflammation, therefore 
reducing brain injury after the induction of ischemia135; 2) improve post-stroke 
effects136; 3) reduce the death and injury of neurons after glutamate-induced 
toxicity, which is an important neurotransmitter that, if released in excess, 
causes neurotoxicity, neuronal death and apoptosis137; 4) protect against 
oxidative damage caused by glucose administration138; 5) protect against 
nutrient deprivation-induced neuronal death139; 6) restore cognitive functions 
after chronic stress-induced cognitive impairment140; and 7) prevent cognitive 
decline134, 141. In addition, there are two ongoing studies aimed to assess the 
efficacy of telmisartan in treating human patients with AD142. The effect of 
telmisartan (Semintra™; Boehringer Ingelheim) on the clinical signs of CDS in 
cats is discussed on Chapter 4.In summary, ever more elderly cats are being 
recognised with behavioural changes suggestive of CDS, including increased 
vocalisation and house-soiling, amongst other signs. However, CDS can be 
challenging to diagnose; it is a diagnosis of exclusion and many other medical 
disorders can cause similar behavioural changes. It is essential that veterinary 
surgeons undertake a full assessment of affected cats and educate owners on 
how to recognise the clinical signs of CDS. Although CDS cannot be cured, 
there are several interventions that can help to improve the health, welfare and 
quality of life of the affected cats. The brains of cats with CDS show 
neuropathological changes similar to those found in the brains of humans with 
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AD; these similarities suggest that the domestic cat could be a natural model 
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1.8 Hypotheses, aims and objectives 
 
In the present study, it was hypothesised that age-related neuropathological 
and neuroanatomical changes in cats would show common features with those 
seen in human AD; furthermore, by better our understanding of these changes, 
early diagnosis and effective interventions/management of CDS can be 
provided that will improve the quality of life and welfare of the affected cats. 
 
The present work assessed neuropathological age-related changes in cats 
with and without CDS (see Chapter 2); furthermore it proposes the use of 
advanced imaging techniques, such as MR imaging as an in vivo tool for the 
assessement of age-related brain changes that could be considered early 
signs of CDS (see Chapter 3); and finally, this work proposes the drug 
telmisartan (Semintra™, Boehringer Ingelheim) as a potential treatment to 
reduce the clinical signs of severe CDS in cats (see Chapter 4). 
 
The present study had three aims: 
 
1. The first aim of the study was to assess the presence and distribution of 
A and tau pathology in the brains of cats of various ages, with and without 
CDS. It was hypothesised that elderly cats would have larger A deposits 
and higher numbers of hyperphosphorylated tau deposits than younger 
cats. It was also hypothesised that these changes would be more evident 
in cats with CDS. Finally, it was hypothesised that these neuropathological 
changes will show similar features to those seen in the human AD brain. 
 
2. The second aim of this study was to ascertain whether there is age-related 
atrophy of the whole brain and/or specific brain structures, including the 
lobes, hippocampus, and the interthalamic adhesion, plus enlargement of 
the ventricles in cats by undertaking measurements of 1.5T MR images. It 
was hypothesised that elderly cats would have a marked atrophy of the 
whole brain and some of the different brain structures assessed (i.e., lobes 
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and hippocampus). Furthermore, it was also hypothesised that elderly 
cats, particularly those with diagnosis of CDS, would have larger lateral 
ventricles and smaller interthalamic adhesions than younger cats. Finally, 
it was hypothesised that these age-related neuroanatomical changes will 
share similarities to those seen in human AD. 
 
3. The third aim of this study was to determine the effects of telmisartan 
(Semintra™, Boehringer Ingelheim) on the clinical signs of CDS in cats at 
its licensed dose (at the time this study commenced) of 1 mg/kg PO q24h, 
given for three months. It was hypothesized that the clinical signs of CDS 
would be significantly reduced in the cats receiving telmisartan 
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Parts of this chapter have been submitted for publication to the Journal 
Frontiers of Aging to their special issue “Rising stars in comparative biology of 
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Sordo L., Martini A.C., Houston F., et al. Neuropathology of ageing in cats and 
its similarities to human Alzheimer’s disease. Frontiers of Aging.  
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Ageing produces several changes in the brain, including brain atrophy, 
neuronal loss, and vascular changes, that may ultimately lead to dementia31, 
32, 35, 143, 144. While these age-related changes have been reported to occur in 
the brains of people with Alzheimer’s disease (AD), the abnormal deposition 
of amyloid- senile plaques and neurofibrillary tangles (NFT) of 
hyperphosphorylated tau proteins are thought to play a key role in the 
development of AD, and are considered to be the major pathognomonic 
neuropathologies53. Interestingly, similar neurodegenerative changes (i.e., 
brain atrophy, neuronal loss, vascular changes, and abnormal protein 
deposition) also occur in the brains of elderly cats64, 67. 
 
 
2.1.1 Amyloid- pathology 
Amyloid- (A) is generated in the amyloidogenic pathway after - and -
secretases cleave the amyloid precursor protein (APP) (See Chapter 1). Since 
these cleavages occur at different sites, various lengths of A can be formed, 
with A40 and A42 being the most commonly found forms in human AD. 
While A40 is the most abundant and tends to accumulate within blood 
vessels; A42 tends to accumulate in the extracellular space and form the 
characteristic senile plaques found in human AD53, 54. 
 
In humans with AD, A pathology is believed to start in the cortex (i.e., Stage 
I); with a later progression to the white matter and hippocampus (i.e., Stage II); 
and finally, in late stage of the disease, it reaches the thalamus, hypothalamus 
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2.1.2 Tau pathology 
Tau is a microtubule-associated protein located in the cytosol of the cells that 
stabilises microtubules70, 72. When abnormally hyperphosphorylated, tau 
aggregates, forming paired helical filaments (PHF) that may later accumulate 
forming neurofibrillary tangles (NFT)53, 54, 70, 73 (See Chapter 1). 
 
In humans with AD, tau pathology starts in the transentorhinal regions (i.e., 
Stages I and II); it later progresses to the hippocampus and begins affecting 
the cortex regions (i.e., Stages III and IV); and finally, at later stages of disease, 
it reaches all cortex regions (Stages V and VI)60. 
 
 
2.1.3 Amyloid- pathology in cats 
Diffuse A accumulation has been previously reported in the brains of cats 
over 10 years of age14, 63-67. Since these deposits do not have dense cores and 
share similarities to the diffuse deposits seen in humans, it has been 
suggested that cats’ A deposits are less mature than the characteristic AD 
senile plaques14, 63, 65, 145, 146. Furthermore, unlike human A, deposits in cats 
are predominantly formed by the A42 peptide63, 64 and are only detectable 
using certain antibodies, such as  anti-A17-24 (4G8) or the conformation 
specific A1-4264. It is believed that the lack of A40 in cats may be due to its 
higher solubility, which also promotes rapid clearance; hence, impeding its 
accumulation in the brain63, 68, 69. However, the A40 peptide has been found 
occasionally within blood vessels in cats, where it is associated with cerebral 
amyloid angiopathy65. It has been suggested that both the pattern and 
distribution of A in cats are more similar to those found in the elderly, non-
demented human brains, rather than people with AD14, 63-66. Nevertheless, 
elderly cats with A deposits are known to display behavioural abnormalities, 





Chapter 2: Neuropathology of ageing and cognitive dysfunction syndrome in cats
  79 
 
 
severity of these behaviours and/or clinical signs does not necessarily 
correlate with the extent of A deposition54, 60, 64, 147. 
 
 
2.1.4 Tau pathology in cats 
Cats have been shown to produce similar tau isoforms to those seen in 
humans52, 64, 67; however, there is still controversy regarding the presence of 
NFT in the brains of elderly cats. While some research suggest that there is 
no evidence of NFT in cats65, 80, others have reported intracytoplasmic 
hyperphosphorylated immunolabelling, which is believed to be an early stage 
of NFT, also known as pre-tangles52, 64, 67.  
 
Of note, most of the available evidence on the neuropathological changes 
associated with ageing in cats has been obtained from elderly cats with no 
diagnosis of CDS52, 63, 65, 66. Only two papers have assessed these changes in 
aged cats displaying behavioural and/or neurological abnormalities64, 67. One 
study assessed neuropathological changes in six elderly cats (aged from 16 to 
20 years old) plus two young cats (< 4 years old). Five of the elderly cats 
displayed between one and five signs of CDS; however, these cats also had 
concomitant illnesses, such as anaemia, seizures, and intestinal bowel 
disease64. Hence, it is possible that some of the apparent signs of CDS 
displayed by these cats were actually caused by their concomitant diseases, 
instead than CDS itself. A separate study assessed 19 cats aged from 16 
weeks to 14 years old, with 17 of these cats displaying signs of neurological 
dysfunction67. While the exact neurological disorders and/or signs were not 
described in this study, it is possible that undisclosed systemic disorders were 
the cause of the neuropathological changes. 
 
The aim of the present study was to assess the presence and distribution of 
A and tau pathology in the brains of cats of various ages, with and without 
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distributed extracellular A deposits, and higher numbers and more widely 
dispersed hyperphosphorylated tau deposits, than younger cats. It was also 
hypothesised that these changes would be more evident in cats with CDS. 
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2.2 Materials and Methods 
 
2.2.1 Sample collection 
The brains of cats of different ages were collected post-mortem through routine 
necropsy submissions. Some of these cats were patients at The Royal (Dick) 
School of Veterinary Studies (RDSVS) and others came from a shelter in 
Scotland. Most of the cats were affected by old age and/or chronic disease 
and were euthanised after veterinary assessments revealed that no further 
treatment could have improved their health. A small number of cats were 
euthanised after being diagnosed with behavioural problems (i.e., untreatable 
aggression) that would impede their rehoming. Of note, none of the cats 
displayed any signs of neurological disease. In all cases the owners or shelter 
carers gave written consent to donate the cats’ bodies for research purposes.  
 
Some of the cats used in this study were diagnosed with CDS before 
euthanasia. Diagnosis of CDS was determined as detailed in Chapter 4. 
 
After collection, brains were fixed by immersion in 10% buffered formalin for 
no less than one week.  
 
After fixation, transversal sections of the brain were taken from the rostral 
cortex (Figure 2.1A); parietal cortex, including hippocampus (Figure 2.1B); 
occipital cortex, including the entorhinal cortex (Figure 2.1C); the locus 
coeruleus and the cerebellum (Figure 2.1D). 
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Figure 2.1 Sectioning of the cat brains. Transversal sections of the brain were taken 
from a) the rostral cortex; b) the parietal cortex, including the hippocampus; c) the 
occipital cortex, including the entorhinal cortex; and d) the locus coeruleus and the 
cerebellum 
 
Sections were processed overnight in hot paraffin (Leica Tissue Processor 
ASP300S; Leica Biosystems™) and blocks were made. Consecutive slices of 
6 m were taken from the blocks by using a microtome (Microtome HM325; 




2.2.2 Grouping of cats 
Since the exact age of some of the cats was less certain, particularly in those 
cats coming from the shelter, age groups were created following the American 
Association of Feline Practitioners (AAFP) and the American Animal Hospital 
Association (AAHA) life stages guidelines (Table 2.1)148. In addition, this 
allowed the assessment of neuropathological changes at the different life 
stages and to determine whether there were differences between them.  
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Table 2.1 Grouping of cats. Cats were grouped into different categories according to 
their age following the American Association of Feline Practitioners (AAFP) and the 
American Animal Hospital Association (AAHA) life stages guidelines 
 
Category Age Number of cats CDS 
Kitten 0 to 6 months n = 0 No 
Junior 7 months to 2 years n = 0 No 
Prime 3 to 6 years  n = 6 No 
Mature 7 to 10 years  n = 24 No  
Senior 11 to 14 years  n = 9 Yes (n = 1) 
Super Senior 
(Geriatric) 
15 years and over  n = 16 Yes (n = 9) 
 
 
2.2.3 Immunohistochemistry (IHC) 
Consecutive 6 m sections were taken from the rostral lobes, parietal lobes 
(including the hippocampus), and occipital lobes (including the entorhinal 
cortex); the cerebellum and locus coeruleus were also sectioned. After 
dewaxing and rehydrating sections, antigen retrieval pre-treatment was 
performed by immersing slides in 90% formic acid for six hours149 for antibody 
4G8, and heat incubation (120 C for 40 minutes) in Sodium Citrate Buffer (10 
mM, pH 6) for the rest of the antibodies. All antibodies were incubated in 3% 
hydrogen peroxide in 10% methanol for 30 minutes to block endogenous 
peroxidase activity. Sections were incubated overnight at room temperature in 
each of the primary antibodies: two anti--amyloid and six anti-tau antibodies, 
listed in Table 2.2. Bound antibody was detected by incubating slides in 
biotinylated goat anti-mouse/rabbit antibodies (1:500; ThermoFisher 
Scientific™) for one hour, followed by incubation in ABC peroxidase (1:100; 
ThermoFisher Scientific™) for 30 minutes. Slides were visualised with 3,3’-
diaminobenzidine substrate (1:100; DAB; Sigma-Aldrich™) under light 
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microscope (Nikon™ Brightfield). Negative controls were used by omitting the 
primary antibodies. 
 
Table 2.2 Primary antibodies used for the detection of amyloid- and tau proteins 
Clone Antigen Dilution Source 
Amyloid-  
4G8 Anti--amyloid 17-24 and APP 1:1500 Biolegend™; San 
Diego, CA 
mOC64 Anti-β-amyloid 1-42 1:6000 Abcam™; 
Cambridge, UK 
Total tau and tau isoforms  








Tau46 Anti-tau 404-421 1:1000 Biolegend™; San 
Diego, CA 







A15091A Purified anti-Tau phospho (Ser 
262) 









In addition, Congo red and thioflavin-S staining were performed for A 
detection; plus, Silver-Gallyas for neurofibrillary tangles.  
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2.2.4 Validation of intranuclear hyperphosphorylated tau 
immunolabelling 
 
2.2.4.1 Isotype controls 
To validate that intranuclear immunolabelling was not caused by an artifact or 
non-specific staining, IHC was performed following the above protocol and 
using antibodies with the same isotypes for AT8 (mouse IgG isotype control; 
ThermoFisher Scientific™), AT100 (mouse IgG1 kappa isotype control; 
ThermoFisher Scientific™), and A15091A antibodies (mouse IgG2b kappa 
isotype control; Biolegend™) as negative controls. Isotype controls are 
antibodies that have the same class and type of the primary antibody, but do 
not bind to the target.  
 
2.2.4.2 Dephosphorylation of the tau protein 
To validate that the intranuclear labelling observed was caused by the 
hyperphosphorylated state of the protein, instead of the non-phosphorylated 
one, the tau protein needed to be dephosphorylated. To achieve this, IHC was 
performed by following the protocol described above, for the same 
hyperphosphorylated tau antibodies (i.e., AT8, AT100, and A15091A), 
separately; however, to dephosphorylate the protein, slides were incubated in 
alkaline phosphatase (FastAP Thermosensitive Alkaline Phosphatase; 
ThermoFisher Scientific™) following manufacturers’ protocol at 37 C for one 
hour, followed by three 5-minutes washes in fresh bovine serum albumin, 
before adding the primary antibodies.  
 
2.2.4.3 Protein extraction 
Extracts from the cytoplasm, the cytoskeleton, the soluble nuclear, and the 
chromatin bound nuclear fractions were obtained from frozen cat brain tissue 
(a 10-year-old cat) by using the Subcellular Protein Fractionation Kit for 
Tissues (ThermoFisher Scientific™) following manufacturer’s protocol.  
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2.2.4.4 Western blot 
Extracts from the different fractions (15 l) obtained with the Subcellular 
Protein Fractionation Kit for Tissues (ThermoFisher Scientific™) were 
prepared in a buffer containing NuPAGE™ LDS Sample Buffer (4x) and 
NuPAGE™ MES running buffer (10x) and were loaded into a 12 well 
NuPAGE™ pre-cast gel, 4-12% bis-tris. The gel ran at 50 V for 20 minutes, 
followed by 120 V for 20 minutes, and 200 V for 40 minutes. The proteins were 
then transferred onto an Immobilon-FL PVDF membrane (Millipore™) using a 
semi-dry electroblotting unit (Trans-Blot® SD semi-dry transfer cell; Bio-
Rad™), run at 0.06 A and 18 V for one hour. The PVDF membrane was 
transferred into LICOR blocking buffer (Licor Biosciences™) for one hour. 
Primary antibodies were added (AT8, 1:1000; and Tau46, 1:5000), and blots 
were incubated at 4 C on a roller overnight. Goat anti-mouse antibodies were 
used as secondary antibodies (IRdye 680RD; Licor Biosciences™). Analysis 
was performed using LICOR odyssey (700 nm wavelength). 
 
 
2.2.5 Quantification of protein deposition 
Initially, all of the slides were visually inspected by light microscopy; this 
included the slides from the rostral, parietal, and occipital regions, plus the 
cerebellum, that had been obtained after performing IHC with all the nine 
antibodies.  
 
For the automated quantification of protein deposition, only the slides stained 
against mOC64 for amyloid-, and AT8 and AT100 for hyperphosphorylated 
tau, from all brain regions, were scanned using a Leica Aperio Versa 200 
scanner (Leica Biosystems™). 
 
Images were transferred to the Aperio eSlide Manager® v12.4.0.5043 and 
visualised with the Aperio ImageScope® v12.3.3.5048. Annotation boxes of 
600 m of width, height and length were manually placed at random on each 
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Figure 2.2 Example of annotation boxes on the parietal cortex of a cat brain. The 
green boxes correspond to the grey matter; yellow boxes correspond to the white 
matter; and red boxes correspond to the hippocampus 
of the slides; in total five annotation boxes were created for grey matter, and 
five for white matter; plus, three boxes for hippocampus, and three for 
cerebellum (Figure 2.2). Fewer boxes were created for the hippocampus and 
cerebellum as the size of the tissue sections available from these two regions 







To analyse the annotation boxes and quantify protein deposition, three 
different algorithms were created by the author. Two versions of the Positive 
Pixel Count v9 algorithm were created by developing different parameters; one 
to detect the positive immunolabelling (i.e., load and burden; see below) of 
amyloid- and another to detect positive immunolabelling (i.e., load and 
burden; see below) of hyperphosphorylated tau (Figure 2.3).  
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Figure 2.3 Positive Pixel algorithm. Example of the Positive Pixel algorithm created 
to detect positive immunolabelling for amyloid- (mOC64 antibody) in the parietal 
cortex of a 10-year-old cat. Positive immunolabelling is highlighted in warm colours. 
Of these, red represents strong staining; orange a moderate staining; and yellow a 
weak staining. Blue represents no staining 
Figure 2.4 Nuclear algorithm. Example of the Nuclear algorithm created to detect 
positive intranuclear immunolabelling for hyperphosphorylated tau (AT100 antibody) 
in the rostral cortex of a 16-year-old cat. Positive immunolabelling is highlighted in 
warm colours. Of these, red represents strong staining; orange a moderate staining; 







A third algorithm was created by using the Nuclear Algorithm v9 to detect and 
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Data from the Positive Pixel Count v9 algorithms were exported to an excel 
file, where the load (i.e., percentage of total positives) and burden (i.e., the 
proportion of the total area assessed that contains positive labelling) of both 




𝐿𝑜𝑎𝑑 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (%) = (
𝑁𝑤𝑝+𝑁𝑝+𝑁𝑠𝑝
𝑁𝑡𝑜𝑡𝑎𝑙
) 𝑥 100                         Equation 2.1 
 
 








Nwp = Number of weak positives 
Np = Number of (moderate) positives 
Nsp = Number of strong positives 
Ntotal = Number of total positives and negatives 
Total area was of 1.8 mm2 for cortical regions and 1.08 mm2 for cerebellum 
and hippocampus. These were calculated by multiplying two dimensions of the 
annotation boxes (i.e., 600 m x 600 m), multiplying the result by the number 
of annotation boxes created for each region (i.e., multiply by five for cortical 
regions and by three for hippocampus and cerebellum) and converting the 
result to mm2 (1 mm2 = 1’000,000 m2).  
 
Data obtained from the Nuclear Algorithm v9, including the total percentage of 
nuclei stained and the degree of staining (i.e., 1 +, 2 +, and 3 +) were exported 
to an excel sheet and used for statistical analyses. 
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2.2.6 Ethical approval 
 
Ethical approval was obtained through the Veterinary Ethical Review 




2.2.7 Data analysis 
Data were analysed using Minitab® v19.2020.1 statistical software for 
Windows. 
 
Anderson-Darling tests were performed to assess normality. Non-normal data 
were transformed using Box-Cox transformation or Johnson transformation. 
Bartlett tests for equal variances with 95% confidence level, assuming normal 
distribution were performed. Non-parametric tests were performed in the 
variables in which transformation failed. 
 
To determine whether there were differences in the positive immunolabelling 
of the proteins (mOC64 for A, and AT8 and AT100 for hyperphosphorylated 
tau) in the different age groups, one-way ANOVA assuming equal variances 
(if applicable) with two-sided 95% confidence interval and a significance level 
of α = 0.05 were performed. To determine differences between groups, Tukey 
tests and Games-Howell post-hoc tests were performed in those structures 
that showed statistically significant differences in the one-way ANOVA. In 
addition, non-parametric Kruskal-Wallis tests were performed to assess 
differences in non-normal data. 
 
To determine whether there were differences in the positive immunolabelling 
of the proteins between grey and white matter, 2-sample t-tests with a 95% 
confidence level and a hypothesized difference of zero, assuming equal 
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variances were performed. Non-parametric Mann-Whitney tests were 
performed to assess differences in non-normal data. 
 
To determine whether there were differences in the positive immunolabelling 
of the proteins between cats with and without CDS, 2-sample t-tests were 
performed as described above. Since cats with CDS were in the Senior and 
Super Senior groups, these cats were compared against the cats without CDS 
in these two same groups. 
 
Finally, chi-square tests were performed to determine whether there was an 
association between cognitive status (i.e., cats with and without CDS) and the 
presence of pre-tangles. 
Results 
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A total of 55 cat brains were collected following submission for routine 
necropsy. The majority of cats were non-pedigree cats (98.2%; n = 54) and 
only one cat was a pedigree breed (a Bengal cat). Half of the cats (50.9%; n = 
28) were females; of these, two thirds (67.9%; n = 19) were neutered, and a 
third (32.1%; n = 9) were intact. A third of the cats (32.7%; n = 18) were males; 
most of them (88.9%; n = 16) were neutered and only 11.1% (n = 2) were 
intact. The sex of 16.4% (n = 9) of the cats was unknown, mainly because this 
was not recorded by the pathologists performing the brain extractions which 
had occurred several years ago. Ages ranged between two and 24 years. After 
being grouped by age, six cats were in the Prime group; 24 in the Mature 
group; nine in the Senior group; and 16 in the Super Senior group. Ten cats 
had a confirmed diagnosis of CDS, nine of these cats were in the Super Senior 
group and one was in the Senior group. There were no cats in the Kitten and 
Junior groups (See table 2.1 in Material and Methods). 
 
 
2.3.2 Amyloid- pathology 
Cats of all ages were shown to have A pathology (i.e., 4G8 and mOC64 
antibodies). Elderly cats had more extracellular A deposition than younger 
cats. In contrast, younger cats had more immunolabelling for intracytoplasmic 
A than older cats. 
 
In this section, the results from the intracytoplasmic A deposits with both 4G8 
and mOC64 antibodies will be presented first, followed by the results from the 
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Figure 2.5 Confirmation of intracytoplasmic amyloid- (A). The presence of 
punctuated intracytoplasmic A labelling was confirmed by using Thioflavin-S 
staining 
Intracytoplasmic labelling of A was found in a number of cats. To determine 
whether this represented A or normal APP, dyes that bind specifically to 
amyloid (i.e., Congo red and thioflavin-S) were used. While Congo red staining 








Intracytoplasmic immunolabelling was found in the younger cats, using 4G8 
antibody, and the percentage of cats with intracytoplasmic immunolabelling 
decreased with age, particularly in the cortex areas (Figure 2.6A). All cats in 
the Prime group showed intracytoplasmic immunolabelling in the occipital and 
parietal cortex, while this was evident in 85% of cats in the Super Senior group. 
Similarly, 83% of the cats in the Prime group had intracytoplasmic 
immunolabelling in the rostral cortex, compared to 77% of cats in the Super 
Senior group.  
 
In contrast, the opposite was found in the hippocampus, locus coeruleus, and 
cerebellum. In these regions, the percentage of cats with intracytoplasmic 
immunolabelling increased with age (67% in Prime group vs 85% in Super 
Results 
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Senior group in the hippocampus; 83% in Prime group vs 92% in Super Senior 
group in both the locus coeruleus and cerebellum).  
 
 
Figure 2.6 Intracytoplasmic amyloid- (A) deposition in the cat brain. 
Intracytoplasmic immunolabelling of A in a) the parietal cortex of a 13-year-old cat 
(4G8 antibody); and b) the occipital cortex of a 13-years-old cat (mOC64 antibody) 
 
 
Positive intracytoplasmic immunolabelling was similar with the mOC64 
antibody. Immunolabelling was present in most of the cats from the Prime 
group and the percentage of cats with positive labelling decreased with age in 
the cortex regions (rostral cortex: 100% of cats in Prime group vs 46% of cats 
in Super Senior group; and occipital cortex: 83% vs 62%) (Figure 2.6B). Only 
half of the cats (50%) in the Prime group had intracytoplasmic immunolabelling 
in the parietal cortex, this increased to 80% of the cats in the Senior group and 
decreased back to 54% of cats in the Super Senior group. As seen with the 
4G8 antibody, the proportion of cats with intracytoplasmic immunolabelling of 
the hippocampus and locus coeruleus increased with age, with none of the 
cats from the Prime group showing labelling in neither the hippocampus nor 
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Most of the extracellular A in cats had a diffuse pattern which, in some cases, 
formed patches (Figure 2.7). However, one single cat had a plaque-like 




Figure 2.7 Pattern of amyloid- (A) deposition in the cat brain. A deposits showed 
a diffuse pattern which, in some cases, formed patches as seen in this image from the 




Figure 2.8 Amyloid- (A) plaque-like formation in the cat brain. Plaque-like 
structures were found in the parietal cortex of a 16-year-old cat stained with mOC64 
antibody. Scale bar 500 m 
Results 
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Diffuse extracellular A deposition was mostly found in the cortex regions 
using the 4G8 antibody. There was an increase with age in both the severity 
of pathology and the numbers of cats with extracellular A. Between 30-50% 
of the cats in the Prime group had extracellular -amyloid deposition, primarily 
in the rostral cortex (50% of the cats), followed by the parietal and occipital 
cortex (33% each). In contrast, 60% of the cats in the Super Senior group had 
extracellular A deposition, predominantly in the rostral and occipital cortex 
(62% of cats, each) followed by the parietal cortex (54%). Extracellular 
deposition of A in the hippocampus and cerebellum appeared with age, from 
none of the cats in the Prime group, to 8% of the cats in the Super Senior 
group. 
 
Similarly, a higher percentage of cats from the Super Senior group had diffuse 
extracellular A deposits in most of the brain regions using the mOC64 
antibody, when compared to the cats in the Prime group (rostral cortex: 77% 
of cats in the Super Senior group vs 50% of cats in the Prime group; parietal 
cortex: 85% vs 67%; occipital cortex: 85% vs 67%; hippocampus 38% vs none; 
and locus coeruleus: 8% vs none). 
 
The extent and intensity of extracellular A immunolabelling was greater with 
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Figure 2.9 Extracellular deposition of amyloid- (A)  in the cat brain. Diffuse 
extracellular deposits of A  in a) the parietal cortex of a 12-year-old cat (mOC64 
antibody); b) the parietal cortex of a 10-year-old cat (mOC64 antibody); and c) the 
parietal cortex of a 16-year-old cat (4G8 antibody) 
 
2.3.2.1 The effect of age in A pathology  
One-way ANOVA were performed to determine whether age has an effect on 
A pathology (mOC64 antibody) and to assess whether there were differences 
between the age groups.  
 
A statistically significant effect of age on positive A labelling (i.e., burden) with 
mOC64 antibody was found in the rostral cortex (F3 = 4.55, p = 0.005) (Table 
2.3). Tukey tests demonstrated a significant difference were between the 
Prime and Mature groups (Difference of means = 10.24; SE of difference = 
2.80; 95% CI [2.94, 17.54]; t = 3.66; p = 0.002) and between the Prime and 
Super Senior groups (Difference of means = 7.93; SE of difference = 2.97; 
Results 
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95% CI [0.17, 15.69]; t = 2.67; p = 0.043) (Figure 2.10). This showed that the 
Prime group had the lowest positive immunolabelling, when compared to the 
other age groups. The complete list of means with standard deviations and 
95% CI can be found on Appendix 2.1. 
 
Table 2.3 Positive amyloid- (A) immunolabelling in the different age groups. One-
way ANOVA was performed to determine whether there were differences in the 
positive A labelling with mOC64 antibody between the age groups 
 F value DF p value 
Rostral cortex    
% Load  0.98 3 0.405 
Burden  4.55 3 0.005 
Parietal cortex    
% Load  0.57 3 0.637 
Burden  2.26 3 0.086 
Occipital cortex    
% Load  0.98 3 0.406 
Burden  0.97 3 0.412 
Hippocampus    
% Load  0.19 3 0.901 
Burden  0.57 3 0.638 
Cerebellum    
% Load  - - - 
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Figure 2.10 Amyloid- (A) burden in the rostral cortex of the different age groups. 
Tukey tests showed statistically significant differences in the burden of A (mOC64 
antibody) between the Prime and Mature groups (p = 0.002); and between the Prime 






Furthermore, when comparing the effect of age between the different brain 
regions, the cerebellum was the brain region with the lowest load of -amyloid 
when compared to the other brain regions (F4 = 4.58, p = 0.001). 
 
2.3.2.2 Differences in A pathology between grey and white matter 
Two-samples t-tests were performed to determine whether there were 
differences in the A pathology between grey and white matter. 
 
Statistically significant differences in the positive A labelling (i.e., load and 
burden; mOC64 antibody) were found in all the cortex regions between grey 
and white matter, with the greatest immunolabelling being present in the grey 
matter (Table 2.4). The complete list of means with standard deviations and 
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Table 2.4 Positive amyloid- (A) immunolabelling in grey and white matter. Two-
sample t-tests were performed to determine whether there were differences in the 
positive A labelling (mOC64 antibody) between grey and white matter 
 
 T value DF p value  
Rostral cortex    
% Load  5.46 104 <0.001 
Burden 5.31 104 <0.001 
Parietal cortex    
% Load  3.89 104 <0.001 
Burden 3.98 104 <0.001 
Occipital cortex    
% Load  4.69 100 <0.001 
Burden 4.59 100 <0.001 
 
 
2.3.2.3 Differences in A pathology between cats with and without CDS 
Two-samples t-tests were performed to determine whether there were 
differences in the A pathology between cats with and without CDS. 
 
No statistically significant differences were found in the positive A labelling 
(mOC64 antibody) between cats with and without CDS (Table 2.5). The 
complete list of means with standard deviations and standard errors of the 
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Table 2.5 Positive immunolabelling in cats with and without cognitive dysfunction 
syndrome (CDS). Two-sample t-tests were performed to determine whether there 
were differences in the positive amyloid- labelling (mOC64 antibody) between cats 
with and without CDS 
 
 T value DF p value 
Rostral cortex    
% Load  0.14 44 0.889 
Burden 0.58 44 0.567 
Parietal cortex    
% Load  -0.79 44 0.433 
Burden -0.47 44 0.644 
Occipital cortex    
% Load  -0.21 40 0.835 
Burden 0.96 40 0.344 
Hippocampus    
% Load  -1.91 16 0.075 
Burden -1.20 16 0.249 
Cerebellum    
% Load  -0.02 19 0.984 
Burden 0.52 19 0.606 
 
 
2.3.3 Tau pathology 
 
2.3.3.1 Non-phosphorylated tau and tau isoforms 
Intranuclear and intracytoplasmic immunolabelling of non-phosphorylated tau 
(i.e., Tau46 antibody) was found in cats of all ages and in all brain regions. 
Furthermore, intracytoplasmic immunolabelling of the two isoforms of tau: 3- 
and 4-repeat (i.e., 8E6/C11 and 1E1/A6 antibodies, respectively) were also 
found in cats of all ages and in all brain regions. 
Results 
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The percentage of cats with intranuclear immunolabelling for non-
phosphorylated tau (Tau46 antibody) increased with age (rostral cortex: 17% 
of the cats in the Prime group vs 38% of cats in the Super Senior group; parietal 
cortex: 33% vs 46%; occipital cortex: 33% vs 38%; locus coeruleus: none vs 
15%; and cerebellum: none vs 23%). 
 
The proportion of cats showing intracytoplasmic immunolabelling for non-
phosphorylated tau (Tau46 antibody) remained the same in the parietal and 
occipital regions, with all of the cats showing positive labelling. In contrast, the 
percentage of cats with positive immunolabelling increased slightly with age in 
some regions (hippocampus: 67% vs 100%; locus coeruleus: 67% vs 77%; 
and cerebellum: 67% vs 69%) and decreased in the rostral cortex (100% of 
cats in Prime group vs 92% of cats in Super Senior group) (Figures 2.11A and 
B). 
 
Intracytoplasmic immunolabelling for the 3-repeat tau isoform (8E6/C11 
antibody) was found in cats from all the age groups (Figures 2.11C and D); 
however, the proportion of cats showing positive immunolabelling tended to 
decrease with age in some brain regions (rostral cortex: 67% of cats in the 
Prime group vs 54% in the Super Senior group; occipital cortex: 83% vs 54%; 
and cerebellum: 17% to 8%) and to increase in the parietal cortex (83% vs 
92%) and hippocampus (83% vs 92%). 
 
Similarly, intracytoplasmic immunolabelling for the 4-repeat tau isoform 
(1E1/A6 antibody) was found in cats from all the age groups and the proportion 
of cats showing positive immunolabelling tended to increase with age (rostral 
cortex: none of the cats in the Prime group vs 38% of the cats in the Super 
Senior group; parietal cortex: 33% vs 62%; occipital cortex: 17% vs 46%; 
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Figure 2.11 Intracytoplasmic labelling of the tau protein and its isoforms in the cat 
brain. Intracytoplasmic immunolabelling of a) total tau (Tau46 antibody) in the 
rostral cortex of a 10-year-old cat; b) total tau (Tau46 antibody) in the hippocampus 
of a 10-year-old cat; c) 3-repeat tau isoform tau (8E6/C11 antibody) in the parietal 
cortex of a 11-year-old cat; d) 3-repeat tau isoform tau (8E6/C11 antibody) in the 
hippocampus of a 7-year-old cat; e) 4-repeat isoform of tau (1E1/A6 antibody) in  the 
rostral cortex of the 19-year-old cat; and f) 4-repeat isoform of tau (1E1/A6 antibody) 





Chapter 2: Neuropathology of ageing and cognitive dysfunction syndrome in cats
  104 
2.3.3.2 Hyperphosphorylated tau 
Positive immunolabelling of hyperphosphorylated tau was found within the 
nucleus and the cytoplasm of the neurons (i.e., AT8, AT100, and A15091A 
antibodies). Intranuclear immunolabelling was mostly found in younger cats, 
whereas intracytoplasmic labelling (i.e., pre-tangles) was found in elderly cats.  
 
In this section, results from the intranuclear tau deposits with all three 
antibodies will be presented first, followed by the results from the 
intracytoplasmic tau deposits. 
 
Intranuclear immunolabelling with AT8 antibody was most commonly found in 
younger cats, and the proportion of cats showing positive immunolabelling 
tended to decrease with age (rostral and occipital cortices: 83% of the cats in 
the Prime group vs 77% in the Super Senior group; and cerebellum (17% vs 
8%). In contrast, the percentage of cats showing intranuclear immunolabelling 
tended to increase with age in the parietal cortex (67% vs 85%), the 
hippocampus (50% vs 54%) and the locus coeruleus (33% vs 54%) (Figures 
2.12A and B). 
Results 
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Figure 2.12 Intranuclear immunolabelling of hyperphosphorylated tau. Intranuclear 
hyperphosphorylated tau deposits in a) the occipital cortex of a 14-year-old cat (AT8 
antibody); and b) the parietal cortex of a 14-year-old cat (AT8 antibody); c) the 
parietal cortex of a 14-years-old cat (AT100 antibody); and d) the rostral cortex of a 
14-years-old cat (A15091 antibody) 
 
Similarly, intranuclear immunolabelling with AT100 was found in cats of all 
ages, and in most of the brain regions, with the percentage of cats showing 
positive immunolabelling decreasing with age in most of them (rostral cortex: 
83% of cats in the Prime group vs 69% of cats in the Super Senior group; 
parietal cortex: 100% vs 92%; occipital cortex: 100% vs 85%; and 
hippocampus: 83% vs 77%). However, it increased in the locus coeruleus 
(17% vs 46%), and the cerebellum (33% vs 46%) (Figures 2.12C). 
 
Finally, intranuclear immunolabelling with A15091 antibody was found in cats 
from all ages, and in most of the brain regions, with the percentage of cats 
showing positive immunolabelling decreasing with age (rostral cortex: 100% of 
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Figure 2.13 Confirmation of the presence of pre-tangles. Silver-Gallyas staining 
confirmed the presence of hyperphosphorylated tau pre-tangles (stained in black) in 
the parietal cortex of a 19-years-old cat 
the cats in the Prime group vs 92% of cats in the Super Senior group; parietal 
and occipital cortices: 100% vs 85%; hippocampus, locus coeruleus, and 
cerebellum 83% vs 77%) (Figure 2.12D). 
 
Intracytoplasmic immunolabelling for hyperphosphorylated tau (i.e., pre-
tangles) was found with all three antibodies, and its presence was confirmed 






Elderly cats showed to accumulate pre-tangles with all three antibodies. A total 
of 14 cats were shown to have pre-tangles with AT8 antibody. Of these, one 
was in the Prime group; two in the Mature group; one in the Senior group; and 
ten in the Super Senior group (Figures 2.14A and B). Similarly, 15 cats were 
shown to have pre-tangles with AT100 antibody. Of these, two were in the 
Prime group; two in the Mature group; one in the Senior group; and ten in the 
Super Senior group (Figures 2.14C and D). Of note, almost half of the cats that 
had pre-tangles with AT8 (n = 6) and AT100 (n = 7) had a confirmed diagnosis 
of CDS. Moreover, the six cats with CDS that had pre-tangles with the AT8 
antibody, had pre-tangles with the AT100 antibody as well, mostly in the cortex 
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regions. The lowest number of cats with pre-tangles (n = 3) were found with 
the A15091A antibody. Of these, one was in the Mature group; and two in the 
Super Senior group. One of these cats from the Super Senior group that had 
pre-tangles, also had a confirmed diagnosis of CDS; of note, this cat also had 
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Figure 2.14 Pre-tangles in the cat brain. Pre-tangles of hyperphosphorylated tau in 
a) the rostral cortex of a 16-year-old cat (AT8 antibody); b) the rostral cortex of a 10-
year-old cat (AT8 antibody); c) the rostral cortex of a 16-year-old cat (AT100 
antibody); d) the occipital cortex of a 19-year-old cat (AT100 antibody); and e) the 
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Of note, the presence of pre-tangles with both AT8 and AT100 antibodies 
tended to increase with age in all of the brain regions (Figure 2.15A and B).  
 
 
Figure 2.15 Pre-tangles and age. The presence of pre-tangles tended to increase with 
age in most of the brain regions with a) AT8 and b) AT100 antibodies 
 
2.3.3.3 The effect of age in tau pathology  
One-way ANOVA were performed to determine whether age has an effect on 
tau pathology (i.e., intranuclear and intracytoplasmic using AT8 and AT100 
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No statistically significant differences were found in the intranuclear 
immunolabelling between the age groups with neither AT8 nor AT100 
antibodies (Table 2.6). The complete lists of means with standard deviations 
and 95% CI can be found in Appendices 2.3 and 2.4.  
 
Table 2.6 Intranuclear immunolabelling of hyperphosphorylated tau in the different 
age groups. One-way ANOVA was performed to determine whether there were 
differences in the intranuclear immunolabelling of the hyperphosphorylated tau (AT8 
and AT100 antibodies) between age groups 
 
 AT8 AT100 
 F value DF p value F value DF p value 
Rostral cortex 0.73 3 0.538 0.49 3 0.689 
Parietal cortex 0.97 3 0.409 0.26 3 0.851 
Occipital cortex 0.76 3 0.521 1 3 0.396 
Hippocampus 1.42 3 0.249 0.05 3 0.985 
 
 
One-way ANOVA showed statistically significant differences in the positive 
immunolabelling (i.e., burden) of hyperphosphorylated tau with the AT8 
antibody in the hippocampus (F3 = 3.08, p = 0.036) (Table 2.7). Tukey tests 
demonstrated that the differences were between the Prime and Senior groups 
(Difference of means = -0.284; SE of difference = 0.102; 95% CI [-0.556, -
0.012]; t = -2.77; p=0.038) (Figure 2.16). This showed that the Prime group 
had the greatest burden in the hippocampus (AT8 antibody), when compared 
to the other age groups. In contrast, there were no statistically significant 
differences in the positive immunolabelling of hyperphosphorylated tau using 
the AT100 antibody between the age groups (Table 2.7). The complete list of 
means with standard deviations and 95% CI can be found in Appendices 2.5 
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Table 2.7 Positive immunolabelling of hyperphosphorylated tau in the different age 
groups. One-way ANOVA was performed to determine whether there were 
differences in the positive immunolabelling of the hyperphosphorylated tau using AT8 
and AT100 antibodies between age groups 
 
 AT8 AT100 
 F value DF p value F value DF p value 
Rostral cortex       
% Load  0.58 3 0.630 0.23 3 0.876 
Burden  1.07 3 0.373 0.37 3 0.775 
Parietal cortex       
% Load  0.66 3 0.579 0.04 3 0.991 
Burden  1.67 3 0.179 0.66 3 0.584 
Occipital cortex       
% Load  0.59 3 0.626 0.06 3 0.980 
Burden  1.20 3 0.313 0.66 3 0.581 
Hippocampus       
% Load  1.97 3 0.130 0.69 3 0.563 
Burden  3.08 3 0.036 0.41 3 0.749 
Cerebellum       
% Load  0.73 3 0.537 1.20 3 0.320 
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Figure 2.16 Hyperphosphorylated tau burden in the hippocampus in the different 
age groups. One-way ANOVA showed that the Prime group had a higher burden of 
hyperphosphorylated tau (AT8 antibody) in the hippocampus than the Senior group 
(p = 0.036) 
 
 
2.3.3.4 Differences in tau pathology between grey and white matter 
Two-samples t-tests were performed to determine whether there were 
differences in the tau pathology between grey and white matter. 
 
There were statistically significant differences in the intranuclear 
immunolabelling with AT8 antibody between grey and white matter, with more 
immunolabelling in the grey matter in all cortical regions (Table 2.8). Similarly, 
there were statistically significant differences in the intranuclear 
immunolabelling with AT100 antibody between grey and white matter; 
however, this antibody showed more immunolabelling in the grey matter in the 
parietal and occipital cortical regions only (Table 2.8). The complete list of 
means with standard deviations and standard errors of the means can be 
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Table 2.8 Intranuclear immunolabelling of hyperphosphorylated tau in grey and 
white matter. Two-sample t-tests were performed to determine whether there were 
differences in the intranuclear immunolabelling of hyperphosphorylated tau with 
both AT8 and AT100 antibodies between grey and white matter 
 
 AT8 AT100 
 T value DF p value T value DF p value 
Rostral cortex 4.73 102 <0.001 0.87 98 0.386 
Parietal cortex 3.63 104 <0.001 5.16 100 <0.001 
Occipital cortex 4.54 104 <0.001 5.22 102 <0.001 
Hippocampus - - - - - - 
 
 
Two-sample t-tests showed statistically significant differences in the positive 
immunolabelling of hyperphosphorylated tau with antibody AT8 in the rostral (t 
= 2.12, p = 0.036) and occipital (t = 2.14, p = 0.035) cortices, with a higher load 
in the grey matter, when compared to white matter (Table 2.9). Statistically 
significant differences were also found with the AT100 antibody; however, 
these were in both the parietal (t = 2.58, p = 0.011) and occipital (t = 2.73, p = 
0.007) cortex between grey and white matter, being higher in the grey matter 
(Table 2.9). The complete list of means with standard deviations and standard 
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Table 2.9  Positive immunolabelling of hyperphosphorylated tau in grey and white 
matter. Two-sample t-tests were performed to determine whether there were 
differences in the positive immunolabelling of hyperphosphorylated tau with both the 
AT8 and AT100 antibodies between grey and white matter 
 
 AT8 AT100 
 T value DF p value T value DF p value 
Rostral cortex       
% Load  2.12 102 0.036 1.36 96 0.176 
Burden 0.69 101 0.490 -0.12 96 0.905 
Parietal cortex       
% Load  1.74 103 0.084 2.58 102 0.011 
Burden -0.05 104 0.960 0.39 101 0.695 
Occipital cortex       
% Load  2.14 104 0.035 2.73 102 0.007 
Burden -0.66 104 0.511 1.34 97 0.183 
 
 
2.3.3.5 Differences in tau pathology between cats with and without CDS 
Two-samples t-tests were performed to determine whether there were 
differences in the tau pathology between cats with and without CDS.  
 
Two-sample t-tests showed no statistically significant differences in the 
intranuclear immunolabelling with neither the AT8 nor the AT100 antibodies 
between cats with and without CDS (Table 2.10). The complete list of means 
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Table 2.10 Intranuclear immunolabelling of hyperphosphorylated tau in cats with 
and without cognitive dysfunction syndrome (CDS). Two-sample t-tests were 
performed to determine whether there were differences in the intranuclear 
immunolabelling of hyperphosphorylated tau (AT8 and AT100 antibodies) between 
cats with and without CDS 
 
 AT8   AT100   
 T value DF p value T value DF p value 
Rostral cortex -0.86 42 0.394 0.27 42 0.790 
Parietal cortex 0.07 42 0.946 0.29 42 0.773 
Occipital cortex -0.40 40 0.690 0.24 40 0.808 
Hippocampus 0.65 20 0.526 -0.63 17 0.539 
 
 
Similarly, no statistically significant differences were found in the positive 
immunolabelling of hyperphosphorylated tau, with neither the AT8 nor the 
AT100 antibodies, when comparing the cats with and without CDS (Table 
2.11). The complete list of means with standard deviations and standard errors 
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Table 2.11 Positive immunolabelling of hyperphosphorylated tau in cats with and 
without cognitive dysfunction syndrome (CDS). Two-sample t-tests were performed 
to determine whether there were differences in the positive immunolabelling of 




2.3.3.6 Association between the presence of pre-tangles and CDS 
Chi-square tests were performed to determine whether there was an 
association between cognitive status (i.e., cats with and without CDS) and the 
presence of pre-tangles.  
 
As previously described, the largest numbers of pre-tangles were found in cats 
with CDS, which was consistent with the statistically significant association 
 AT8 AT100 
 T value DF p value T value DF p value 
Rostral cortex       
% Load  -0.53 42 0.598 -0.06 40 0.955 
Burden -0.54 42 0.591 0.44 40 0.659 
Parietal cortex       
% Load  -0.26 44 0.793 -0.45 42 0.656 
Burden 0.04 44 0.970 -0.01 39 0.990 
Occipital cortex       
% Load  -0.61 42 0.543 -0.27 40 0.792 
Burden -0.65 42 0.517 -0.70 39 0.490 
Hippocampus       
% Load  0.51 21 0.613 1.58 17 0.132 
Burden -0.21 21 0.833 1.11 17 0.284 
Cerebellum       
% Load  -0.57 18 0.578 0.13 18 0.899 
Burden -0.56 18 0.584 -0.07 18 0.944 
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found between CDS and the presence of pre-tangles with both antibodies 
(Figure 2.17).  
 
 
Figure 2.17 Pre-tangles in the brain of a cat with cognitive dysfunction syndrome 
(CDS). The largest numbers of pre-tangles were found in the brains of cats with a 
confirmed diagnosis of CDS. Image from the parietal cortex of a 19-year-old cat with 
a diagnosis of CDS (stained with AT100 antibody) that also was part of the double-
blinded placebo-controlled study (see Chapter 4). Scale bar 900 m 
 
Most of the cats with CDS had pre-tangles with both the AT8 and AT100 
antibodies in the rostral (X2 = 31.534, p < 0.001; and X2 = 35.224, p < 0.001, 
respectively); the parietal (X2 = 11.6, p = 0.001; and X2 = 19.512, p < 0.001, 
respectively); the occipital cortex (X2 = 22.25, p < 0.001; and X2 =  32.245, p < 
0.001, respectively); and the hippocampus (X2 = 8.709, p = 0.003; and X2 = 
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2.3.4 Validation of intranuclear hyperphosphorylated tau 
immunolabelling 
 
2.3.4.1 Isotype controls 
To validate that intranuclear immunolabelling was not caused by an artifact or 
non-specific staining, IHC was performed using antibodies with the same 
isotypes for AT8, AT100, and A15091A antibodies as negative controls 






Figure 2.18 Isotype controls for the validation of intranuclear immunolabelling for 
hyperphosphorylated tau (AT8 antibody) in the rostral cortex of a 14-years-old cat. 
A) positive control shows intranuclear immunolabelling using AT8 antibody; and b) 
the use of the isotype as negative control showed no positive immunolabelling  
Results 
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2.3.4.2 Dephosphorylation of the tau protein 
 
To validate that the intranuclear labelling obtained was caused by the 
hyperphosphorylated protein, instead of the non-phosphorylated one, the tau 
protein was dephosphorylated by using alkaline phosphatase, showing no 









Figure 2.19 Dephosphorylation of the tau protein with alkaline phosphatase for 
the validation of intranuclear tau immunolabelling (AT8 antibody) in the rostral 
cortex of an 18-years-old cat. A) positive control shows intranuclear 
immunolabelling using AT8 antibody; and b) no positive immunolabelling was found 
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Figure 2.20 Western blot for the validation of intranuclear tau. Left: the presence of 
intranuclear hyperphosphorylated tau (AT8 antibody) was confirmed by Western Blot 
with a slightly higher expression in the soluble nuclear (Sol. Nuc.) fraction, when 
compared to the chromatin-bound nuclear (Chrom. Nuc.) fraction. 
Hyperphosphorylated tau was also expressed in the cytoplasm fraction (Cytopl.) but 
not in she cytoskeleton (Cytosk.). Right: expression of total tau (Tau46 antibody) was 
observed in all fractions 
 
2.3.4.3 Western blot 
Western blots were performed to determine whether the intranuclear tau was 
in a non-phosphorylated (Tau46 antibody) and/or phosphorylated (AT8 
antibody) state. The tau protein has a molecular weight of 79 kDa. A western 
blot of the different fractions confirmed the presence of intranuclear 
hyperphosphorylated tau in both the soluble nuclear and the chromatin bound 
fractions with the AT8 antibody, with a slightly higher expression in the soluble 
nuclear fraction. Hyperphosphorylated tau was also found in the cytoplasm; 
however, it was not detected in the cytoskeletal fraction (Figure 2.20). 
Similarly, a western blot using an antibody against total tau (Tau46) showed 
the presence of tau protein in both nuclear fractions, with higher levels in the 
soluble nuclear fraction. As expected, total tau was detected in both the 
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2.4 Discussion 
 
The age-related neuropathology seen in the cat brain shares many similarities 
to that seen in the elderly human brain, including in those with AD. Elderly cats 
have been shown to develop both A and tau pathologies; with large 
extracellular A deposits and the presence of pre-tangles. Of note, the largest 
numbers of pre-tangles were found in the brains of cats with CDS. In contrast, 
younger cats have mostly intracellular A deposits and no pre-tangles; while 
young cats did not form pre-tangles, they do have intranuclear tau.  
 
 
2.4.1 A pathology in the cat brain  
Extracellular deposits of A were found in the brains of most of the cats in this 
study. While there was some variability between individual brains, which also 
occurs in humans60, a similar distribution pattern was observed in most (see 
below).  
 
Cats of all ages had extracellular A deposits; however, the extent of these 
deposits varied between age groups. Smaller deposits were found in younger 
cats, whereas the largest deposits were found in cats of the Mature and Super 
Senior group, particularly in the rostral cortex. 
 
Contrary to what has been reported by others, the youngest cat with 
extracellular A deposits in this study was four years old; in previous studies 
A deposits were only found in cats over eight years of age52, 63, 64, 150. 
Extracellular A deposits in cats in the Prime group were only found in the 
cortical areas (mainly the rostral cortex with 4G8 labelling, and the parietal and 
occipital cortices with mOC64). It is perhaps not surprising to find A deposits 
in the brains of young cats. This finding suggests that A deposits start 
accumulating in these regions in the cat brain which, according to Braak and 
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Braak, are the same regions in which A deposition starts (i.e., Stage I) in the 
human brain60. Furthermore, in humans, A starts accumulating in individuals 
as young as 20-years-old, which is decades before they develop any type of 
cognitive decline and/or dementia151. According to International Cat Care and 
their equivalence table between human and cat years, four cat years 
correspond to ~32 in humans148, which correlates to finding A deposits in 
young individuals. 
 
Extracellular A deposits in the hippocampus were only found in cats in the 
Super Senior group. Since cats in this age group also had A in all cortical 
brain regions, it is logical to conclude that, after accumulating in the cortical 
areas, A pathology in cats progresses to the hippocampus. This same pattern 
has been described in the human brain during Stages II and III of A 
progression60.  
 
While the cortical regions and the hippocampus were the regions most affected 
by extracellular A deposition in cats, the cerebellum was least affected. In 
humans, the cerebellum is known to be affected only during the final stage of 
A progression (i.e., Stage V)60. Hence, it is possible that these cats did not 
live long enough to allow for A deposition to progress to the cerebellum.  
 
Larger extracellular A deposits were found in grey matter, when compared to 
white matter, and this occurred in all cortical regions. This correlates with the 
A progression proposed by Braak and Braak, as grey matter is initially 
affected during Stage I, progressing to the white matter during Stage II of 
disease60. Of note, while A pathology in humans with AD has been mainly 
reported in grey matter, one study has shown that A deposits also increase 
in the white matter152. 
 
Extracellular A deposits in cats have a diffuse pattern, which may explain why 
they were not detected with Congo red staining. In some cases, however, 
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these diffuse deposits formed patches (see Figure 2.7 in Results). This 
distribution pattern, including the formation of patches, has been previously 
documented in the cat brain52, 64, 150. Of note, these deposits are only formed 
by the A42 peptide63, 64.  
 
Similarly, diffuse deposits in humans are mainly formed by this same peptide 
(A42) and are believed to be an early stage of plaques53, 54. Interestingly, a 
16-year-old cat in this study showed A accumulating into plaque-like 
structures (see Figure 2.8 in Results). While this might be a sporadic finding, 
it could also suggest that cats may not only form diffuse A deposits, but they 
can also develop senile plaques. However, it is likely that most cats do not live 
long enough to develop these. Nevertheless, further studies are required to 
confirm this hypothesis. 
 
No statistically significant difference was found in the presence and/or extent 
of A pathology between cats with and without CDS. This may be due to the 
low numbers of cats with a confirmed diagnosis of CDS in the present study. 
It is also plausible that A pathology in cats does not correlate to the 
behavioural changes related to CDS, as previously suggested64. In humans, 
there is still contradictory evidence regarding the correlation between A 
pathology and cognitive impairment. It is true that some studies have found a 
correlation between A deposition and cognitive decline153. However, these 
studies have some caveats; for instance, they used silver stains that do not 
differentiate between senile plaques and diffuse deposits. In contrast, there is 
mounting evidence showing that A pathology does not correlate with 
cognitive decline; moreover, they have shown that there have been individuals 
with significant A accumulation that did not display any signs of cognitive 
impairment55, 79, 154, 155.  
 
In humans, A deposits accumulate in the extracellular spaces, and also inside 
neurons, within their cytoplasm156-158. Initial studies found intracytoplasmic 
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deposits in the brains of individuals ranging from 38 to 83 years old, with and 
without AD; while variations were found between the different age groups and 
across individuals, these deposits did not correlate to AD156. However, in these 
studies, the intracellular accumulation of A was detected by using antibodies 
against residues 17-24 of A (i.e., 4G8 antibody), which also bind to the 
amyloid precursor protein (APP). For this reason, recent studies have used 
antibodies against the C-terminus of A instead. These studies have confirmed 
that these intracytoplasmic deposits are mainly formed by the -cleaved portion 
of the A42 peptide157, 158 and can have either a smooth or a granular 
appearance158. 
 
The presence of A within the neurons is believed to occur as a result of two 
processes56, 157, 159. It has been suggested that, after the amyloidogenic 
pathway of APP, some of the A that was released from the neurons into the 
extracellular spaces is being reabsorbed into the cell by the action of 
Apolipoprotein E and/or nicotinic and lipoprotein receptors56, 157, 159. On the 
other hand, it has also been suggested that small fragments of A, produced 
during the amyloidogenic pathway of APP, are not released into the 
extracellular space and, instead, are retained intracellularly56, 157, 159.  
 
Intracellular A deposition is believed to be an early event that begins at a 
young age and progresses with age157, 158. For this reason, it has been 
suggested that intracellular A has a normal function, potentially as an 
antioxidant160, 161. During early years, intracytoplasmic A is expressed at very 
low concentrations and does not produce significant damage56; however, as 
individuals get older, it continues to accumulate, until it reaches higher 
concentrations and becomes toxic162. High concentrations of intracytoplasmic 
A have been linked to mitochondrial and cytoskeleton dysfunction, plus 
synaptic alterations56, 157, 159. Furthermore, once a neuron dies, 
intracytoplasmic A is released into the extracellular space, promoting further 
A accumulation in this region159. Unsurprisingly, correlations between the 
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concentrations of intra and extracellular A have been reported, as intracellular 
A tend to decrease when extracellular deposits accumulate158, 163. 
 
Studies in humans and mice models of AD have shown that intracellular A 
can abnormally accumulate inside the mitochondria159, 164, 165. The 
accumulation of A in the mitochondria alters glucose metabolism and limits 
adenosine 5’-triphosphate (ATP) production, promoting further A 
aggregation164. Abnormal A accumulation in the mitochondria alters several 
of its functions, leading to multiple mitochondrial defects159, 164, 165. For 
instance, in AD, mitochondrial dysfunction plays a vital role in the development 
of oxidative stress166. Accumulation of A in the mitochondria causes 
hyperpolarization of its membrane potential (i.e., the difference in the electric 
potential between the interior and the exterior of a cell), increasing the 
production of reactive oxygen species (ROS), including free radicals, which 
results in oxidative stress and neuronal death164. The exact location of 
intracellular A in the cat brain was not assessed in the present study; 
however, it is possible that cats also accumulate A within their mitochondria, 
increasing the release of free radicals and promoting oxidative stress. Further 
studies are needed to determine whether A aggregates inside the 
mitochondria in the cat brain and its involvement in the development of 
oxidative stress and CDS in this species. 
 
Finally, in the AD brain, intracytoplasmic A has been found in the areas that 
are affected the earliest, such as the hippocampus and the entorhinal 
cortex157; furthermore, intracytoplasmic A has been found to affect the same 
cells where NFT are present, although any relationship with the NFT is 
unclear156. 
 
In the present study, cats of all ages were shown to have intracytoplasmic A 
deposition; it had a granular appearance, and the amyloid structure was 
confirmed by staining with thioflavin-S. These deposits were predominantly 
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found in the cortical areas. In these regions, intracellular immunolabelling was 
more pronounced in the Prime group and it tended to decrease with age, 
especially where large extracellular A deposits were found. However, in other 
areas, such as the hippocampus, the locus coeruleus, and the cerebellum, it 
tended to increase with age. It could be argued that this positive 
intracytoplasmic labelling could be APP, instead of A, especially as the 4G8 
antibody binds to the residues 17-24 of A, plus APP; however, 
intracytoplasmic labelling was also found with the antibody mOC64, which is a 
conformation-specific antibody that recognises monomers, oligomers, and 
fibrils of A42. As is the case with humans (as discussed above), these 
findings suggest that intracytoplasmic A also starts accumulating within 
cortical areas of the cat brain at a young age, then decreases in these regions 
as cats get older and extracellular A accumulation increases. However, 
further longitudinal studies are needed to determine the progression of these 
deposits both within the cells and in the extracellular spaces, and to determine 
if there is any correlation between them.  
 
The presence of A oligomers in the cat brain has been previously described52. 
Oligomers in cats consist of hexamers and dodecamers of A52, which are 
believed to be the most toxic form of A and are known to be associated with 
tau pathology in AD167. It has been suggested that this form of A may be 
involved in the development of pre-tangles, as both A oligomers and pre-
tangles have been found in the same regions of the aged cat brain52.  
 
While both the extra and intracellular accumulation of A have been 
extensively studied in humans, it is still unclear which of them (if any) triggers 
the process that leads to neurodegeneration and the development of AD157. 
 
The amyloid cascade hypothesis was originally created by Hardy and Higgins 
(1992) and it proposes that AD is solely triggered by the abnormal production 
of A58. They hypothesised that this abnormal A production is caused by 
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mutations on the APP gene58 which, after being cleaved during the 
amyloidogenic pathway, releases abnormal quantities of A to the extracellular 
space56. Extracellular deposits then trigger further events that may eventually 
lead to neurodegeneration56. While these mechanisms remain unclear, they 
suggested that this could be due to A being a neurotoxic peptide58. 
Furthermore, they suggested that A neurotoxicity disrupts calcium 
homeostasis within neurons; hence, promoting hyperphosphorylation of tau 
and the formation of NFT that will eventually lead to neuronal death55, 58. 
Interestingly, it has been shown that NFT rarely appear in the absence of A 
pathology168. 
 
While there is extensive evidence supporting the amyloid cascade hypothesis, 
there is also emerging evidence that challenges it. This new evidence is based 
in the fact that, while mutations on the APP gene have been proven, these 
have only been linked to cases of familial AD55. However, most of the AD cases 
are known to be caused by the sporadic form of the disease, in which no 
mutations on the APP gene have been found55. This suggests that there could 
be different and/or additional mechanisms involved in the development of AD. 
 
 
2.4.2 Tau pathology in the cat brain  
Non-phosphorylated tau protein was detected in the brains of cats of all ages 
with all three tau antibodies. One of the antibodies, Tau46, binds to the C-
terminus of the protein; while the other two (8E6/C11 and 1E1/A6) bind to the 
three and four repeats isoforms of the protein, respectively. Labelling with 
these three antibodies showed that tau was highly expressed in all brain 
regions of cats of all ages, as expected. This correlates to the expression of 
this protein and its isoforms in the adult human brain73, 74. 
 
Immunolabelling of hyperphosphorylated tau was detected within the 
cytoplasm of neurons in some cats. Since these aggregates tended to occupy 
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the whole cytoplasm and no shape alterations were found, these are thought 
to be pre-tangles77, as have been previously described in the cat brain52, 64, 150. 
 
Pre-tangles were visualised with the three antibodies against 
hyperphosphorylated tau (i.e., AT8, AT100, and A15091A). The number of pre-
tangles appeared to increase with age, although this was not shown to be 
statistically significant.  
 
Pre-tangles were mostly found in the cortex of cats in the Super Senior group, 
suggesting that tau pathology starts in the cortical regions of the cat brain. If 
true, this may represent a difference in the onset of tau pathology between 
cats and humans, as this pathology starts in the transentorhinal cortex in the 
human brain60. However, since the transentorhinal cortex was not assessed in 
the present study, it is impossible to say whether tau pathology truly begins in 
the cortical regions or in the transentorhinal cortex. Of note, a few of the cats 
in this study were shown to have small numbers of pre-tangles in the entorhinal 
cortex.  
 
The amount of pre-tangles varied between grey and white matter. Greater 
numbers of pre-tangles were mostly found in the rostral and occipital cortices 
in grey matter; far fewer were found in the white matter.  
 
Positive labelling for hyperphosphorylated tau was also found in the 
hippocampus, where statistically significant differences were found in their 
burden between the Prime and Senior groups, with more being seen in the 
Prime group, which was unexpected. However, this finding could be due to 
inaccuracies in the algorithm created to quantify the protein deposition 
because the Positive Pixel algorithm only recognises positive pixels. This 
means that the software efficiently recognises positive staining; however, it 
fails to recognise the location of this labelling (i.e., cytoplasmic or nuclear). 
Hence, it is possible that this algorithm recognised both cytoplasmic and 
nuclear staining when quantifying hyperphosphorylated tau. If this is true, it is 
Discussion 
 
Chapter 2: Neuropathology of ageing and cognitive dysfunction syndrome in cats
  129 
possible that the positive staining seen in the Prime group corresponds to 
intranuclear staining, rather than pre-tangles. Of note, after visual inspection 
of the slides, this did appear to be the case, with more intranuclear staining in 
the cats in the Prime group.  
 
Interestingly, pre-tangles were found in the brains of two cats in the Prime 
group (i.e., one 4-year-old cat, which was the same cat showing extracellular 
A deposits; and one 6-year-old cat). While this finding was unexpected, it was 
not entirely surprising. It is possible that these cats had a non-diagnosed 
neurological disorder that produced tauopathy, or that their age was 
miscalculated (particularly if they came from the shelter), and they might have, 
in fact, been older than recorded. However, it is also plausible that tau 
pathology starts at a young age in some cats. Braak suggested that the early 
stages of the tau pathology may occur in younger individuals, as NFT have 
been found in people under 25 years of age77; however, as individuals get 
older the number of NFT increase, leading to more severe stages of disease77. 
 
While no statistically significant differences were found in the load and burden 
of pre-tangles between cats with and without CDS, associations were found 
between the presence of pre-tangles and CDS; this is nuanced, but important. 
This is not surprising, as half of the cats with pre-tangles (as shown using all 
three antibodies) had a confirmed diagnosis of CDS. Chi-square tests showed 
that cats with CDS had larger numbers of pre-tangles, when compared to cats 
without CDS. In humans, a strong association has been reported between the 
presence of NFT and cognitive impairment169. Furthermore, the progression 
stages of tau pathology have been associated with different stages of cognitive 
impairment and dementia. While cognition is known to remain unaffected 
during Stages I and II, mild cognitive impairment has been associated with 
Stages III and IV and, finally, AD has been associated with the most severe 
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Of note, three of the cats with CDS included in this study were previously part 
of the double-blinded placebo-controlled study (see Chapter 4); interestingly, 
these cats had the largest numbers of pre-tangles within their brains (see 
Figure 2.17 in Results). To be included in that study the cats had to have 
significant signs of CDS; hence, as is the case in people, severe clinical 
impairment is associated with significant tau pathology. 
 
In AD, hyperphosphorylated tau is also known to abnormally accumulate inside 
the mitochondria, leading to alterations in its morphology (e.g., changes in size 
and shape) and functions (e.g., alterations in glucose metabolism), plus 
defects in mitochondrial transport170. It is plausible that hyperphosphorylated 
tau accumulates within the mitochondria of cats; however, this was not 
assessed in the present study. 
 
The role of tau in the development of AD and cognitive decline remains 
unclear. On one hand, tau is believed to be the cause and potential trigger of 
neurodegenerative disease, on the other, more recent evidence proposes that 
it plays a protective role instead. If tau is believed to be associated with 
neurodegeneration, any link with APP mutation and A deposition is also 
debated. 
 
As a potential cause of disease, tau in its hyperphosphorylated state, is 
believed to be neurotoxic and to trigger neurodegeneration, known as the tau 
hypothesis70. Abnormal hyperphosphorylation of tau affects microtubule 
function and stability, and promotes its disassembly, leading to neuronal death 
and neurodegeneration171. Of note, it has been suggested that APP, with our 
without mutation, can act as a receptor of abnormal tau, promoting intracellular 
tau aggregates172. However, in some cases, the presence of NFT has been 
observed in the human brain long before A senile plaques develop173, 
suggesting that it may be abnormally hyperphosphorylated tau that triggers the 
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A different hypothesis suggests that NFT are not toxic, and instead, tau 
oligomers (i.e., an intermediate stage between hyperphosphorylated tau 
monomers and NFT) trigger neurodegeneration174, 175. A recent study has 
shown that mice develop significant cognitive decline and memory impairment, 
as well as synaptic loss and mitochondrial dysfunction after intracerebral 
injection of tau oligomers176. To date, there is no evidence of the presence of 
tau oligomers in cats; however, since cats do not produce NFT, it is possible 
that the pre-tangles seen in the aged cat brain are formed by tau oligomers. In 
the present study, elderly cats with CDS were shown to have the greatest 
numbers of pre-tangles, suggesting that these pre-tangles, potentially formed 
by tau oligomers, are highly toxic in this species. Further studies are needed 
to confirm which form of tau is present in the pre-tangles and to determine the 
involvement of tau oligomers in the development of CDS in cats. 
 
An interesting, alternative hypothesis of tau as a cause of disease suggests 
that tau initially accumulates in a small number of cells, then later propagates 
to other cells and regions, in a prion-like manner, leading to 
neurodegeneration72, 177, 178. Although the mechanism behind this propagation 
remains unclear, it is believed that after being released into the extracellular 
space, either freely or within vesicles, cells nearby uptake the released tau, 
where it is then seeded. This means that a pathogenic species is created which 
has the ability to self-amplify. This seed acts as a template for the further 
recruitment of proteins and formation of aggregates178. This is believed to 
promote further aggregation and spreading to other cells and regions177. Of 
note, while tau seeds are in a non-phosphorylated state, seeded tau 
aggregates are hyperphosphorylated177. Interestingly, the pattern of 
propagation observed in this hypothesis is identical to the stages of tau 
pathology proposed by Braak177. 
 
Contrary to these hypotheses, emerging evidence suggests that tau may not 
trigger neurodegeneration. Recent studies have found that cells containing 
NFT can survive for long periods, even decades70, 77. For this reason, it has 
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been proposed that NFT are not, in themselves, neurotoxic and that neuronal 
death is not produced by the presence of NFT, but by alterations derived by its 
presence within the cells, such as microtubule instability and impaired 
axon/dendrite transport77. 
 
It has also been suggested that NFT provide protection to the cells from 
oxidative damage, which is one of the earliest events in AD160, 161. This 
hypothesis proposes that tau phosphorylation is upregulated and modified by 
oxidative stress, which also promotes its aggregation as NFT179. Furthermore, 
it has been found that oxidative damage decreases as the disease progresses 
and the number of NFT increases160, 161. 
 
Finally, a reversible tau hyperphosphorylation and formation of NFT has been 
reported in animals during hibernation, where it has been shown to have a 
neuroprotective effect180. 
 
The presence of intranuclear tau has been previously described in both 
human181 and mouse brains182. While the presence of intranuclear paired 
helical filaments (PHF) was described in 1988183, intranuclear non-
phosphorylated tau was first reported in the early nineties in human 
neuroblastoma184 and other cells, such as fibroblasts and lymphocytes185. 
Interestingly, one of these studies showed that around 16% of the total tau 
protein is located within the nucleus, particularly in the chromatin186. 
 
In the present study, in addition to IHC labelling of intranuclear tau, Western 
blots demonstrated that both phosphorylated and non-phosphorylated states 
of tau were present in the nuclear fraction of cat brain extracts. In humans, 
both states of intranuclear tau are also known to exist and are believed to have 
different functions181, 186.  
 
Studies in rodents have shown that nuclear non-phosphorylated tau binds and 
protects DNA after induced oxidative stress or heat-shock182, 187, 188. These two 
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processes promote the translocation and accumulation of non-phosphorylated 
tau to the nucleus and nucleolus in order to protect and maintain the integrity 
of DNA182, 187. These studies show a significant dephosphorylation of the 
cytoplasmic tau and an increase in nuclear phosphorylated tau immediately 
after inducing stress; whereas the opposite was observed after 24 hours, with 
an increase in phosphorylated cytoplasmic tau and a decrease in nuclear 
tau182. Because of this, it has been suggested that phosphorylation may 
regulate the translocation of tau between the nucleus and the cytoplasm182. 
Furthermore, abnormal phosphorylation may alter the ability of tau to 
translocate and/or may affect its ability to bind to DNA and protect it from 
damage182, 189-191. 
 
It has been suggested that phosphorylation of tau does not occur in the 
nucleus, but rather it occurs in the cytoplasm, before it is translocated186. 
However, some other studies have shown that tau phosphorylation at specific 
residues, such as T181, T212 and S404, is increased within the nucleus191. 
Furthermore, it has been shown that some other epitopes, such as those that 
recognise Thr212, Ser214 residues (i.e., that are detected by antibody AT100) 
are located in the nucleus of human neurons192. 
 
Nuclear tau has also been reported in the AD brain; however, its role in the 
development of disease remains unclear188. Following the amyloid cascade 
hypothesis, it has been suggested that A deposits promote abnormal 
phosphorylation of tau, altering its translocation to the nucleus, and impeding 
its binding and protection to the DNA188, as described above.  
 
In the present study, intranuclear hyperphosphorylated tau was mostly found 
in the cortex of cats, particularly in the grey matter. While no statistically 
significant differences were found between the different age groups, cats in 
the Prime group tended to have more intranuclear hyperphosphorylated tau, 
compared to the older age groups. Interestingly, the cats that had pre-tangles 
showed little or no intranuclear tau immunolabelling. In contrast, intranuclear 
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non-phosphorylated tau (Tau46 antibody) tended to increase with age in all 
brain regions. Similarly, studies in humans have shown that nuclear tau 
increases with age, reaching the highest levels at geriatric stages193; however, 
in AD, intranuclear tau decreases significantly in the hippocampus and cortex, 
and completely disappears in advanced stages of disease192.  
 
Even though several hypotheses have been proposed to try to understand the 
development of AD, the relationship between A and tau pathologies is still 
under debate. The amyloid cascade hypothesis is potentially the most 
recognised hypothesis, which states that abnormal A accumulation triggers 
mechanisms that promote tau hyperphosphorylation and aggregation (e.g., 
mitochondrial dysfunction and release of free radicals), leading to 
neurodegeneration and eventually to cognitive decline56, 58. Similarly, the 
relationship between A and tau pathologies in the aged cat brain remains 
unclear. Chambers et. al. (2015) suggested that abnormal A accumulation in 
cats might also trigger hyperphosphorylation of tau and pre-tangle formation52; 
however, further studies are needed to investigate these interactions and the 
underlying processes that lead to CDS in this species.  
 
The neuroinflammation produced by activation of glial cells (i.e., microglia and 
astrocytes) is believed to play an important role in the development of AD. 
Under physiological conditions, microglia are immune cells that provide 
maintenance of the brain tissue as they respond to injury and the presence of 
pathogens194, 195. When microglial processes detect either injury or a 
pathogen, microglial cells migrate to the damaged or vulnerable area where 
they engulf and degrade the debris produced by impaired or dying cells196, 197. 
In AD, abundant glial cells (both microglia and astrocytes) have been found 
surrounding A plaques198-200. It has been suggested that glial cells keep the 
extracellular spaces clear of A, reducing its deposition and slowing its 
progression198, 200-202. Reactive microglia form a barrier around A deposits, 
compressing and containing A fibrils inside, and preventing further 
aggregation into new or existing plaques203. However, ageing and/or genetic 
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factors are known to alter microglial functions, promoting an inadequate 
degradation and clearance of A, and increasing the risk of developing AD194, 
201. Furthermore, the presence of protein aggregates in the brain promotes 
microglial responses that may be damaging. For instance, activation of 
microglia promotes an inflammatory response and the release of pro-
inflammatory mediators (e.g., TNFα and IL-1) that induce neurotoxicity in 
reactive astrocytes, leading to neuronal death204, 205 206, 207.  Astrocytes 
promote homeostasis of the brain, give shape to grey matter, and mediate 
neurotransmitters and synaptic activity199, 208-210. Similar to microglia, protein 
deposition in the brain activates astrocytes199; reactive astrocytes are also 
involved in the degradation and clearance of A and promote an inflammatory 
response200, 202. However, abnormal protein deposition may alter calcium 
signalling in astrocytes affecting neuronal homeostasis that may lead to 
neuronal death211. To date, there is no evidence of the role of 
neuroinflammation in the aged cat brain. In a separate ongoing study, the 
author has been assessing neuroinflammatory markers (i.e., microglia, 
astrocytes, oligodendrocytes, amongst others), their role in ageing and the 
development of CDS, and their correlation to abnormal A and tau deposition 
in the cat brain. 
 
Some limitations were identified in the present study. Since the 
neuropathology was only assessed post-mortem, the findings only represent 
a snapshot of the neuropathology of ageing and CDS in these cats. Further 
longitudinal studies are needed to determine at what age these changes begin 
to occur and how the disease progresses over time. Furthermore, since 
behavioural changes were only fully assessed in three cats (those recruited for 
the placebo-controlled study; Chapter 4), and cognition was not formally 
assessed in any cat, no correlation could be made between the cognitive state 
of these cats and the presence and/or severity of the neuropathology found.  
 
Another limitation arose when trying to trace and retrieve the cats’ information, 
particularly where brains were collected several years before the study started; 
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no information was recorded for some of the cats (i.e., sex, exact age, or 
medical record). Having this information would have helped to understand 
and/or explain the neuropathological changes observed in these cats, 
especially in the younger ones.  
 
A limitation concerning the sectioning of the brains was also identified. All 
brains were manually sectioned by the author without using a brain slicer, as 
had been developed for rats’ and mice’s brains. This resulted in slight 
variations in the thickness of the brain slices. In addition, there were natural 
individual variation in both the size and the shape of the brains.  Even though 
anatomical landmarks were used to minimise variation when slicing the brains, 
there were differences in the size of some of the structures such as the 
hippocampus and cerebellum. This impeded analysing these regions in more 
detail; for example, since the hippocampus was not sectioned in the exact 
same places for all the cats, assessing differences between the regions of the 
hippocampus could not be assessed. For future studies, a 3D cat brain slicer 
could be developed and printed; however, a specialist would be needed to 
design the template (i.e., veterinary neuroanatomist/neurologist and 3D 
designer); plus, the high costs of using a 3D printer should be considered. 
 
The inability of the Positive Pixel algorithm to differentiate between nuclear or 
cytoplasmic immunolabelling represented a limitation. Since the author visually 
inspected all the slides by light microscopy, this issue was identified promptly. 
As a result of this limitation, and to examine the nuclear immunolabelling in 
more detail, the Nuclear algorithm was purchased by Professor Elizabeth 
Head (The University of California, Irvine). To minimise this problem in the 
future, different algorithms could be used. A similar algorithm to the Nuclear 
one, identifies cytoplasmic labelling; however, these algorithms have to be 
purchased separately and are very expensive. 
 
The relationship between the neuropathological findings described in this 
chapter and behavioural changes in cats was not assessed. This was due to 
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the small number of cats with a diagnosis of CDS and the lack of information 
on some of the cats (i.e., no medical records and/or behavioural assessments). 
As discussed above, evidence in humans and mice models of AD suggests 
that the abnormal accumulation of A and tau, particularly of oligomers, 
triggers different mechanisms (e.g., synaptic loss and mitochondrial 
dysfunction) that promote neuronal dysfunction and neurodegeneration167, 174-
176. Furthermore, the abnormal aggregation of A and tau is known to be 
associated with the appearance of clinical signs in AD77, 153, 169. It is possible 
that similar mechanisms, derived by abnormal deposition of A and tau, may 
also lead to neurodegeneration and behavioural changes in cats with CDS. 
Future studies, assessing behavioural changes plus cognition (e.g., 
visuospatial memory and problem-solving tests), being conducted alongside in 
vivo assessments of protein expression in different body fluids (i.e., levels of 
A and tau in CSF and/or blood) are needed. These would provide with robust 
evidence of the initial alterations in A and tau levels in cats and how these 
change over time until behavioural changes start to appear and CDS is 
developed, which can be followed by post-mortem histopathological 
examination of the brains.
Conclusion 
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2.5 Conclusion 
Cats have been shown to accumulate diffuse extracellular and 
intracytoplasmic deposits of A, plus, pre-tangles of hyperphosphorylated tau 
within their brains. The severity of both pathologies and the number of cats 
affected were shown to increase with age; three cats with severe CDS had the 
most pre-tangles. Of note, the presence and progression of these pathologies 
are similar to those seen in humans with AD, suggesting that the cat has the 
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The impact that normal ageing has on the brain, its anatomy, and structures 
has been widely studied in humans. As individuals get older, vascular changes 
and shrinkage of the brain may occur that can lead to deterioration of cognition. 
Recently, imaging techniques have emerged as potential tools for the 
diagnosis and assessment of brain atrophy, with Magnetic Resonance (MR) 
imaging and computed tomography (CT) scans being the most commonly 
used.  
 
In humans over 40 years old, the brain reduces its volume at a rate of 5% per 
decade30; however, not all brain regions shrink at the same rate. The prefrontal 
cortex is the most affected region, followed by the temporal lobe and the 
hippocampus31; although some contradictory evidence suggests that the 
hippocampus may be the most affected33, 34. In contrast, the occipital cortex is 
the least affected31. Interestingly, sex-related differences may also occur. The 
frontal and temporal lobes are the most affected in men, compared to the 
hippocampus and parietal lobes in women144, 212. 
 
The use of these modern imaging techniques is not limited to the assessment 
of brain atrophy in normal ageing. Recently, MR imaging has grown as a 
potential diagnostic tool for the investigation of neurodegenerative disorders, 
such as Alzheimer’s disease (AD). Longitudinal studies have been conducted 
in cognitively healthy elderly individuals who later developed cognitive decline, 
including mild cognitive impairment and AD. These studies have shown subtle 
abnormalities, such as shrinkage, primarily in the medial temporal lobe and 
parietal regions of the brain213, 214. Hippocampal36-38 and entorhinal38 atrophy 
have also been reported, as well as changes in the size of the ventricles35. 
These subtle changes can be detected a decade before these individuals get 
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Figure 3.1 Atrophy of the brain in Alzheimer’s disease (AD). Comparative image of a 
healthy human brain (left) and the brain of a patient with severe AD (right). Image 
from the National Institute of Aging, USA 
The progression of brain atrophy in patients with AD has also been studied 
(Figure 3.1). In the pre-symptomatic stage of AD, non-specific whole brain 
atrophy has been reported, along with more specific shrinkage of the medial 
temporal lobe39, 92, 215, in early AD, ventrolateral and lateral parietal lobes, 
along with the posterior cingulate are believed to be most involved92-95, while 
in later stages of the disease, non-specific total brain atrophy is again 








Age-related brain changes have also been studied in other species, such as 
dogs. Enlargement of the ventricles219-221, in particular the temporal horn222, 
plus reduction of the total brain volume and the hippocampus220-222 have been 
reported to occur in aged dogs (Figure 3.2). It has been suggested that the 
total brain volume remains stable in dogs aged between three months and 11 
years of age but begins decreasing at 12 years and older222. Atrophy is more 
evident in the frontal lobe, which is believed to remain the same between six 
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months and seven years but decreases significantly after eight years old222, 
223. In addition, dogs have shown a reduction of the interthalamic adhesion 
thickness224, 225 associated with  ageing. Measuring the thickness of this 
structure has become a method of diagnosing brain atrophy in dogs as it has 
been shown to become thinner with age225, particularly in dogs with cognitive 








As with dogs and humans, two studies looking at aged cats demonstrated an 
increase in the size of the ventricles with age, in particular the right lateral and 
the third ventricles40, an increase of the temporal horn40, a reduction in the total 
cerebral volume, and a reduced interthalamic adhesion thickness226. 
 
It is evident that MR imaging and CT scans may potentially be useful tools for 
the assessment and diagnosis of normal age-related brain changes and 
Figure 3.2 Enlargement of the ventricles in the dog brain. MR images from the brains 
of A) a four-year-old dog, B) a nine-year-old dog, and C) a 15-year-old dog. Marked 
increment in the size of the lateral ventricles (red arrows) and cortical atrophy is seen 
as dogs get older. Measurement of the interthalamic adhesion thickness is 
represented by yellow lines. Image taken from Su et. al. 1998 
Introduction 
 
Chapter 3: The use of 1.5T Magnetic Resonance imaging for the assessment of 
brain atrophy and other age-related brain changes in cats
  144 
 
general pathologies in both human and veterinary medicine, including some 
neurodegenerative diseases, such as AD. However, further studies are 
needed to fully describe these changes in the cat, and define the changes 
associated with CDS in this species. 
 
The aim of this study was to ascertain whether there is age-related atrophy of 
the whole brain and/or specific brain structures, including the lobes, 
hippocampus, and the interthalamic adhesion, plus enlargement of the 
ventricles in cats by undertaking measurements of 1.5T MR images. It was 
hypothesised that elderly cats would have a marked atrophy of the whole brain 
and some of the different brain structures assessed (i.e., lobes and 
hippocampus). Furthermore, it was also hypothesised that elderly cats, 
particularly those with diagnosis of CDS, would have larger lateral ventricles 
and smaller interthalamic adhesions than younger cats. Finally, it was 
hypothesised that these age-related neuroanatomical changes will share 
similarities to those seen in human AD. 
 
 
Materials and Methods 
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3.2 Materials and Methods 
 
 
3.2.1 Study populations 
 
Two populations were used in this study, one consisting of living feline patients, 
while the other consisted of brains collected and fixed post-mortem. 
 
3.2.1.1 Live cats 
 
Magnetic resonance images of the brains of live cats of various ages were 
obtained from medical records from the Hospital for Small Animals at the Royal 
(Dick) School of Veterinary Studies (RDSVS), The University of Edinburgh. A 
retrospective database search was conducted for all MR images of feline 
heads obtained from January 2009 to January 2018. Scans of cats that had 
one or more of the following criteria were not included in the study (Table 3.1):  
 
Table 3.1 Exclusion criteria list. Scans of cats that were shown to have any of the 
following were excluded from the study 
Exclusion criteria 
• Diagnosis of intracranial mass lesions 
• Diagnosis of extracranial mass lesions invading the skull 
• Diagnosis of metabolic and/or inflammatory disease (i.e., 
meningitis/encephalitis) 
• Any other obvious brain pathology 
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3.2.1.2 Fixed brains 
 
The cats that formed this part of the study came from two different routes. 
Some of them were pet cats that were patients of the Hospital for Small 
Animals at the RDSVS, while others were from a shelter in Scotland. Owner 
and/or shelter consent for the donation and use of the cats’ bodies for research 
was obtained at the time of euthanasia in all cases. No cats were euthanised 
specifically for this study, rather due to their advanced age, to chronic diseases 
where further treatment would not improve their quality of life, or if the cats had 
undesirable behavioural problems (i.e., untreatable aggression) that would 
impede their rehoming. Brains were collected at routine necropsy at the 
Pathology Department of the RDSVS. Of note, some brains of cats over 10 
years old were collected several years before this study started. No information 
other than being of over 10 years of age was available for these brains, (e.g., 
breed, sex, or exact age). However, they were all clinical patients attending 
the Hospital for Small Animals at the RDSVS that were euthanised because of 
terminal disease. After collection, brains were fixed by immersion, by placing 
them inside large plastic containers filled with approximately 200 ml of 10% 
formalin for no less than one week. 
 
 
3.2.2 Grouping of cats 
 
Cats of all ages were recruited. Since the exact age of some of the cats was 
less certain, particularly in those cats coming from the shelter, age groups were 
created following the American Association of Feline Practitioners (AAFP) and 
the American Animal Hospital Association (AAHA) life stages guidelines (Table 
3.2)148. In addition, this allowed the assessment of neuroanatomical changes 
at the different life stages and to determine whether there were differences 
between them.  
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Table 3.2 Grouping of cats. Cats were grouped into different categories according to 
their age following the American Association of Feline Practitioners (AAFP) and the 
American Animal Hospital Association (AAHA) life stages guidelines 
 
Category Age Number of cats CDS 
Kitten 0 to 6 months n = 0 n = 0 
Junior 7 months to 2 years n = 12 n = 0 
Prime 3 to 6 years n = 13 n = 0 
Mature 7 to 10 years n = 21 n = 0 
Senior 11 to 14 years n = 17 n = 2 
Super Senior 
(Geriatric) 
15 years and over n = 11 n = 2 
 
 
3.2.3 1.5T MR image acquisition 
 
Since this study proposes the use of MR imaging as a clinical tool for the 
diagnosis of CDS in cats, it was logical to use equipment that is routinely used 
by clinicians. Even though there are more powerful MR imaging scanners that 
provide higher resolution and better image quality (i.e., 3T and 7T), the 
decision to use a 1.5T in the present study was based on this MRI scanner 
being the most commonly used in veterinary practice for diagnostic purposes. 
 
Dorsal, sagittal, and transversal T1-weighted (i.e., images produced by using 
short time to echo [TE; the time elapsed between the delivery of the 
radiofrequency and obtaining the signal] and repetition time [TR; the amount 
of time elapsed between successive pulsations that are applied to the same 
slice]. On T1-weighted images, cerebrospinal fluid (CSF) spaces are dark) and 
T2-weighted sequences (i.e., images produced by using longer TE and TR 
times. On T2-weighted images, CSF spaces are bright) for both in vivo and 
post-mortem brains were taken using a 1.5 Tesla MRI scanner (Philips Intera, 
Philips Healthcare™, Reigate, Surrey, UK and Siemens Magnetom Avanto, 
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Figure 3.3 Containers used for the acquisition of MRI scans of the fixed brains. 
Brains were placed inside plastic containers filled with formalin, and plastic straps 
were placed around the brains to prevent them from floating and to minimise 
movement during the scanning procedure    
Siemens Healthineers™, Erlangen, Germany). For this, scans of the whole 
head were obtained from anesthetised live cats. Fixed brains were put into 
plastic containers with plastic lids, filled with formalin; plastic straps were 
placed around the brains to prevent them from floating and to minimise 







3.2.4 Image assessment 
 
Images were assessed using Horos™ DICOM viewer v3.3.6 for Mac OS by 
two different people. The first observer (OD) measured all the in vivo scans, 
and the second observer (author) measured all the post-mortem scans. In 
order to accurately identify each of the structures, anatomical landmarks were 
determined with the help of an ECVIM Board-certified veterinary neurologist 
(KMH). Both observers measured the first three scans together. To minimise 
variability and to ensure consistency, a printed guide with a picture of the 
annotated brain regions and the description of the anatomical landmarks with 
the desired structures outlined was created and given to both observers. 
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Since CSF spaces are brighter on T2-weighted images, the area of the lateral 
ventricles was measured on this sequence, as well as the interthalamic 
adhesion thickness. The rest of the measurements were assessed on T1-
weighted images. 
 
Nota bene: Both observers remained blinded throughout the image 
assessment. The age of the cats was not disclosed until all the areas were 
measured in all the cats, and these were grouped into the different age 
categories for data analysis. 
 
3.2.4.1 Frontal lobe area 
 
Frontal lobe areas were measured in the T2-weighted sagittal sequence in the 
slice where the interthalamic adhesion was visible. Using the free-hand 
drawing tool, the frontal lobe was outlined by drawing a line following the 
cruciate sulcus until the anterior commissure; at this point the line was drawn 
in the ventral direction, finishing at the bottom of the cortex, and outlining, in 
the rostral direction, the lobe until the starting point, without including the 
olfactory bulb (Figure 3.4A). 
 
 
Figure 3.4 Examples of measurements taken on T2 sagittal sequence from a) frontal 
(left) and occipital (right) lobes areas; and b) total sagittal brain area 
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3.2.4.2 Occipital lobe area 
 
Occipital lobes were measured in the T2-weighted sagittal sequence in the 
slice where the interthalamic adhesion is visible. Using the free-hand drawing 
tool, the occipital lobe was outlined by drawing a straight line starting at the 
level of the rostral side of the rostral/superior colliculus, continuing in the dorsal 
direction to the top of the cortex; then continuing in the caudal direction, 
outlining the lobe until the starting point, excluding the cerebellum and the 
rostral/superior colliculus (Figure 3.4A). 
 
3.2.4.3 Total sagittal brain area 
 
The total sagittal brain area was measured in the T2-weighted sagittal 
sequence in the same slice as the frontal and occipital lobes were measured. 
Using the free-hand drawing tool, the total sagittal brain area was outlined by 
drawing a line around the brain, including the cerebellum (Figure 3.4B). 
 
3.2.4.4 Temporal lobe area 
 
Temporal lobes were measured in the T2-weighted transversal sequence in 
the slice where the third ventricle appears for the first time. Using the free-hand 
drawing tool, the temporal lobes were outlined by drawing a line following the 
rhinal sulcus until the white matter; continuing in the ventral direction to the 
bottom of the cortex, outlining the lobe until the starting point (Figure 3.5A). 
This was measured in both hemispheres. 
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Figure 3.5 Examples of measurements taken on a) T1 transversal sequence of both 
temporal lobes; and b) T2 transversal sequence of the hippocampal area of both 
hemispheres 
 
3.2.4.5 Hippocampal area 
 
The hippocampal area was measured in the T2-weighted transversal 
sequence in the slice where the mesencephalic aqueduct and the 
rostral/superior colliculus are visible. Using the free-hand drawing tool, the 
hippocampal area was outlined by drawing a line around the hippocampus in 
both hemispheres (Figure 3.5B).  
 
3.2.4.6 Left and right hemispheres area 
 
Both hemispheres were measured in the T2-weighted dorsal sequence in the 
slice where the caudal/inferior colliculus is visible. Using the free-hand drawing 
tool, the hemispheres area was outlined by drawing a line around the left and 
the right hemispheres, separately, excluding the caudal/inferior colliculus and 
the cerebellum (Figure 3.6A).  
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Figure 3.6 Examples of measurements taken on a T2 dorsal sequence of a) both 
hemispheres area; and b) total dorsal brain area 
 
3.2.4.7 Total dorsal brain area  
 
Total dorsal brain area was measured in the T2-weighted dorsal sequence in 
the same slice as the hemisphere areas were measured.  Using the free-hand 
drawing tool, the total dorsal brain area was outlined by drawing a line around 
the whole brain, including the cerebellum (Figure 3.6B).  
 
3.2.4.8 Lateral ventricles area 
 
The area of the lateral ventricles was measured in the T1-weighted transversal 
sequence in the same slice as the interthalamic adhesion thickness was 
measured. Using the free-hand drawing tool, both lateral ventricles were 
outlined (Figure 3.7). 
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3.2.4.9 Interthalamic adhesion thickness 
 
Interthalamic adhesion thickness was measured in the T1-weighted 
transversal sequence in the slice of its maximum height224. Using the straight-
line tool, the interthalamic adhesion length was measured by drawing a dorso-




3.2.4.10 Transversal brain height 
 
Figure 3.7 Example of measurements taken on a T1 transversal sequence of the 
lateral ventricles area  
 
Figure 3.8 Example of measurements taken on a T1 transversal sequence of the 
interthalamic adhesion length and transversal brain height  
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The transversal brain height was measured in the T1-weighted transversal 
sequence in the same slice as the interthalamic adhesion thickness and lateral 
ventricles were measured224. Using the straight-line tool, a line was drawn 
measuring at midline, from the top to the bottom of the lobes, excluding the 
pituitary gland (Figure 3.8). 
 
3.2.4.11 Calculation of the total transversal brain area 
Since the total transversal brain area was not measured, it had to be calculated 
using Equation 3.1. This equation was obtained from the standard geometry 
equation to calculate the area of an ellipse (i.e., A = 𝜋 ab) created by 
Archimedes; however, this had to be modified using a three-equation system 
due to having two unknown variables: 
 






}       Equation 3.1 
 
where, 
A3 is the estimated total transversal brain area 
A1 is the total dorsal brain area 
A2 is the total sagittal brain area 
b2 is the transversal brain height 
 
3.2.4.12 Calculation of ratios 
 
For accuracy and to minimise for breed variability (e.g., big breeds of cats 
having larger brains), corrections were performed by calculating ratios in 
percentages by using Equation 3.2. This was done by dividing the area of each 
structure by the total brain area of the same plane (e.g., dividing the frontal 
lobe ratios by the total sagittal brain area, and multiplying the result by 100 to 
obtain a percentage). For this, frontal (FROr) and occipital lobes (OCCr) ratios 
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were obtained using the total sagittal brain area; hemispheres ratio (HEMr) 
was obtained using the total dorsal brain area; and the temporal lobes (TEMr), 
hippocampal (HIPr), and lateral ventricles ratios (LVr) were obtained using the 
estimated total transversal brain area. For bilaterally symmetrical structures 
(i.e., temporal lobes, hippocampus, hemispheres, and lateral ventricles), both 
measurements were added to each other and the resulting sum was used to 
estimate the ratios. Finally, interthalamic adhesion ratio (ITAr) was obtained 
using the interthalamic adhesion length and transversal brain height. 
 
 
𝑅𝑎𝑡𝑖𝑜 % = (
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒 
𝑇𝑜𝑡𝑎𝑙 𝑏𝑟𝑎𝑖𝑛 𝑎𝑟𝑒𝑎




3.2.5 Data analysis 
 
Data were analysed using Minitab® v19.2020.1 statistical software for 
Windows. 
 
Data were analysed for both datasets combined (i.e., in vivo and post-mortem 
MR images) and separately.  
 
Anderson-Darling tests were performed to assess normality. Non-normal data 
were transformed using Box-Cox transformation or Johnson transformation, 
as appropriate. Bartlett tests for equal variances were performed, with 95% 
confidence level, assuming normal distribution. Non-parametric tests were 
performed in the variables in which transformation failed. 
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3.2.5.1 Differences in the size of structures between age groups 
 
To determine whether there were differences in the size of the structures in 
the different age groups, one-way ANOVA were performed, assuming equal 
variances (if applicable) with two-sided 95% confidence interval (CI) and a 
significance level of α = 0.05. To determine differences between groups, Tukey 
tests and Games-Howell post-hoc tests were performed for those structures 
that showed statistically significant differences in the one-way ANOVA. In 
addition, non-parametric Kruskal-Wallis tests were performed to assess 
differences in non-normal data. 
 
3.2.5.2 Sex-related differences in the size of structures 
 
Since there were only three intact males and no intact female cats, intact and 
neutered males were grouped together and were compared against the female 
cats. To determine whether there were sex-related differences in the size of 
the structures, two-sample t-tests were performed, with a 95% confidence level 
and a hypothesized difference of zero, assuming equal variances. Non-
parametric Mann-Whitney tests were performed to assess differences in non-
normal data. 
 
3.2.5.3 Differences in the size of structures between cats with and 
without CDS 
 
To determine differences in the size of the structures between cats with and 
without CDS, cats with CDS were compared to the cats without CDS in the 
same age-groups; since cats with CDS were in the Senior and Super Senior 
groups, these cats were compared against the cats without CDS in these two 
same groups. Two-sample t-tests were performed, as described previously. 
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3.2.5.4 Correlations between the size of the structures, age, and 
cognitive status 
 
Spearman rank correlations were performed to determine whether there were 
correlations between the size of the different structures, the age groups and 
cognitive status (i.e., cats with and without CDS). For this, cats’ ages were 
used as decimals (e.g., one year six months corresponded to 1.5 years) 
instead of being grouped into categories. 
 
3.2.5.5 Differences between in vivo and post-mortem scans 
 
To determine differences between in vivo and post-mortem scans, two-sample 
t-tests were performed, as described previously. Given that there were no 
Junior cats in the post-mortem database this group was removed from the in 
vivo dataset; hence, only Prime, Mature, Senior and Super Senior groups were 
compared.  
 
3.2.5.6 Inter-rater reliability 
 
To assess inter-rater reliability between both observers (i.e., one measuring in 
vivo scans and another measuring post-mortem scans) Kendall’s coefficients 
for attribute agreement analysis were performed, with 95% confidence level. 
For this, the MRI scans of five cats were selected at random and both 
observers measured all the structures, as described above, independently. 
The data obtained from the measurements were compared to determine 
whether there was an agreement between the observers and to confirm that 
this agreement was not attributed to chance.
Results 
 
Chapter 3: The use of 1.5T Magnetic Resonance imaging for the assessment of 
brain atrophy and other age-related brain changes in cats







3.3.1.1 In vivo and post-mortem brain scans 
 
MR images from a total of 74 live cats and fixed cat brains were assessed. 
Most of the cats were non-pedigree cats (77%; n = 57) with 23% (n = 17) being 
pedigree breeds. Most of the cats were neutered males (55.4%; n = 41), 
followed by neutered females (33.8%; n = 25), and intact males (4%; n = 3); 
no intact females were present. However, the sex of some of the cats (6.8%; 
n = 5) was unknown. Ages ranged between four months and 20 years old. Of 
these cats, 12 were in the Junior group, 13 in the Prime, 21 in the Mature, 17 
in the Senior, and 11 in the Super Senior. 
 
3.3.1.2 In vivo scans 
 
The retrospective database search resulted in 90 live cats that had undergone 
MR imaging of their brain. After inspection of the scans and following the 
exclusion criteria, MR images from a total of 47 cats were included in this 
study. Most of the cats (66%; n = 31) were non-pedigree cats (e.g., domestic 
shorthair [DSH; n = 28]; domestic longhair [DLH; n = 1]; and domestic semi 
longhair [n = 2]), with 34% (n = 16) being pedigree breeds (e.g., Bengal [n = 
1]; Birman [n = 1]; British shorthair [n = 2]; Burmese [n = 2]; Burmilla [n = 1]; 
Maine Coon [n = 2]; Norwegian Forest [n = 1]; Oriental [n = 1]; Persian [n = 1]; 
Ragdoll [n = 2]; Siamese [n = 1]; and Siberian [n = 1]). Most of the cats (66%; 
n = 31) were neutered males, followed by neutered females (27.7%; n = 13), 
and intact males (6.3%; n = 3); there were no intact female cats. Ages ranged 
from four months to 17 years. Of these cats, 12 were in the Junior group, 10 
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3.3.1.3 Post-mortem scans 
 
A total of 27 cat brains were assessed. The majority of cats (96.3%; n = 26) 
were non-pedigree cats and only one cat was a pedigree breed (a Bengal cat). 
Most of the cats (44%; n = 12) were neutered females, followed by neutered 
males (37%; n = 10); while the sex of the remaining 20% (n = 5) of cats was 
unknown. Ages ranged from four to 20 years old. Of these cats, none were in 
the Junior group, three in the Prime, 12 in the Mature, four in the Senior, and 
eight in the Super Senior. Finally, four of these cats were diagnosed with CDS 
before euthanasia (see Chapter 4); these cats were in groups Senior (n = 2) 
and Super Senior (n = 2). 
 
 
3.3.2 Differences in the size of structures between age 
groups 
 
One-way ANOVA and Kruskal-Wallis tests were performed to determine 
differences in the size of the structures in the different cat age groups. Tukey 
tests and Games-Howell post-hoc tests were performed to determine 
differences between groups.  
 
3.3.2.1 In vivo and post-mortem scans 
 
One-way ANOVA showed statistically significant differences in the size of the 
HEMr (F4 = 2.98, p = 0.026) and the OCCr (F4 = 5, p = 0.003) between the age 
groups (Table 3.3). Tukey tests demonstrated that the differences in the HEMr 
were between the Junior and Super Senior age groups (Difference of means 
= 3.38; SE of difference = 1.09; 95% CI [0.30, 6.47]; t = 3.09, p = 0.024), with 
cats in the Junior group having smaller HEMr than cats in the Super Senior 
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Figure 3.9 Differences in the hemispheres ratios (HEMr) in the different age 
groups. The size of the hemispheres tended to increase with age and statistically 
significances were found between the Junior and the Super Senior groups (p = 0.024) 
Table 3.3 Differences in the size of the structures in the different age groups. One-
way ANOVA was performed to determine whether there were differences in the size 
of the structures between age groups 
Structure F value DF p value 
ITAr 1.59 4 0.187 
LVr 1.15 4 0.344 
TEMr 0.28 4 0.866 
Total transversal area 0.82 4 0.516 
HEMr 2.98 4 0.026 
Total dorsal area 0.49 4 0.746 
OCCr 5 4 0.003 
FROr 0.32 4 0.862 








Games-Howell tests demonstrated that the statistically significant differences 
in the OCCr were between groups Junior and Prime age groups (Difference of 
means = -1.801; SE of difference = 0.558; 95% CI [- 3.491, - 0.112], t = -3.23, 
p = 0.034); and between the Junior and Super Senior groups (Difference of 
means = -2.238; SE of difference = 0.653; 95% CI [-4.265, -0.211], t = -3.43, 
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Figure 3.10 Differences in the occipital lobe ratios (OCCr) in the different age 
groups. The size of the occipital lobe tended to decrease with age and statistically 
significant differences were found between groups Junior and Prime (p = 0.034); and 
between Junior and Super Senior (p = 0.027) 
p = 0.027), with cats in the Junior group having larger OCCr than cats in the 







Furthermore, there were some trends in the means of some structures 
between the Junior and Super Senior age groups (Table 3.4), including the 
HEMr, OCCr, and total sagittal brain area (Figure 3.11). The Junior group were 
shown to have larger OCCr and total sagittal brain area than the Super Senior 
group; in contrast, the Super Senior group had larger HEMr than the Junior 
group. The complete list with the means of all structures and age groups with 
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Figure 3.11 Differences in the total sagittal brain areas in the different age 
groups. The total sagittal brain area tended to decrease with age 
Table 3.4 Comparison of means between the Junior and the Super Senior groups for 
hemisphere ratio (HEMr), occipital ratio (OCCr), and Total sagittal brain area. Only 
the lowest and the highest means of each structure are shown 
 
Structure Lowest mean Highest mean 
 Age group (n) Mean Age group (n) Mean 
HEMr Junior (11) 33.37 Super Senior (9) 36.75 
OCCr Super Senior 
(11) 












Kruskal-Wallis tests showed no differences in the size of the hippocampus 
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3.3.2.2 In vivo scans 
 
One-way ANOVA showed statistically significant differences in the size of the 
LVr between the age groups (F4 = 5.96, p = 0.001) (Table 3.5). Games-Howell 
tests demonstrated differences between the Junior and Mature age groups 
(Difference of means = 0.2277; SE of difference = 0.0770; 95% CI [0.0056, 
0.4498]; t = 2.96, p = 0.042); between Prime and Mature groups (Difference of 
means = 0.3361; SE of difference = 0.0858; 95% CI [0.0887, 0.5835]; t = 3.92, 
p = 0.004); between Prime and Senior groups (Difference of means = 0.2817; 
SE of difference = 0.0835; 95% CI [0.0408, 0.5226]; t = 3.37, p = 0.015); and 
between the Prime and Super Senior groups (Difference of means = 0.357; 
SE of difference = 0.114; 95% CI [0.027, 0.687]; t = 3.12, p = 0.028), with the 
Junior and Prime groups having smaller LVr than the rest of the age groups. 
(Figure 3.12). The complete list with the means of all structures and age groups 
with standard deviations and 95% CI can be found in Appendix 3.2. 
  
Table 3.5 Differences in the size of the structures in the different age groups in the 
live cats. One-way ANOVA was performed to determine whether there were 
differences in the size of the structures between age groups in the in vivo scans 
Structure F value DF p value 
ITAr 2.13 4 0.095 
LVr 5.23 4 0.008 
TEMr 0.50 4 0.733 
HIPr 1.07 4 0.387 
Total transversal area 0.15 4 0.961 
HEMr 0.93 4 0.459 
Total dorsal area 0.28 4 0.886 
OCCr 1.20 4 0.328 
FROr 0.81 4 0.529 
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Figure 3.12 Differences in the lateral ventricles ratios (LVr) in the different age 
groups of live cats. The LVr tended to increase with age and statistically significant 
differences were found between groups Junior and Mature (p = 0.042); Prime and 
Mature (p = 0.004); Prime and Senior (p = 0.015); and between Prime and Super Senior 






3.3.2.3 Post-mortem scans 
 
One-way ANOVA showed no statistically significant differences in the size of 
any of the structures between the age groups (Table 3.6). The complete list 
with the means, standard deviations and 95% CI can be found in Appendix 
3.3. 
 
Table 3.6 Differences in the size of the structures in the different age groups in the 
fixed brains. One-way ANOVA was performed to determine whether there were 
differences in the size of the structures between age groups in the post-mortem scans  
Structure F value DF p value 
ITAr 0.99 3 0.418 
LVr 1.44 3 0.262 
TEMr 0.50 3 0.689 
HIPr 2.09 3 0.136 
Total transversal area 0.89 3 0.466 
HEMr 0.22 3 0.882 
Total dorsal area 0.03 3 0.993 
OCCr 1.03 3 0.399 
FROr 0.29 3 0.835 
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While it was not statistically significant, the ITAr (Figure 3.13A) and the LVr 
(Figure 3.13B) were smaller in the Super Senior group (16.878 ± 2.202; and 
4.302 ± 1.428, respectively) when compared to the Prime group (19.025 ± 






Both the HIPr (Figure 3.14A) and the OCCr (Figure 3.14B) tended to increase with 
age and then decrease in the Super Senior group; however, these were not 








Figure 3.13 Differences in the interthalamic adhesion ratios (ITAr) and lateral 
ventricles ratios (LVr) in the different age groups of fixed brains. While no 
statistically significant differences were found, both a) the ITAr; and b) the LVr tended 
to decrease more in the Super Senior group 
Figure 3.14 Differences in the hippocampal ratios (HIPr) and occipital lobe ratios 
(OCCr) in the different age groups of fixed brains. Despite not being statistically 
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3.3.3 Sex-related differences in the size of structures  
 
Two-sample t-tests and Mann-Whitney tests were performed to determine 
differences between sexes in the size of the structures. These were performed 
by grouping all female cats and comparing them to all male cats, regardless of 
their age. 
 
3.3.3.1 In vivo and post-mortem scans 
 
The two-sample t-tests demonstrated statistically significant sex-related 
differences in the total dorsal brain area (t58 = -2.95, p = 0.005) (Figure 3.15A); 




Figure 3.15 Sex-related differences in the total dorsal and sagittal brain areas. Male 
cats had larger a) total dorsal (p = 0.005); and b) total sagittal brain areas (p < 0.001) 
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Table 3.7 Sex-related differences in the size of the structures. Two-sample t-tests 
were performed to determine whether there were sex-related differences in the size 
of structures  
Structure T value DF p value 
ITAr -0.32 63 0.749 
LVr 0.94 55 0.350 
TEMr 0.11 38 0.911 
Total transversal area -1.05 56 0.297 
HEMr 1.95 57 0.056 
Total dorsal area -2.95 58 0.005 
OCCr -0.87 51 0.391 
FROr 0.22 63 0.826 
Total sagittal area -4.16 63 <0.001 
 
 
Male cats had larger dorsal (14.3 ± 1.45) and sagittal brain areas (11.75 ± 
1.03) than female cats (13.13 ± 1.5; and 10.66 ± 1.03, respectively). There 
were no differences in the ITAr, LVr, TEMr, total transversal area, HEMr, 
OCCr, and FROr between female and male cats. The complete list with the 
means of all structures, with standard deviations and SE of the means can be 
found in Appendix 3.4. 
 
Mann-Whitney tests showed no differences in the size of the hippocampus 
between female and male cats (W = 1101, p = 0.750).  
 
3.3.3.2 In vivo scans 
 
Two-sample t-tests demonstrated that there were statistically significant sex-
related differences in the HIPr (t38 = 2.04, p = 0.049); total transversal brain 
area (t38 = -2.71, p = 0.010); total dorsal brain area (t39 = -4.20, p < 0.001); and 
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Table 3.8 Sex-related differences in the size of the structures of live cats. Two-sample 
t-tests were performed to determine whether there were sex-related differences in 
the size of structures for in vivo scans 
Structure T value DF p value 
ITAr -0.02 44 0.983 
LVr 0.12 17 0.904 
TEMr -0.17 37 0.869 
HIPr 2.04 38 0.049 
Total transversal area -2.71 38 0.010 
HEMr 0.64 38 0.528 
Total dorsal area -4.20 39 <0.001 
OCCr 0.02 41 0.988 
FROr 0.12 41 0.901 
Total sagittal area -2.75 41 0.009 
 
 
Male cats had larger total dorsal brain areas (14.11 ± 1.36) (Figure 3.16A), 
total sagittal brain areas (12.071 ± 0.854) (Figure 3.16B), and total transversal 
brain areas (9.6 ± 0.894) (Figure 3.16C), than female cats (12.25 ± 1.11; 
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In contrast, female cats had larger HIPr (10.48 ± 1.5) (Figure 3.17) than male 
cats (9.51 ± 1.33). The full list of means with standard deviations and SE of 






Figure 3.16 Sex-related differences in the total dorsal, sagittal, and transversal 
brain areas of live cats. Male cats had larger a) total dorsal (p < 0.001); b) total 
sagittal (p = 0.009); and c) total transversal brain areas (p = 0.010) than the female 
cats in the in vivo dataset 
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Figure 3.17 Sex-related differences in the size of the hippocampus (HIPr) of live cats. 
Female cats had larger HIPr than male cats (p = 0.049) in the in vivo dataset 
 
3.3.3.3 Post-mortem scans 
 
The two-sample t-tests demonstrated statistically significant sex-related 
differences in the HEMr (t17 = 2.57, p = 0.020) (Table 3.9) with female cats 
having larger HEMr (37.96 ± 0.804) than male cats (36.99 ± 0.841) (Figure 
3.18).  
 
Table 3.9 Sex-related differences in the size of the structures of fixed brains. Two-
sample t-tests were performed to determine whether there were sex-related 
differences in the size of structures for post-mortem scans 
Structure T value DF p value 
ITAr -0.64 17 0.532 
LVr 1.67 16 0.115 
TEMr -0.09 16 0.928 
HIPr 0.80 16 0.437 
Total transversal area -0.24 16 0.810 
HEMr 2.57 17 0.020 
Total dorsal area -0.83 17 0.420 
OCCr 0.29 20 0.774 
FROr -0.87 20 0.395 




Chapter 3: The use of 1.5T Magnetic Resonance imaging for the assessment of 
brain atrophy and other age-related brain changes in cats
  171 
 
Figure 3.18 Sex-related differences in the size of the hemispheres (HEMr) in the fixed 







While not being statistically significant, male cats had larger total dorsal (14.83 
± 1.66), total sagittal (10.77 ± 0.914), and total transversal brain areas (11.49 
± 1.19), when compared to female cats (14.29 ± 1.14; 10.02 ± 0.841; and 11.37 
± 0.614, respectively) as reported in the live cats. In contrast, female cats had 
larger HIPr (5.236 ± 0.791) than male cats (4.962 ± 0.667). The full list of 
means with standard deviations and SE of the means for all the brain 
structures can be found in Appendix 3.6. 
 
 
3.3.4 Differences in the size of structures between cats with 
and without CDS 
 
Two-sample t-tests and Mann-Whitney tests were performed to determine 
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3.3.4.1 In vivo and post-mortem scans 
 
Two-sample t-tests showed differences between cats with and without CDS in 
the total dorsal brain area (t19 = -2.21, p = 0.040), OCCr (t24 = 2.47, p = 0.021), 
and HEMr (t18 = -2.12, p = 0.048) (Table 3.10).  
 
Table 3.10 Differences in the size of the structures in cats with and without cognitive 
dysfunction syndrome (CDS). Two-sample t-tests were performed to determine 










Cats without CDS had smaller total dorsal brain areas (13.47 ± 1.56) (Figure 
3.19A) and HEMr (35.96 ± 1.91) (Figure 3.19B) than cats with CDS (15.97 ± 





Structure T value DF p value 
ITAr -0.11 22 0.910 
LVr 0.54 18 0.595 
TEMr 0.42 18 0.677 
HIPr -0.08 18 0.937 
Total transversal area -1.42 18 0.172 
HEMr -2.12 18 0.048 
Total dorsal area -2.21 19 0.040 
OCCr 2.47 24 0.021 
FROr -1.11 24 0.277 
Total sagittal area 0.67 24 0.511 
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Figure 3.19 Differences in the total dorsal brain area and hemispheres ratios (HEMr) 
in cats with and without cognitive dysfunction syndrome (CDS). Cats with CDS had 
larger a) total dorsal brain areas (p = 0.040); and b) HEMr (p = 0.048) than cats 
without CDS 
 
Figure 3.20 Differences in the occipital lobe ratios (OCCr) in cats with and without 
cognitive dysfunction syndrome (CDS). Cats with CDS had smaller OCCr (p = 0.021) 






Furthermore, cats with CDS had smaller OCCr (9.43 ± 2.45) than cats without 
CDS (11.56 ± 1.42) (Figure 3.20). The complete list with the means of all 
structures and cognitive status with standard deviations and SE of the means 
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While not being statistically significant, cats with CDS had smaller total sagittal 
brain areas (10.73 ± 1.25), LVr (0.283 ± 0.237), and TEMr (6.741 ± 0.543) than 
cats without CDS (11.14 ± 1.11; 0.372 ± 0.220; and 7.15 ± 1.34, respectively). 
 
3.3.4.2 In vivo scans 
 
Since there were no cats with CDS in this database, this was not examined in 
the live cat data.  
 
3.3.4.3 Post-mortem scans 
 
Since there were not sufficient data, two-sample t-tests were not performed for 
ITAr, LVr, TEMr, HIPr, and total transversal brain areas. However, one-way 
ANOVA could be performed to analyse these structures, and showed no 
differences (Table 3.11). 
  
Table 3.11 Differences in the size of the structures in cats with and without cognitive 
dysfunction syndrome (CDS) in the fixed brains. One-way ANOVA was performed to 
determine whether there were differences in the size of the structures between cats 






Two-sample t-tests showed differences in the total dorsal brain areas (t7 = -
2.90, p = 0.023) (Table 3.12), which was larger in cats with CDS (15.97 ± 
0.547) when compared to cats without CDS (13.96 ± 0.907). Furthermore, 
despite not being statistically significant, cats with CDS had smaller OCCr 
(9.43 ± 2.45) and FROr (11.71 ± 1.84) than cats without CDS (10.37 ± 1.08; 
and 14.36 ± 2.83, respectively). The complete list with the means of all 
Structure F value DF p value 
ITAr 0.23 1 0.645 
LVr 0.07 1 0.803 
TEMr 0.13 1 0.729 
HIPr 0.21 1 0.664 
Total transversal area 0.05 1 0.823 
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structures and cognitive status with standard deviations and SE of the means 
can be found in Appendix 3.8. 
 
Table 3.12 Differences in the size of the structures in cats with and without cognitive 
dysfunction syndrome (CDS) in the fixed brains. Two-sample t-tests were performed 
to determine whether there were differences in the size of structures between cats 
with and without CDS on the post-mortem scans 
 
Structure T value DF p value 
HEMr -1.95 7 0.092 
Total dorsal area -2.90 7 0.023 
OCCr 0.95 10 0.363 
FROr 1.68 10 0.124 




3.3.5 Correlations between the size of the structures, age, 
and cognitive status 
 
Spearman rank correlations were performed to determine whether there were 
associations between the size of the different structures, the age groups and 
cognitive status (i.e., cats with and without CDS). 
 
3.3.5.1 Correlation between the size of structures and age 
 
3.3.5.1.1 In vivo and post-mortem scans 
 
There were weak negative linear correlations between age and total sagittal 
brain area (r = -0.252, p = 0.036) (Figure 3.21A), OCCr (r = -0.243, p = 0.043) 
(Figure 3.21B), and HIPr (r = -0.248, p = 0.05) (Figure 3.21C). Furthermore, 
moderate positive linear correlation was found between HEMr and age (r = 
0.452, p < 0.001) (Figure 3.21D). Total sagittal brain area, OCCr, and HIPr 
tended to decrease with age, while HEMr tended to increase with age. No 
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correlations were found between age and ITAr, LVr, TEMr, total transversal 






3.3.5.1.2 In vivo scans 
 
There was a weak positive linear correlation between age and LVr (r = 0.450, 
p = 0.005) (Figure 3.22); showing that LVr in live cats tended to increase with 
age. No correlations were found between age and any other brain structure in 








Figure 3.21 Correlations between age and a) the total sagittal brain area (p = 0.036), 
b) the occipital lobe ratio (OCCr; p = 0.043), c) the hippocampal ratio (HIPr; p = 0.05), 
and d) the hemispheres ratio (HEMr; p < 0.001) 
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Figure 3.22 Correlation between age and the lateral ventricles ratio (LVr). There 
was a positive correlation between age and LVr (p = 0.005) in the in vivo scans 
Figure 3.23 Correlation between age and the hippocampal ratio (HIPr). There was a 




3.3.5.1.3 Post-mortem scans 
 
There was a moderate positive linear correlation between age and HIPr (r = 
0.523, p = 0.011) (Figure 3.23); showing that HIPr in the fixed brains tended to 
increase with age. No correlations were found between age and any other 
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3.3.5.2 Correlation between the size of structures, age, and sex 
 
3.3.5.2.1 In vivo and post-mortem scans 
 
There was a weak negative linear correlation between the total sagittal brain 
area, age, and sex (r = -0.252, p = 0.036), which was larger in male cats and 
tended to decrease with age. A weak positive linear correlation was found 
between sex and HEMr, which was larger in female cats (r = 0.452, p < 0.001) 
and tended to increase with age. There were no correlations between sex and 
ITAr, LVr, TEMr, total transversal brain area, OCCr, and FROr. 
 
The total sagittal brain area tended to decrease equally in both male and 
female cats as they get older (Figure 3.24A). Similarly, HEMr tended to 






Despite not being statistically significant, the HIPr tended to decrease with age 
equally in both female and male cats (Figure 3.25A). Furthermore, ITAr tended 
to decrease slightly more in male cats (Figure 3.25B); while OCCr tended to 
decrease more in female cats (Figure 3.25C) as they get older. 
a b 
Figure 3.24 Correlations between age, sex, and a) the total sagittal brain area (p = 
0.036); and b) the hemispheres ratio (HEMr; p < 0.001) 
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3.3.5.2.2 In vivo scans 
 
There were no statistically significant correlations between the size of 
structures, age, and sex in the live cat scans; however, the cortical areas 
tended to decrease in size more abruptly with age in female than in male cats; 






Figure 3.25 Correlations between age, sex, and a) hippocampal ratios (HIPr); b) 
interthalamic adhesion ratios (ITAr); and c) occipital ratios (OCCr) 
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3.3.5.2.3 Post-mortem scans 
 
There were no correlations between the size of structures, age, and sex in the 
fixed brains. 
 
3.3.5.3 Correlation between the size of structures, age, and cognitive 
status 
 
3.3.5.3.1 In vivo and post-mortem scans 
 
There was a weak positive linear correlation between age and cognitive status 
(r = 0.379, p = 0.046), showing that as cats get older, they tended to develop 
CDS; however, this finding should be interpreted with caution as only four cats 
(from the post-mortem dataset) had a confirmed diagnosis of CDS. Further 
studies, with larger numbers of cats with CDS are needed to confirm this.  
 
There were no correlations between the size of structures and the cognitive 
status of the cats. Interestingly and, despite not being statistically significant, 
the OCCr (Figure 3.27A) and FROr (Figure 3.27B) tended to decrease more 
with age in the CDS cats, when compared to cats without CDS. 
a b 
Figure 3.26 Correlations between age, sex, and a) occipital lobe ratios (OCCr); and 
b) frontal lobe ratios (FROr) for in vivo scans 
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Figure 3.27 Correlations between age, cognitive status, and a) occipital lobe ratios 





3.3.5.3.2 In vivo scans 
 
Since there were no cats with CDS in this database, correlations between the 
size of structures, age, and cognitive status were not performed in the in vivo 
scans.  
 
3.3.5.3.3 Post-mortem scans 
 
There were no correlations between the size of structures, age, and cognitive 
status in the post-mortem scans. 
 
 
3.3.6 Differences between in vivo and post-mortem scans 
 
Two-sample t-tests showed differences in LVr (t49 = 3.46, p = 0.001), TEMr (t48 
= 2.91, p = 0.006), HIPr (t50 = -13.95, p < 0.001), total transversal brain area 
(t50 = 7.61, p < 0.001), HEMr (t51 = 6.64, p < 0.001), total dorsal brain area (t52 
= 2.37, p = 0.021), OCCr (t57 = -4.47, p < 0.001), total sagittal brain area (t57 = 
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Table 3.13 Differences between in vivo and post-mortem scans. Two-sample t-tests 
were performed to determine whether there were differences between in vivo and 
post-mortem scans 
 
Structure T value DF p value 
ITAr 0.87 56 0.387 
LVr 3.46 49 0.001 
TEMr 2.91 48 0.006 
HIPr -13.95 50 <0.001 
Total transversal area 7.61 50 <0.001 
HEMr 6.64 51 <0.001 
Total dorsal area 2.37 52 0.021 
OCCr -4.47 57 <0.001 
FROr 3.26 57 0.002 
Total sagittal area -6.55 57 <0.001 
 
 
For in vivo scans, the HIPr, OCCr, and total sagittal brain area were larger, 
and the FROr, LVr, TEMr, total transversal brain area, HEMr, and total dorsal 
brain area were smaller, when compared to the post-mortem scans (Table 
3.14). The complete list with the means of all structures with standard 
deviations and SE of the means can be found in Appendix 3.9. 
 
Table 3.14 Table of means for in vivo and post-mortem scans 
 In vivo  Post-mortem  
Structure Mean St. Dev. Mean St. Dev. 
ITAr 17.13 2.41 17.70 2.47 
LVr 1.815 0.692 2.426 0.536 
TEMr 6.58 2.06 8.00 1.16 
HIPr 9.95 1.46 5.193 0.814 
Total transversal area 9.337 0.897 11.317 0.975 
HEMr 34.15 2.33 37.522 0.948 
Total dorsal area 13.54 1.55 14.50 1.39 
OCCr 11.89 1.56 9.96 1.76 
FROr 11.75 1.25 13.87 3.43 




Chapter 3: The use of 1.5T Magnetic Resonance imaging for the assessment of 
brain atrophy and other age-related brain changes in cats
  183 
 
3.3.7 Inter-rater reliability 
 
Kendall’s coefficients for attribute agreement analysis with 95% confidence 
level showed that there was an agreement between observers’ measurements 
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This study assessed age-related structural changes in in vivo and post-mortem 
MR images from a total of 74 cat brains. Several structures showed statistically 
significant differences in size between the age groups (i.e., hemispheres, 
occipital lobe, and lateral ventricles); sexes (i.e., hippocampus, hemispheres, 
total dorsal brain area, and total sagittal brain area); and cognitive status (i.e., 
occipital lobe and total dorsal brain area). Furthermore, all brain 
areas/structures, except the interthalamic adhesion, were statistically different 
between in vivo and post-mortem scans. For this reason, the advantages and 
disadvantages of both in vivo and post-mortem MR imaging will be discussed 
first, as well as the effect that chemical fixatives have on brain tissue, which 
may explain many of these differences. 
 
 
3.4.1 Differences between in vivo and post-mortem MR 
imaging and the effect of fixation on brain tissue 
 
Two-sample t-tests showed statistically significant differences between the in 
vivo and post-mortem MR images in all the structures, except in the 
interthalamic adhesion. 
 
Magnetic resonance imaging is a powerful diagnostic tool used both in vivo 
and post-mortem to examine individuals and tissue samples, where it has 
advantages and disadvantages in both situations.  
 
In vivo MR imaging is widely used in longitudinal studies for which several 
scans from the same individuals are needed at different time-points. It can also 
be used in studies that require a number of different assessments from the 
same live animals, such as MR images plus behavioural changes227. In order 
to perform in vivo MR imaging in animals, they need to be anesthetised and 
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Figure 3.28 Comparison of in vivo and post-mortem MRI scans. Post-mortem 9.4T 
MRI scans provide better image quality and resolution as seen in this comparison of 
in vivo and post-mortem sagittal sections of a rat’s brain. Image taken from Oguz et 
al. 2013 
then restrained. While this reduces movement artefacts, it increases the 
appearance of confounding factors derived from the exposure to stress and 
drugs227. This also has repercussion in the time allowed for the acquisition of 
the images, which is limited due to animals being anaesthetised, and can result 
in scans with poor image quality and resolution227.  
 
In contrast, scans of post-mortem tissue use longer acquisition times so they 
have higher resolution and improved image quality227, 228 (Figure 3.28); in 
addition, contrast agents can be perfused into the tissue, enhancing 
contrast227. However, the major disadvantage of using post-mortem MR 
imaging is proving its validity, as there is still uncertainty about the potential 
morphological changes caused by death and/or the fixation process227 such 
as shrinkage of the tissue, alterations of T1 and T2 relaxation times, and 
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Chemical fixatives, including formalin, preserve tissues after slowly 
disseminating into it. The decomposition process is prevented by the effect of 
the cross-linking between formalin and proteins in the tissue229. However, 
since formalin disrupts water motion within the tissue, there may be alterations 
in the MR features229.  
 
The effect of death and fixation in different tissues has been studied by using 
Diffusion Tensor Imaging (DTI), which is a type of MR imaging that measures 
the diffusion of water within the tissues. For this, DTI evaluates diffusion 
anisotropy and water diffusivity. Anisotropy assesses how water molecules 
“move” within the tissue. While under normal conditions water diffuses freely, 
“obstacles” within the healthy tissue (e.g., cell membranes) or unhealthy tissue 
(e.g., vascular disease, neoplasia) may impede and/or alter a free diffusion of 
water leading to variations in anisotropy230. While anisotropy assesses how 
well water “moves” within the tissue, diffusivity assesses the magnitude of this 
movement231.  
 
Water content in the brain varies between regions, with most of it 
corresponding to cerebrospinal fluid (CSF; 99%), followed by grey matter 
(80%) and white matter (70%)228. Interestingly, while anisotropy is almost 
identical in both in vivo and post-mortem scans, water diffusivity is known to 
decrease in fixed post-mortem tissues232. Of note, water diffusivity decreases 
more in white matter than in grey matter after fixation232; in addition, fixation 
also reduces the mobility of water between grey and white matter228. It has 
been suggested that this lack of water diffusion is due to limited water motility 
and the degradation of the tissue structure, particularly in tissue that was fixed 
by immersion in formalin228, as opposed to perfused brains232. 
 
The post-mortem interval (PMI) is the time between when an individual dies 
and the beginning of the fixation process. It is believed that an increased PMI 
reduces water diffusion and anisotropy, as well as T1 and T2 relaxation times, 
both of which rely on water mobility within the tissue228. The T1 relaxation time 
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measures longitudinal relaxation (i.e., how quickly the excited protons return 
to stability and realign with the magnetic field after being hit by the 
radiofrequency; while T2 relaxation time measures transverse relaxation (i.e., 
the rate at which the excited protons dephase from each other). Studies have 
suggested that this reduction in T1 and T2 relaxation times might instead be 
due to dehydration of the tissue caused by fixation and whether this was 
performed by immersion or perfusion233. Initial reductions in both T1 and T2 first 
occur soon after fixation begins and stabilise after 3-4 weeks234, 235. Moreover, 
it has been proposed that these changes can potentially be reversed by 
rehydrating the tissue in phosphate-buffered saline (PBS) after fixation has 
been completed229.  
 
The effect of fixation has been studied in both immersed and perfused tissues. 
A study with mice brains showed that the brains swell soon after being 
immersed in 10% formalin, with a subsequent reduction/shrinkage in both size 
and weight236. This is believed to be due to a sudden increase in water content, 
and was more evident in the cerebral cortex, while the cerebellum was less 
affected236. After 24 hours of fixation, the mice brains gained on average of 
54% of their initial “fresh” weight; however, this swelling quickly reversed within 
the first nine days, with a further slower reversion over time, reaching their 
original “fresh” weight after 213 days236. Interestingly, while changes in 
size/weight were consistent between mice brains, their shapes remained 
unchanged236. Finally, these physical changes were more obvious in the brains 
of younger mice than in older individuals236, which has also been reported in 
other mammals, such as macaques237, dogs238, and humans239. 
 
Fixation by perfusion has advantages and disadvantages over fixation by 
immersion. Perfusion fixation is completed in less time and it does not affect 
the histological quality of the tissue240; however, it is a more expensive 
technique that requires training and expertise240.  As reported for fixation by 
immersion, perfusion promotes swelling of the tissue, increasing its weight237; 
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however, unlike with immersion, perfusion can lead to uneven fixation if 
vascular disease is present240.  
 
The effect of fixation over time was reported in a study that assessed changes 
in human brains before and during fixation. For this, brains were extracted and 
immersed in 20% formalin; several MR scans were then obtained at different 
time points to assess the progression of the fixative. After the first 18 hours of 
fixation, a hyperintense band of formalin was detected delimiting the whole 
surface of the brain in T1 sequences. This band increased in size over time, 
from the surface to the centre of the brain, as the formalin progressed through 
the tissue, reaching a complete diffusion after 14.8 weeks of fixation. In 
addition, reductions in both T1 and T2 relaxation times were observed in grey 
and white matter. Interestingly, the reduction in T1 relaxation times and the 
diffusion of fixative were both simultaneously progressive. Finally, water 
diffusivity remained unchanged before and during fixation241.  
 
One of the major physical changes caused by death and fixation, particularly 
in the brain, is the collapse of CSF spaces. The ventricles increase their size 
with age, which is used as an indicator of brain atrophy and predictor of AD35; 
however, the opposite has been reported to occur in fixed tissue. In a study 
that assessed anatomical changes in MR images of post-mortem fixed human 
brains, the size of the ventricles in the fixed brains were significantly smaller 
than those in living patients. This study found that the ventricles of the fixed 
brain of a 61-year-old person were similar in size to those of a 25-year-old 
living person, instead of exhibiting the age-related ventricle dilation normally 
seen in people in their sixties228. Another study in human brains that assessed 
MR changes pre- and post-fixation by immersion in formalin showed that the 
ventricles expanded  after extraction, with the whole brain expanding up to 
5.2% after one day of formalin fixation242. These changes are thought to result 
from pressure changes inside and outside the skull, plus the osmotic pressure 
of the formalin242. However, the total brain volume then shrank up to 8.1%, 
returning back to normal over time242.  
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The effect of fixation on the size and shape of the brain has also been 
evaluated in a study of rat brains that assessed volumetric differences between 
in vivo and post-mortem MR images  at three different time points227 (i.e., one 
in vivo and two post-mortem after perfusion fixation). This study showed there 
were no significant changes in the volumetric measurements of the total brain 
volume, the ventricles, the neocortex, the hippocampus, the corpus callosum, 
or the cerebellum227. Furthermore, there was a correlation between age, the 
brain volume, body weight, and brain weight, all being shown to increase with 
age; of note, these were similar in both in vivo and in post-mortem scans227.  
 
Interestingly, similar alterations have also been reported to occur as a result of 
normal ageing and in AD. In normal ageing, DTI has shown a reduction of 
white matter anisotropy that is believed to be caused by myelination 
disturbances, alterations of the microtubule structure and/or changes in axon 
density231. Similarly, in AD, there are reductions in anisotropy and increased 
water diffusivity due to myelination disturbances; however, the 
neuroinflammation and glial reaction resulting from cell death may lead to a 
decrease in both anisotropy and water diffusivity231. 
 
In conclusion, the available evidence suggests that there may be slight 
differences between in vivo and post-mortem MR images. This is supported 
by the current study, which found that all brain areas/structures (other than the 
interthalamic adhesion) were statistically different between in vivo and post-
mortem MR scans. Each method has advantages and disadvantages, and 
both have been shown to be equally useful and valid tools for the assessment 
of anatomical/structural changes and for the diagnosis of disease; however, 
they cannot be used interchangeably. 
 
Finally, combining the datasets from live cats and fixed cat brains has its own 
advantages and disadvantages. For instance, combining datasets increases 
the sample size of the study, making it more likely to find significant differences 
between age groups. On the other hand, it can be argued that death and the 
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fixation process may produce several changes in the post-mortem tissue, 
making the fixed brains dataset unsuitable for combining with the in vivo 
dataset. However, as discussed above, there is a plethora of evidence 
showing that these changes are minimal and that using fixed tissue is as valid 
as using scans from live individuals. 
 
 
3.4.2 Differences in the size of structures between age 
groups 
 
The size of several structures was assessed and compared between age 
groups, showing differences in the occipital lobe, the hemispheres, and the 
lateral ventricles. In addition, correlations with age were demonstrated for the 
occipital lobe, the hemispheres, the lateral ventricles, the hippocampus, and 
the total sagittal brain area. 
 
Normal ageing has an impact on brain anatomy and on its different structures. 
Atrophy of the frontal cortex is the first and most common age-related change 
reported in dogs222, 223 and humans31, 32. While other brain regions are affected 
by age in humans, reports have shown that these are more subtle, including 
atrophy of the temporal and parietal cortices31, 32. Interestingly, in the present 
study, cats were shown to develop atrophy of the occipital cortex, which in 
humans is the least affected by ageing31. This might be the result of combining 
datasets from in vivo and post-mortem scans, as atrophy of the occipital lobe 
was not found in the in vivo scans. Alternatively, this might be true age-related 
atrophy that differs from what has been previously reported in other species. 
While no statistical difference was found in the size of the occipital lobe 
between the different age groups in the post-mortem scans, there was a clear 
trend showing an age-related atrophy of this lobe (being more evident in the 
Super Senior group), which was negatively correlated with age. Furthermore, 
cats with CDS had smaller occipital lobes than cats without CDS, suggesting 
that this lobe could be the first brain region affected by ageing and CDS in cats. 
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The progressive increase in the size of the hemispheres and its positive 
correlation with age are difficult to explain, as the size of the hemispheres was 
expected to decrease with age instead. In humans, the hemispheres remain 
unchanged from ages 20 to 50 years old29, although an age-related asymmetry 
has been reported, showing that the left hemisphere tends to be larger than 
the right one32. While hemisphere asymmetry was not assessed in the current 
study, it has been reported previously in cats40; however, unlike in humans, it 
is the right side of the cat brain that is larger than the left one. Since very young 
cats were included in this study (the youngest was four months old), it is 
possible that the brains of these cats had not been fully developed, leading to 
a significant difference between these and older cats with more developed 
brains. Studies in dogs support this hypothesis; a study performed in dogs at 
different stages of development showed there is a linear increase of 10-19% 
in brain volume from birth to six weeks of age, followed by a gradual growth of 
up to 20% into adulthood238. In humans, full development of the brain occurs 
around 22 years of age243, with peaks of growth at 11 and 15 years old244. 
According to the International Cat Care and their equivalence table between 
human and cat years, 22 human years correspond to 18 to 24 months of age 
in the cat, which is the Prime group of this study148. Another potential 
explanation suggests that the enlargement of the hemispheres with age might 
not necessarily be true. Hemispheres were measured on the dorsal plane in 
which they occupy most of the image, with only the cerebellum being excluded 
from the measurement (see Figures 3.6A and B in the Material and Methods 
section). While the size of the cerebellum was not measured for this study, it 
was included to measure the total dorsal brain area, and thus used for 
calculating the ratios for the hemispheres. It is therefore possible that there 
were changes in the size of the cerebellum, including shrinkage due to ageing 
and/or fixation process, which affected the ratios used for the analysis.  
 
Assessment of in vivo scans showed differences in the size of the lateral 
ventricles between age groups, which was positively correlated with age. Both 
Junior and Prime groups had smaller lateral ventricles when compared to the 
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Mature, Senior and Super Senior groups. It is widely recognised that, as 
individuals get older, the brain tissue atrophies, and this shrinkage leads to an 
increase in the size of the CSF spaces, such as the ventricles32. In humans, 
while the brain shrinks at a rate of 2-5% per decade29, 30, enlargement of the 
ventricles occurs at a rate of 3-4% per year245, with this being accelerated by 
ageing246. This increase in the size of the ventricles has been proposed as a 
predictor for the development of AD35. A similar enlargement of the ventricles 
has also been reported to occur in both cats40 and dogs219-221, and is commonly 
used as a diagnostic criteria for brain atrophy and ageing225. A study in dogs 
showed that the lateral ventricles increase slowly until 10 years of age, 
followed by a rapid progression thereafter220. Interestingly, the opposite was 
found in the post-mortem scans. In these, the Super Senior group had the 
smallest lateral ventricles of all age groups. This reduction appears to have 
been caused by the extraction and fixation of the brain; these procedures are 
known to collapse the ventricles due to the loss of CSF fluid and/or pressure 
changes228, 242, as described above.  
 
The interthalamic adhesion is a round structure that connects the left side of 
the thalamus with the right one. A reduction of the size of this structure has 
been previously reported to occur in live healthy aged cats226 and dogs, 
particularly in those with CDS224, 225. The thinning of the interthalamic adhesion 
is also believed to be correlated with enlargement of the ventricles224. While 
there were no statistically significant changes in the size of this structure in the 
present study, the interthalamic adhesion thickness tended to reduce with age 
in the post-mortem scans, with the Super Senior group having the smallest 
interthalamic adhesion of all age groups. As mentioned previously, all of the 
cats with CDS were part of the post-mortem dataset, suggesting that the 
interthalamic adhesion does reduce in size with age and is potentially linked to 
CDS in cats.  
 
Atrophy of the hippocampus is another important age-related change reported 
in humans31-34 and dogs219-222. A study that assessed MR images from people 
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with and without AD showed that those people with AD had smaller 
hippocampal volumes (up to 38%) compared with healthy participants247. In 
addition, hippocampal atrophy has been used as an early diagnostic tool, as it 
has been reported to occur in healthy humans that later develop AD36-39. In 
agreement with reports in dogs and humans, the size of the hippocampus in 
the in vivo cats in the current study was negatively correlated with age, which 
was expected. Unexpectedly, the opposite was found in the post-mortem 
scans, where a positive correlation was found. In these scans, an initial and 
progressive increase in size was evident; however, this was followed by a 
marked decline in the Super Senior group. While the initial increase in 
hippocampal size could be the result of the tissue expansion caused by death 
and the fixation process in the younger groups, the drastic decline in the oldest 
group could also suggest that this atrophy is real, only being evident in the 
oldest individuals.  
 
Finally, the total sagittal brain area was negatively correlated with age. As 
discussed previously, age-related shrinkage of the brain has already been 
reported in humans30, dogs219-222 and cats226. Interestingly, atrophy of the 
whole brain is considered an early indicator of AD, as it has been reported to 
occur in the pre-symptomatic stage of the disease39, 92, 215.  
 
 
3.4.3 Sex-related differences in the size of brain structures 
 
It has been proposed that age-related atrophy of the brain is not predominantly 
produced by neuronal death (i.e., a decline in the number of neurons) but 
rather by a reduction in their volume instead144. This is believed to be linked 
with sex, affecting different areas of the brain differently in men and women144. 
In the present study, there were sex-related differences in the size of 
structures, including the three planes of the total brain areas (i.e., dorsal, 
sagittal, and transverse), the hippocampus and the hemispheres. In addition, 
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correlations were found between age, sex, and the total dorsal and sagittal 
brain areas, as well as the hemispheres. 
 
Male cats from the combined datasets had larger total dorsal and sagittal brain 
areas, compared to female cats; while the male cats from the in vivo scans 
had larger total dorsal, sagittal, and transversal brain areas, when compared 
to female cats. This could be due to male cats tending to be physically bigger 
than female cats, hence, they have bigger heads and brains. Since the weight 
of the cats in this study was not recorded, it was not possible to calculate the 
correlation between body weight and brain weight. Interestingly, while the 
dorsal, sagittal, and transversal brain areas were larger in the male cats of the 
post-mortem group, when compared to the females, these were not statistically 
significant different. This could suggest that removing the brain from the skull 
and the fixation process produce changes, such as expansion and then 
shrinkage of the brain, which could mask any potential changes. There were 
also positive correlations with age and the dorsal brain area which were larger 
in the male cats and tended to decrease with age. In contrast, female cats from 
the in vivo scans had larger hippocampi than male cats. In humans, sex-related 
differences have also been identified, showing that the total brain volume and 
hippocampal size tend to be larger in men than in women32. Even though, on 
average, men have larger hippocampi than women, there is contradictory 
evidence on the sex-related differences in the size of this structure248, 249. 
These inconsistencies are more evident after adjusting the size of the 
hippocampus for total brain size248, 249; although the different methods used for 
these adjustments may also contribute to this variation249.   All the structures 
assessed in the present study were adjusted for the overall brain size, which 
might explain why female cats have larger hippocampi than male cats. 
 
Age-related atrophy of the frontal and temporal lobes is most prominent in 
men144, 212; while the hippocampus and parietal lobes are most affected in 
women144, 212. While any reduction in size of the cats’ brain structures was not 
statistically significant between sexes, the assessment of in vivo scans showed 
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that the frontal and occipital lobes tended to decrease more rapidly with age in 
female cats. 
 
In the post-mortem scans, female cats had larger hemispheres than males. 
This is difficult to explain, especially as male cats from the in vivo dataset had 
larger brain areas. It is possible that this could be due to death and the fixation 
process. Since the cat brains were not treated in a standard fashion post-
mortem, some may have been fixed for longer than others prior to sectioning. 
It is possible that some brains experienced swelling and a further shrinkage, 




3.4.4 Differences in the size of structures between cats with 
and without CDS 
 
There was a positive correlation between age and cognitive impairment, which 
adds evidence to support that cats are more likely to develop CDS as they 
become older. Furthermore, there were statistically significant differences in 
the size of structures between cats with and without CDS, including the total 
dorsal brain area, the occipital lobe, and the hemispheres.  
 
As described previously, the main changes associated with ageing and AD in 
humans are atrophy of the whole brain, which is more evident in the frontal 
and temporal lobes, plus hippocampi216-218. However, while similar changes 
were expected in the cats of this study, the opposite was found, with cats with 
CDS having larger dorsal brain areas and hemispheres. As discussed 
previously, this could be the result of death and fixation, and/or due to 
differences in the collection and fixation times between the samples. In 
contrast, cats with CDS had smaller occipital lobes, which the author proposes 
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Of note, given the small number of cats with CDS (n = 4) the results of the 
present study are an under-representation of the changes that can potentially 
happen in the brains of cats affected by CDS, which is one of the limitations of 
this study. Further studies, with larger numbers of cats with CDS, are needed. 
 
There are other limitations that have been identified in the present study. Since 
the collection of brains for the post-mortem scans was undertaken at different 
times, the fixation times changed between samples. Hence, some brains 
remained immersed in formalin for longer than others. This could potentially 
had affected the results, as physical changes such as swelling and shrinkage 
of the tissue could have occurred at different times. Ideally, to minimise this 
variation, all of the brains should have been collected and fixed using exactly 
the same procedure; furthermore, brains could have been temporarily placed 
in PBS before being scanned, in order to reverse the effects of the fixative. To 
minimise these changes, fixation by perfusion, instead than immersion, could 
have been performed. However, this is a more expensive technique that 
requires training and expertise, plus further ethical issues as special consent 
would have been needed from the cat owners, as would a Home Office license. 
 
It is possible that scanning the post-mortem brains while being suspended in 
formalin could have had an effect in the quality of the image and resolution. To 
test this theory, agar was assessed as it is commonly used as an MR imaging 
phantom250. For this test, a brain was placed inside a 5% agar block and 
scanned using the same protocol as described above; however, the image 
quality and resolution were poor, being insufficient to identify structures or 
accurately measure them. The use of Fomblin® (Sigma-Aldrich™), a 
fluorinated lubricant, may have helped to minimise these problems. Since it is 
a hydrogen-fee fluid, it has been anecdotally recognised as better a 
suspension media for MR studies; however, it is an expensive fluid.  
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3.5 Conclusion 
Magnetic resonance imaging has the potential to be an accurate tool for the 
early recognition of age-related changes in the brains of cats. As cats get older, 
they develop atrophy of the whole brain, particularly of the occipital lobe, with 
enlargement of the ventricles. It is possible that the live cats whose brain scans 
were assessed in this study may experience these age-related changes over 
time and may even develop cognitive decline later in life; however, large 
longitudinal studies are needed to investigate this possibility, and to determine 
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Cognitive dysfunction syndrome (CDS) is a complicated and poorly 
understood condition in cats. Diagnosing CDS is difficult for veterinary 
practitioners, especially as the diagnosis can only be made by ruling out all 
other potential causes for the behavioural changes displayed by the affected 
cats15, 90. In addition, these behavioural changes can be misinterpreted as 
normal ageing; highlighting the importance of accurately differentiating 
between what is normal, and what is a reason of concern and needs to be 
explored further. Furthermore, treating CDS in cats may also be challenging. 
While some interventions have been extrapolated from other species, such as 
the dog, there is no proven treatment for this condition in cats. 
 
To date, most research has assessed the effect of different drugs on the 
cognition of non-feline species; recent studies in rodents and humans have 
shown that drugs that block a specific receptor of the renin-angiotensin system 
(i.e., the AT1 receptor) might be beneficial to cognition and memory131, 251. It is 
therefore possible that these drugs could also have positive effects in cats with 
CDS. If true, this could be a turning point, as a treatment for this condition will 
significantly improve the quality of life and welfare of affected cats. 
 
 
4.1.1 Renin-angiotensin system 
 
The renin-angiotensin system (RAS) is a hormone pathway involved in the 
regulation of many physiological functions, including the modulation of the 
cardiovascular system, by controlling blood pressure, as well as the body’s 
water balance and thirst252, 253. It involves three major hormones (renin, 
angiotensin II, and aldosterone) which affect the kidneys, lungs, vascular 
system, and the brain254.  
 
The RAS is activated by decreased systemic blood pressure. When blood 
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pressure falls, juxtaglomerular cells in the kidneys activate, cleaving the 
inactive precursor prorenin into renin253, 254. Renin is then released into the 
blood stream where it cleaves angiotensinogen, a precursor protein produced 
in the liver and found in circulating plasma, into inactive angiotensin I. 
Angiotensin I is then converted to angiotensin II (Ang II) by the action of 
angiotensin converting enzyme (ACE), which is found mainly in the lungs and 
kidneys. The resulting Ang II binds to angiotensin II type I (AT1) and type II 
(AT2) receptors, and has an effect on various organs, including the kidneys, 
adrenal cortex, vascular system, and the brain253, 254 (Table 4.1). In these same 
organs, the enzyme aminopeptidase A (APA) then converts angiotensin II into 
angiotensin III, which is later converted into angiotensin IV (Ang IV) by the 
action of aminopeptidase N (APN)255 (Figure 4.1). 
 
Table 4.1 Effects of angiotensin II on AT1 receptors on different organs 
Target organ Effect Result 
Adrenal cortex Release of aldosterone  Increased sodium 
reabsorption and 
potassium excretion 
from the kidneys 




Brain Stimulation of the 
hypothalamus 
 
Stimulation of the 
posterior pituitary 
Stimulates thirst and 
promotes water intake 
 
Release of antidiuretic 
hormone which 
increases water 
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Figure 4.1  Renin-angiotensin system (RAS). The RAS activates in response to a reduction of blood pressure. Renin converts 
angiotensinogen into angiotensin I, which is later converted into angiotensin II by angiotensin converting enzyme (ACE). Angiotensin II 
acts on AT1 receptors to regulate blood pressure, and on AT2 receptors to promote vasodilation, regeneration of tissues, and reduction of 
inflammation. Angiotensin receptor blockers (ARBs) inhibit the effect of angiotensin II on the AT1 receptors. Angiotensin II can be 
converted into angiotensin III by aminopeptidase A (APA), and angiotensin III can be converted into angiotensin IV by aminopeptidase N 
(APN). Angiotensin IV acts on AT4 receptors, which are involved in learning, memory consolidation, and cognition
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Studies in rats have shown that Ang II plays an important role in maintaining 
the water and thirst balance256, 257. In one of these studies, rats were initially 
trained to press a bar to be given water. Once they had learned this, the rats 
were then deprived of water for 24 hours. After the water deprivation period, 
the rats were placed back in the chamber where they were able to press the 
bar to obtain water until they were satiated. Once satiated, the rats were then 
moved to a different chamber and received an intracranial injection of Ang II. 
Immediately after the injection, rats were moved back into the initial chamber, 
where they pressed the bar and drank more water. A control experiment was 
performed seven days later; however, during that experiment, the rats received 
an intracranial injection of saline instead of Ang II. This study found that, 
despite being satiated, the motivational levels of the rats after receiving the 
intracranial injection of Ang II were the same as for when they were water-
deprived256. This response is believed to be due to Ang II binding to the AT1 
receptors, which are known to control thirst and water intake; hence, the 
intracranial administration of Ang II resembles the motivation induced by water 
deprivation256, 257.  
 
Besides its involvement in regulating blood pressure and water/thirst balance, 
the RAS is known to be implicated in several other functions and to act in many 
tissues, including the brain. In this organ, it has been shown to regulate 
cerebral blood flow, and to be involved in learning and memory 
consolidation253; furthermore, it has been shown to be involved in the etiology 
of neurodegenerative diseases, such as Alzheimer’s disease (AD)253, 258, 259. 
 
It has been suggested that of the different forms of Angiotensin, it is Ang II, in 
particular, that affects learning and memory. Some of this evidence comes 
from the role of Ang II in cognitive disorders and neurodegenerative diseases, 
such as AD. One of the hypothesized causes of AD is the cholinergic 
hypothesis. This hypothesis suggests that a decreased number of cholinergic 
fibres in the brain reduces the release of acetylcholine (ACh), leading to further 
cognitive decline260. This correlates with the levels of choline acetyltranferase, 
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the enzyme that synthethises Ach, which are significantly reduced in people 
with AD259. This may result from the suppressive effect of Ang II on ACh, as 
high levels of Ang II are known to reduce the release of ACh259.  
 
However, recent studies have proposed that Ang IV may be involved in 
learning and memory, instead of Ang II. For instance, one study assessed 
memory after induced ischemia in rats before and after intracerebral injection 
of Ang IV261. In that study, two different types of memory were evaluated: 1) 
associative memory was assessed by using the passive avoidance test, in 
which rats learned to avoid an unpleasant stimulus (i.e., a foot shock); and 2) 
spatial memory, which was assessed by using the circular water maze. The 
findings of this study showed that, firstly, induced ischemia produced 
significant cognitive impairment in the rats; furthermore, injection of Ang IV was 
shown to reduce this impairment, as animals improved their performance in 
both tests261. This has been suggested to be the result of the agonistic effect 
of Ang IV on AT4, which are receptors that are believed to be mostly involved 
in cognition255. Interestingly, unlike Ang II receptors, Ang IV receptors have 
been identified in several brain areas associated with memory function, such 
as the hippocampus, facilitating the retrieval and retention of memory262. 
 
It has been suggested that Ang II and Ang IV might not be the only hormones 
of the RAS involved in the development of AD. It is believed that  ACE also 
plays a role in this disease; however, this role may not be causative of disease, 
but rather neuroprotective263. In vitro studies have shown that ACE can cleave 
the amyloid- protein; this cleavage produces less toxic fragments that are less 
likely to aggregate263. Moreover, increased activity levels of ACE have been 
found in the AD brain; suggesting that ACE may play a protective role in the 
disease, especially as these increases have been correlated with high 
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4.1.2 Angiotensin II receptors 
 
4.1.2.1 Subtype 1: AT1 receptors 
 
In the brain, these receptors are located in the anterior pituitary gland, the third 
ventricle, the hypothalamus, the olfactory bulb, and the locus coeruleus, 
amongst others. These receptors regulate the main functions of the brain RAS, 
including maintaining cerebral blood flow and the integrity of the blood-brain 
barrier (BBB), water/thirst balance, blood pressure, and release of hormones, 
such as vasopressin (also known as antidiuretic hormone) and aldosterone253, 
264, 265. 
 
However, chronic over-activation of AT1 increases vulnerability to brain 
ischaemia130. Evidence obtained from rat models of human hypertension have 
shown that over-activation of AT1 is associated with cerebrovascular stiffness 
and inflammation266. Fortunately, the negative effects produced by this over-
activation can be normalised by administrating AT1 receptor blockers (ARBs) 
and ACE inhibitors130, 267. 
 
4.1.2.2 Subtype 2: AT2 receptors 
 
In the brain, AT2 receptors are located in the amygdala, caudate putamen, 
locus coeruleus, and thalamus, amongst other regions. However, there are 
only low numbers of these receptors within the brain, so little is known about 
their functions, although they are believed to be involved in the regulation of 
cerebral blood flow and have been shown to counteract the effect of overactive 
AT1 receptors on blood pressure129, 264, 268. 
 
4.1.2.3 Subtype 3: AT3 receptors 
 
These receptors have only been identified in cultured mouse neuroblastoma 
cells269 and their presence in human or cat tissue has not yet been 
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4.1.2.4 Subtype 4: AT4 receptors 
 
In the brain, these receptors are located in the cerebral cortex, hippocampus, 
thalamus, cerebellum, and anterior pituitary gland, amongst others. These 
receptors are believed to be involved in learning and memory, cognition, and 
in the regulation of cerebral blood flow264. 
 
 
4.1.3 Angiotensin II type 1 receptor blockers  
 
Some drugs are frequently used to manipulate the RAS in order to treat heart 
disease, hypertension, and diabetes, including ACE inhibitors (e.g., enalapril, 
benazepril), angiotensin receptor blockers (e.g., losartan, telmisartan), and 
aldosterone antagonists (e.g., spironolactone)254. 
 
Angiotensin II type 1 receptor blockers (ARBs) reverse the effects of over-
activation of AT1 by reducing vasoconstriction and inflammation129, 130. For this 
reason, ARBs are commonly used for the treatment of metabolic (e.g., 
diabetes), and cardiovascular disorders129, 130.  
 
Similarly, in the brain, ARBs have been shown to reduce inflammation and to 
slow down the inflammatory cascade by inhibiting the pro-inflammatory effect 
of microglia130. It has been suggested that this anti-inflammatory effect may be 
neuroprotective, as it prevents vasoconstriction and minimises hypoxia130. For 
these reasons, ARBs have also been proposed as potential treatments to 
improve cognition in both stroke and AD patients130.   
 
Sartans (e.g., losartan, candesartan, telmisartan) are ARBs derived from 
biphenyltetrazole that share similar pharmacological profiles270. They are 
widely used for the treatment of hypertension in people271 which, if untreated, 
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is known to increase the risk of vascular dementia and AD272-274. Studies in 
humans have shown that sartans improve cognition and memory in 
hypertensive patients, as well as reducing the incidence and later development 
of AD in these patients275-277.  
 
Moreover, studies in rats have shown that sartans reduce acute brain 
inflammation after induced stroke130, 266. Sartans have also been shown to 
improve cerebral blood flow and to reduce the risk of ischaemia and brain 
damage; and to improve the neurological outcome in models of hypertension 
and stroke278, 279. In addition, sartans have been shown to protect cognition 
and to reduce amyloid- toxicity after brain inoculation of this protein251.  
 
In mice, sartans have been shown to improve memory in models of 
diabetes280; and to interrupt the pro-inflammatory response of both microglia 





The differing pharmacological profiles of the sartans result in differences in 
their neuroprotective effectiveness282. Telmisartan is considered to be the 
most potent of the sartans134, 282 as it not only blocks AT1 receptors, it also 
activates the peroxisome proliferator activated receptor gamma (PPAR)282.  
 
PPAR is a hormone receptor that plays an important role in the regulation of 
both carbohydrate and lipid metabolism within the body283. When activated, 
PPAR improves the sensitivity to insulin, making PPAR agonists a potential 
treatment of diabetes284. Activation of PPAR also reduces inflammation285, 
provides neuroprotection134, 137, 139, 286, reduces neurotoxicity induced by 
glutamate137 (a neurotransmitter involved in neurological disease) by 
promoting cell death and release of reactive oxygen species287, and reduces 
neuronal damage after focal cerebral ischemia288, 289. It also improves memory 
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and cognition in AD290.  
 
The beneficial effect of PPAR agonists in AD is mainly attributed to their anti-
inflammatory properties. PPAR activation suppresses the activation of 
microglial cells, which occurs as a result of the accumulation of amyloid-291, 
and inhibits their pro-inflammatory effect292. Moreover, studies in mice have 
suggested that PPAR activation also inhibits the production of amyloid- 
protein293 and promotes its clearance133.  
 
Activation of PPAR has also been shown to improve memory and cognition 
due to its effect on mitochondrial functions. Mitochondria are involved in the 
energy and glucose metabolism of the cells; this metabolism and the utilisation 
of glucose are believed to be reduced in the brain of patients with AD292, 294. In 
particular, when this metabolic deficit occurs alongside alterations in the 
regulation of mitochondrial calcium and increased oxidation, it can lead to 
hypoxia, brain damage, cognitive impairment, and AD294. Studies in mice have 
shown that activation of PPAR improves mitochondrial function and utilisation 
of glucose, leading to an improvement of cognition295. 
 
As mentioned previously, telmisartan is considered to be the most potent of 
the sartans as it activates PPAR134, 282. Studies in rodents have shown that 
treatment with telmisartan restored cognitive function after induced chronic 
stress140, induced ischemia296, 297, and after intra-cerebral injection of amyloid-
134 that can accumulate abnormally in the brain leading to cognitive decline. 
Furthermore, in mouse models of AD, intranasal administration of telmisartan 
reduced amyloid- deposition and neuronal loss, and improved cognition298. 
Finally, in vitro studies have shown that telmisartan reduced inflammatory 
mediators, such as cytokines and chemokines, that are involved in the 
aggregation of amyloid- and promoted its clearance133. Telmisartan also 
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The experimental evidence obtained from in vitro and rodent models suggest 
that telmisartan has the potential to be beneficial as a treatment for 
neurodegenerative diseases and to improve cognition. Currently, there are two 
ongoing clinical trials assessing the efficacy of telmisartan for the treatment of 
AD in human patients142. One of the studies started in March 2014 and entered 
Phase 2 at the time the present study was being conducted. That study aims 
to evaluate the effect of telmisartan administered for one year at a daily dose 
of 40-80 mg/kg (depending on age and tolerance) on the blood vessels of the 
brain and whether it slows down brain atrophy in patients with mild to moderate 
AD142. The trial is expected to be completed by March 2022. The second study 
has been running for eight months and aims to assess the effect of telmisartan 
(at a daily dose of 20 or 40 mg/kg) on the cognitive abilities and development 
of AD in African-Americans, an ethnic group known to be at high risk of 
developing this disease142. This study started in April 2015 and was expected 
to be completed by June 2020. 
 
In cats, telmisartan (Semintra™, Boehringer Ingelheim; at a dose of 1 mg/kg 
PO q24h) has been shown to be effective in the reduction of proteinuria 
associated with chronic kidney disease300. Furthermore, it has shown to be 
effective at reducing hypertension in this species, at a dose ranging from 1-3 
mg/kg301-303.  
 
The beneficial effects of telmisartan by reducing neuroinflammation and 
improving cognition makes this drug a potentially good treatment for CDS in 
cats.  
 
The aim of this study was to determine the effects of telmisartan (Semintra™, 
Boehringer Ingelheim) on the clinical signs of CDS in cats at its licensed dose 
(at the time this study commenced) of 1 mg/kg PO q24h, given for three 
months. It was hypothesized that the clinical signs of CDS would be 
significantly reduced in the cats receiving telmisartan (Semintra™, Boehringer 
Ingelheim). 
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4.2  Materials and methods 
 
The effects of telmisartan (Semintra™, Boehringer Ingelheim) on the 
behavioural signs of CDS in cats were assessed by running a double-blinded 
placebo-controlled study in cats with a confirmed diagnosis of CDS90. Changes 
in the abnormal behaviours were assessed based on the cat owners’ 
responses to a series of questionnaires. The study consisted of a 7-day pre-
treatment period, a 90-day treatment period, and a 30-day post-treatment 
washout period. 
 
Of note, the format of the double-blinded placebo-controlled trial and the 
questionnaires were designed by Professor Danièlle Gunn-Moore. 
 
 




Cats were recruited through The Hospital for Small Animals of The Royal 
(Dick) School of Veterinary Studies (RDSVS) and the Bishop's Stortford 
Veterinary Hospital. To be considered for the study, cats had to be at least 10 
years old and have a confirmed diagnosis of CDS (as per the CDS criteria – 
see below) and to be otherwise healthy. Cats with chronic diseases (i.e., 
diabetes mellitus, chronic kidney disease, or hyperthyroidism) were 
considered and recruited only if the disease was stable and had been so for at 
least three months. The complete inclusion and exclusion criteria for the 
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Table 4.2 Inclusion and exclusion criteria for the recruitment of cats 
Inclusion criteria 
• Age of 10 years or older 
• Lived with owner for at least six months 
• Meet the cognitive dysfunction criteria (see below) 
• Unremarkable physical examination, including retinal examination 
• Unremarkable routine haematology and serum biochemistry  
• Normotensive (< 180 mmHg systolic*) 
• Feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV) 
negative on blood 
• Stable systemic diseases for at least three months (e.g., hyperthyroidism 
or diabetes mellitus; chronic kidney disease only accepted if IRIS ≤ stage 
2 and stable for ≥ 3 months) 
Exclusion criteria 
• Displaying signs of acute disease 
• Currently receiving treatment for “old age behaviour” (e.g., selegiline 
hydrochloride, propentofylline, etc.)  
• Signs of CDS started before the age of eight years old 
 
* While cats are now considered to have mild hypertension when the systolic 
blood pressure is > 140 mmHg, the higher cut off of 180 mmHg was accepted 
when the study started304. 
 
4.2.1.2 Diagnosis of CDS 
 
At the time of the first consultation, the cat owners responded to the first of a 
series of questionnaires (Questionnaire 1) (Appendix 4.1) that assessed 
changes in a total of 27 behaviours (Table 4.3). Some of these behaviours 
related to CDS (i.e., vocalisation at night, and affection to people, amongst 
other options), whilst others are not typically associated with CDS (i.e., 
vomiting, hair loss, etc.); the latter were added so that owners did not know 
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which were signs of CDS or not, so they acted as distractors; moreover, they 
also provided evidence of undisclosed signs of ill-health. Cats had to have 
been displaying behaviours consistent with CDS for at least one month prior 
to this time point. For this questionnaire, owners were asked to report if these 
behaviours have decreased significantly (- 2), decreased mildly (- 1), remained 
the same (0), increased mildly (1), or increased significantly (2), when 
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Table 4.3 List of the 27 behaviours included in the questionnaires that were assessed 
by the owners. The behaviours that are strongly related to cognitive dysfunction 
syndrome are highlighted in bold 
List of behaviours included in the questionnaires 
• Activity levels/time spent playing 
• Affection with people in the house 
• Agitation and restlessness 
• Aggression towards animals or people 
• Aimless activity (i.e., staring into space, pacing, etc.) 
• Change in appetite 




• Hair loss or hair thinning 
• Hearing loss 
• Passing faeces in the house outside litter tray 
• Passing urine in the house outside litter tray 
• Repetitive or compulsive behavior (e.g., over-grooming, etc.) 
• Time spent grooming 
• Time spent sleeping at night 
• Time spent sleeping during the day 
• Tolerance of handling 
• Tolerance of being left alone 
• Tolerance of other animals in the house 
• Vision loss 
• Vocalisation during the day 
• Vocalisation at night 
• Vomiting (including hairballs) 
• Wanting to spend time outdoors 
• Willingness to jump up or down (including climbing stairs) 
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In order to diagnose CDS in the cats, the results from Questionnaire 1 (Q1) 
were evaluated according to pre-determined cognitive decline criteria 
(Appendix 4.2). This questionnaire was modified from a similar questionnaire 
previously used for the diagnosis and severity of CDS in dogs and cats8, that 
has been used for similar studies for over a decade; however, it is not yet a 
fully validated clinical metrology instrument. At present, an improved 
instrument based on this previous one is being developed. The diagnosis for 
CDS was made when cats displayed a significant number of CDS-associated 
behavioural changes for at least one month and medical or stress-related 
causes of the behaviour could not be found. Given that there is no published 
clinical metrology instrument for the diagnosis of CDS in cats, a scoring system 
was developed based on the frequency of the different behaviours and how 
commonly they were associated with CDS cases in the clinic (DGM, 
unpublished data). For this, the most frequent behaviours associated with CDS 
(i.e., vocalisation at night, increased affection to people) were scored as 1*; 
slightly less frequent behaviours (e.g., vocalisation during day, increased time 
spent sleeping) were scored as 1; even less frequent behaviours (e.g., activity 
levels, house-soiling) were scored as 2; and the least frequent behaviours 
(e.g., willingness to jump, hearing loss) were scored as 3. The number of 
behavioural changes required for a diagnosis of CDS to be made varied 
depending on how commonly the behaviours were associated with CDS. For 
example, cats displaying only one behavioural change that is strongly 
associated with  CDS90 (scored as 1*) were diagnosed easily. In contrast, cats 
needed to display a minimum of two of the frequently associated behaviours 
which were not as strongly associated with CDS (scored as 1), and at least 
four of the behaviours that are only mildly associated with CDS (scored as 2) 
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Table 4.4 Cognitive dysfunction criteria. The number of behavioural changes required 
for a diagnosis of cognitive dysfunction syndrome (CDS) to be made depended on how 
closely these behaviours are associated with CDS in cats 
Changes in ONE of the following 
• Affection to people 
• Tolerance of being left alone 
• Vocalisation during the night  
Changes in TWO of the following 
• Aimless activities (i.e., staring into space) 
• Repetitive or compulsive behaviour (i.e., overgrooming, licking objects, 
etc.) 
• Time spent grooming 
• Time spent sleeping during day 
• Time spent sleeping at night  
• Vocalisation during the day 
Changes in FOUR of the following 
• Activity levels/time spent playing 
• Aggression towards animals or people 
• Agitation/restlessness 
• Appetite 
• Tolerance of handling 
• Wanting to spend time outdoors 
• Tolerance of other animals in the house  
• Passing faeces in house outside the litter tray 
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4.2.1.3 Medical examination 
 
Only cats displaying significant signs of CDS were recruited to undertake a 
complete medical examination, including full physical examination, joint 
palpation, mobility assessment, limited neurological examination (i.e., hands-
off examination305), assessment of systolic blood pressure using the Doppler 
method304, retinal examination (looking for changes suggestive of 
hypertension, toxoplasmosis, and other pathologies), haematology, serum 
biochemistry and assessment of serum FeLV and FIV status. Cats with pre-
existing diseases, such as diabetes mellitus or hyperthyroidism, could be 
recruited if their disease had remained stable for at least three months prior to 
being recruited.  
 
4.2.1.4 Medication and dosage 
 
Recruited cats were randomly separated without replacement into two groups. 
Group A received the placebo and Group B received telmisartan (Semintra™, 
Boehringer Ingelheim). Cats from both groups were dosed so they would 
receive 1 mg/kg of telmisartan or a placebo (Appendix 4.3), orally, once a day, 
for a total of three months. 
 
The telmisartan and placebo were both provided by Boehringer Ingelheim 
Animal Health UK Limited. To reduce bias, both compounds were identical, 
including colour, smell, taste, tub, and packaging; with the only difference that 
the placebo did not have the active ingredient telmisartan.  
 
Nota bene:  Throughout the drug trial and the data analyses, the owners and 
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4.2.2 Treatment period  
 
Cats from both groups received the randomised trial treatment for a total of 
three months, and owners were asked to stop the medication exactly 90 days 
after the treatment began. During the treatment period, owners had to respond 
to three questionnaires at different time points, at 30 days after the treatment 
began (i.e., Questionnaire 30 days), and then every 30 days (i.e., 
Questionnaires 60 and 90 days) (Figure 4.2). These questionnaires were 
almost identical to Questionnaire 1; the only difference was that the owners 
were asked to compare their cat’s current behaviour to when they began the 
trial (i.e., Questionnaire 1). The questionnaires were available online at the Vet 
Professionals website (https://www.vetprofessionals.com/scs-30-120.html; 
since the study had ended this link is no longer active) or could be posted to 
the owners.  
 
The follow-up questionnaires also asked owners to report any potential side 
effects their cat may have been showing, to comment on how easy or difficult 
it was to give the medication, and how palatable it was for their cat. 
 
 
4.2.3 Post-treatment period 
 
Once the treatment stopped, cats underwent a second complete medical 
examination and blood sampling to assess their health. After a washout period 
of 30-days, owners were asked to respond to a final questionnaire (i.e., 
Questionnaire 120 days). For this questionnaire, owners had to report changes 
on their cat’s behaviours since the treatment stopped. 
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Figure 4.2 Timeline of the double-blinded placebo-controlled study. Owners were asked to respond to a series of questionnaires. The 
first one (Questionnaire 30) had to be completed 30 days after starting the administration of the medication/placebo to the cats. Two 
more questionnaires (Questionnaires 60 and 90) had to be completed every 30 days after that. The administration of both compounds 
stopped on the 90th day of the trial and after a washout period of 30 days owners had to complete a final questionnaire (Questionnaire 
120)
      End of 
trial 
Medication 
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4.2.4 PPARγ in the cat brain 
 
To assess whether PPARγ was expressed in cat brains, 
immunohistochemistry was performed on the same brain sections described 
in Chapter 2, following the same immunohistochemistry protocols, and using 
a PPARγ monoclonal antibody (1:1000; Clone: K.242.9; ThermoFisher 
Scientific™; Massachusetts, USA) as the primary antibody. 
 
 
4.2.5 Ethical approval 
 
Ethical approval was obtained through the Veterinary Ethical Review 
Committee from the RDSVS, The University of Edinburgh (VERC 98.14). 
 
 
4.2.6 Data analysis 
 
All data were analysed using SAS v9.4 statistical software for Windows. 
 
4.2.6.1 Correlation between age and behaviours 
 
Ordinal logistic regressions were performed to assess the correlation between 
age and the different behaviours, and to determine whether the age of the cats 
had an effect on these behaviours. For this, responses provided by the owners 
in Questionnaire 1 (Q1) were compared against the age of the cat, regardless 
of their treatment group.  
 
4.2.6.2 Differences in the behaviours between treatment groups and at 
different time points 
 
Ordinal categorical data were treated as continuous and fitted into general 
linear models for repeated measures in which the behaviours were adjusted 
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for treatment, the different time points, breed, and sex. These models were 
used to determine whether there were differences in the behaviours between 
treatment A and B (i.e., all responses at the different time points together for 
each behaviour for treatment A vs the ones for treatment B; for example, all 
the responses for changes in activity levels for treatment A vs treatment B); 
and between treatments at the different time points (i.e., A vs B at 
Questionnaire 30 days (Q30); A vs B at Questionnaire 60 days (Q60); A vs B 
at Questionnaire 90 days (Q90); and A vs B at Questionnaire 120 days (Q120); 
for example, responses from Q30 for changes in activity levels for treatment A 
vs treatment B. 
 
In addition, ordinal categorical data were treated as continuous and fitted into 
general linear models for repeated measures to determine whether there were 
differences in each of the behaviours during and after the treatment. For this, 
changes in each of the behaviours reported by the owners were compared at 
the different time points of the treatment period versus the post-treatment 
period (i.e., Q30 vs Q120; Q60 vs Q120; and Q90 vs Q120) for both 
treatments, separately. Finally, the means of the three questionnaires 
completed during the treatment period (i.e., Q30, Q60, and Q90) were 
compared against Q120, for both treatments, separately. 
Results 
 
Chapter 4: The effects of Telmisartan (Semintra™, Boehringer Ingelheim) on the 







A total of 60 cats were assessed for this study; however, only 34 of them met 
the inclusion/exclusion criteria and were recruited. Most of the cats (82.4%; n 
= 28) were non-pedigree cats (i.e., domestic shorthair [DSH] and domestic 
longhair [DLH]), with 17.6% (n = 6) being pedigree breeds (i.e., Bengal [n = 2], 
British Shorthair [n = 1], Devon Rex [n = 1], and Siamese [n = 2]). More than 
half of the cats (61.8%; n = 21) were females, all neutered except for one; and 
38.2% (n = 13) of the cats were neutered males. Ages ranged between 10 and 
20 years old, with a mean of 15.3 years old and a median of 16 years old. 
 
4.3.1.1 Group A: Placebo 
 
Most of the cats in Group A (88.2%; n = 15) were non-pedigree cats and 11.8% 
(n = 2) were pedigree cats. Of the 17 cats in this group, more than half of them 
(58.8%; n = 10) were females, and 41.2% (n = 7) were males. The ages of cats 
in Group A ranged between 10 and 18 years old, with a mean of 14.8 years 
old and a median of 15 years old. 
 
4.3.1.2 Group B: Telmisartan (Semintra™, Boehringer Ingelheim) 
 
More than three quarters of the cats in Group B (76.5%; n = 13) were non-
pedigree cats and 23.5% (n = 4) were pedigree cats. Of the 17 cats in this 
group, 64.7% (n = 11) were females, and 35.3% (n = 6) were males. The ages 
of cats in Group B ranged between 10 and 20 years old, with a mean of 15.7 
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4.3.2 PPARγ in the cat brain 
 
Immunohistochemistry revealed that PPARγ was expressed in all regions of 
the cat brain, in all age groups (Figure 4.3); however, since the aim of this 
experiment was only to determine whether or not these receptors are present 
in the cat brain, differences between the brain regions and the age groups 
were not assessed.  
 
 
Figure 4.3 PPARγ in the cat brain. PPARγ were found to be present in all regions of 
the cat brains, and in all age groups. In this image, nuclear and cytoplasmic 
immunolabelling of PPARγ is present in the parietal cortex of a 15-years-old cat 
 
 
4.3.3 Correlation between age and behaviours 
 
Ordinal logistic regressions were performed to assess any correlation between 
age and the different behaviours. There was a correlation between age and 
some behaviours, showing that as cats get older, they are more likely to house-
soil (i.e., in this case, to be passing faeces outside the litter box) (p = 0.05), to 
display repetitive and compulsive behaviours (p = 0.01), and to lose weight (p 
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4.3.4 Differences in the behaviours between treatments and 
at different time points 
 
General linear models for repeated measures were performed to determine 
whether there were differences in each of the behaviours between the two 
treatments, and at the different time points. The complete table of results can 
be found in Appendices 4.5 and 4.6. Furthermore, graphs showing the 
changes in the different behaviours as reported by the owners and 
demonstrated by the percentage of cats displaying an increase, decrease or 
staying the same, for both treatments before, during, and after the treatment 
can be found in Appendix 4.7.  
 
There were no statistically significant differences between treatment A and B 
for any of the behaviours assessed. Despite not finding any differences 
between treatments, there were some statistically significant differences in 
several of the behaviours in either one or both treatment groups. Interestingly, 
most of the behaviours that were reported to change were the ones related to 
CDS (Table 4.5); differences were reported in eight of the 12 behaviours 
potentially directly related to CDS. In contrast, there were only significant 
differences in four of the 15 behaviours added as distractors and were not 
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Table 4.5 Changes in behaviours as reported by the owners. Statistically significant 
differences were mostly found in behaviours believed to be related to cognitive 
dysfunction syndrome (CDS) in either one or both treatment groups, shown in 
brackets. In this list, the behaviours related to CDS were listed in order of how 
frequently they had previously been reported to occur with CDS20 
 
Behaviours related to CDS Behaviours not related to CDS 
(Distractors) 
• Vocalisation at night  
A (p = 0.02) and B (p = 0.06) 
• Vocalisation during the day  
A (p = 0.05) 
• Affection with people in the house 
A (p = 0.03)  
• Tolerance of handling  
A (p = 0.04) 
• Time spent sleeping at night  
B (p = 0.05) 
• Time spent sleeping during the 
day  
Overall females from A and B (p = 
0.007) 
• Passing urine in the house 
outside litter tray  
A (p = 0.05) 
• Aimless activity (i.e., staring into 
space, pacing)  
A (p = 0.02) 
 
• Activity levels/time spent playing 
A (p = 0.04) and B (p = 0.04) 
• Agitation and restlessness  
A (p = 0.01) and B (p = 0.03) 
• Drinking  
A (p = 0.04) 
• Hair loss or hair thinning  





The following section presents descriptive statistics showing the percentage of 
cats displaying changes in each of the behaviours (i.e., increase and 
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decrease) when the cats were receiving the treatment and after it was finished. 
Only statistically significant results are presented for any differences in the 
behaviours for each overall treatment (i.e., if a specific behaviour was different 
when cats were receiving the treatment vs when it was finished); and when 
comparing the different time points (i.e., Q30 vs Q60, Q30 vs Q120, and Q60 
vs Q120). 
 
4.3.4.1 Activity levels 
 
4.3.4.1.1 Treatment A 
 
During the trial, a small proportion of cats (17.6%; n = 3) were more active, 
while 5.9% (n =1) of the cats were less active. In contrast, once the treatment 
finished, 5.9% (n = 1) of the cats were more active than before, and almost a 
quarter (23.5%; n = 4) were less active at this time point. Overall, cats were 
more active when receiving treatment A, compared to when it was stopped (p 
= 0.04) (Figure 4.4A).  
 
4.3.4.1.2 Treatment B 
 
During the treatment, 15.7% (n = 3) of cats were more active than before, and 
9.8% (n = 2) were less active. In contrast, after the treatment stopped, none of 
the cats were more active than before, and 17.7% (n = 3) of cats were less 
active. When comparing the different time points, cats receiving treatment B 
were more active in Q30, when compared to Q120 (p = 0.04) (Figure 4.4A).  
 
4.3.4.2 Agitation and restlessness 
 
4.3.4.2.1 Treatment A 
 
During the treatment, 17.6% (n = 3) of cats were less agitated than before, and 
a similar proportion of cats (13.8%; n = 2) were more agitated than before. 
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Once the treatment finished, none of the cats were less agitated than before, 
and 41.2% (n = 7) were more agitated. Cats were less agitated during the 
treatment, compared to when it was finished (p = 0.01) (Figure 4.4B). 
 
4.3.4.2.2 Treatment B 
 
During the treatment, almost a quarter of the cats (23.5%; n = 4) were less 
agitated, while 17.7% (n = 3) were more agitated than before. After the 
treatment finished, none of the cats were less agitated than before, and less 
than a third of cats (29.4%; n = 5) were more agitated. Cats were less agitated 
while they were receiving treatment B, when compared to when it was finished 
(p = 0.03) (Figure 4.4B). 
 
4.3.4.3 Aimless activity 
 
4.3.4.3.1 Treatment A 
 
During the treatment, owners reported that a quarter of the cats (25.5%; n = 4) 
displayed less aimless activity, and 11.8% (n = 2) displayed more than before. 
In contrast, after finishing the treatment, 5.9% (n = 1) of the cats displayed less 
aimless activity, and almost a quarter (23.5%; n = 4) displayed more aimless 
activity than before. Overall, cats displayed less aimless activity during 
treatment A, compared to when it was finished (p = 0.02) (Figure 4.4C). 
 
4.3.4.3.2 Treatment B 
 
During the treatment, a small percentage of cats (13.7%; n = 2) displayed less 
aimless activity than before, and the same percentage of cats (13.7%; n = 2) 
displayed more aimless activity. However, once the treatment finished, none 
of the cats displayed less aimless activity than before, and 11.8% (n = 2) 
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4.3.4.4 Repetitive/compulsive behaviour 
 
4.3.4.4.1 Treatment A 
 
During the treatment, none of the cats displayed less repetitive or compulsive 
behaviours than before, and only 7.8% (n = 1) displayed more than before. 
After the treatment, 11.8% (n = 2) of cats displayed less repetitive or 
compulsive behaviours than before, and none displayed more than before 
(Figure 4.4D). 
 
4.3.4.4.2 Treatment B 
 
During the treatment, 7.8% (n = 1) of cats displayed less repetitive or 
compulsive behaviours than before, and 9.8% (n = 2) display more than before. 
After the treatment, none of the cats displayed less repetitive or compulsive 
behaviours than before, and 11.8% (n = 2) displayed more than before (Figure 
4.4D). 
 
4.3.4.5 Willingness to go outside 
 
4.3.4.5.1 Treatment A 
 
During the treatment, almost a quarter of the cats (21.6%; n = 4) wanted to 
spend more time outside, and 7.8% (n = 1) wanted to spend less time outside. 
In contrast, once the treatment finished, 17.6% (n = 3) of the cats wanted to 
spend more time outside, and 17.6% (n = 3) of cats wanted to spend less time 
outside (Figure 4.4E). 
 
4.3.4.5.2 Treatment B 
 
During the treatment, 21.6% (n = 4) of cats wanted to spend more time outside 
than before, and 9.8% (n = 2) wanted to spend less time outside. In contrast, 
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once the treatment finished, 23.5% (n = 4) of cats wanted to spend more time 
outside, and 11.8% (n = 2) wanted to spend less time outside (Figure 4.4E). 
 
4.3.4.6 Willingness to jump 
 
4.3.4.6.1 Treatment A 
 
During the treatment, 7.8% (n = 1) of cats jumped more than before, and the 
same percentage of cats (7.8%; n = 1) jumped less than before. After the 
treatment finished, 5.9% (n = 1) of cats jumped more than before, and 5.9% (n 
= 1) of cats jumped less (Figure 4.4F). 
 
4.3.4.6.2 Treatment B 
 
During the treatment, a small number of cats (11.8%; n = 2) jumped more than 
before, and 13.7% (n = 2) of cats jumped less than before. Once the treatment 
finished, none of the cats jumped more than before, and 5.9% (n = 1) of them 
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Figure 4.4 Behavioural changes. Changes through time (mean ± SD), for both 
treatments, in A) activity levels; B) agitation and restlessness; C) aimless activity; D) 
repetitive and/or compulsive behaviour; E) wanting to spend time outside; and F) 
willingness to jump. Negative scores in the y axis represent a decrease (i.e., - 1 = mild, 
and – 2 = significant), while positive scores represent an increase (i.e., 1 = mild, and 2 







Chapter 4: The effects of Telmisartan (Semintra™, Boehringer Ingelheim) on the 
clinical signs of CDS in cats  230 
 
4.3.4.7 Affection with people in the house 
 
4.3.4.7.1 Treatment A 
 
During the treatment, more than a third of the cats (37.2%; n = 6) were more 
affectionate than before, and 2% (n = 1) of cats were less affectionate than 
before. After the treatment, 17.6% (n = 3) of cats were more affectionate than 
before, and 11.8% (n = 2) were less than before. When comparing the different 
time points, cats on this treatment were more affectionate during Q60, when 
compared to Q120 (p = 0.03) (Figure 4.5A). 
 
4.3.4.7.2 Treatment B 
 
During the treatment, a third of cats (33.3%; n = 6) were more affectionate than 
before, and 2% (n = 1) were less than before. In contrast, once they finished 
the treatment, 5.9% (n = 1) of cats were more affectionate than before, and the 
same percentage (5.9%; n = 1) were less than before (Figure 4.5A). 
 
4.3.4.8 Aggression towards animals or people 
 
4.3.4.8.1 Treatment A 
 
During the treatment, 9.8% (n = 2) of cats were more aggressive than before, 
and 2% (n = 1) were less aggressive than before. After the treatment, 11.8% 
(n = 2) of the cats were more aggressive, and 5.9% (n = 1) were less than 
before (Figure 4.5B). 
 
4.3.4.8.2 Treatment B 
 
During the treatment, 2% (n = 1) of cats were more aggressive than before, 
and 5.9% (n = 1) of them were less than before. After receiving the treatment, 
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none of them were more aggressive than before, and 5.9% (n = 1) were less 
than before (Figure 4.5B). 
 
4.3.4.9 Tolerance of handling 
 
4.3.4.9.1 Treatment A 
 
During the treatment, almost a quarter of the cats (21.6%; n = 4) tolerated 
being handled more than before, and 15.7% (n = 3) less than before. After the 
treatment, none of the cats tolerated being handled more than before, and 
17.7% (n = 3) less than before. In addition, cats tolerated being handled more 
during treatment A, compared to when it was finished (p = 0.04) (Figure 4.5C). 
 
4.3.4.9.2 Treatment B 
 
During the treatment, 15.7% (n = 3) of cats tolerated being handled more than 
before, and 5.9% (n = 1) less than before. After the treatment, 11.8% (n = 2) 
of the cats tolerated being handled more than before, and 11.8% (n = 2) less 
than before (Figure 4.5C).  
 
4.3.4.10 Tolerance of being left alone 
 
4.3.4.10.1 Treatment A 
 
During the treatment, a small proportion of cats (5.9%; n = 1) tolerated being 
left alone more than before, and 11.8% (n = 2) less than before. After the 
treatment, none of the cats tolerated being left alone more than before, and 
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4.3.4.10.2 Treatment B 
 
During the treatment, 7.8% (n = 1) of cats tolerated being left alone more than 
before, and 7.8% (n = 1) less than before. In contrast, after the treatment, none 
of these cats tolerated being left alone more than before, and 23.5% (n = 4) 
less than before (Figure 4.5D). 
 
4.3.4.11 Tolerance of other animals in the household 
 
4.3.4.11.1 Treatment A 
 
During the treatment, a few cats (2%; n = 1) tolerated other animals more than 
before, and 5.9% (n = 3) less than before. After the treatment, none of the cats 
tolerated other animals more than before, and 11.8% (n = 2) less than before 
(Figure 4.5E). 
 
4.3.4.11.2 Treatment B 
 
During the treatment, the same proportion of cats tolerated other animals more 
(2%; n = 1) and less (2%; n = 1) than before. In contrast, after the treatment, 
none of the cats tolerated other animals more than before, and 11.8% (n = 2) 
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Figure 4.5 Behavioural changes. Changes through time (mean ± SD), for both 
treatments, in A) affection with people in the house; B) aggression towards animals 
or people; C) tolerance of handling; D) tolerance of being left alone; and E) tolerance 
of other animals in the household. Negative scores in the y axis represent a decrease 
(i.e., - 1 = mild, and – 2 = significant), while positive scores represent an increase (i.e., 
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4.3.4.12 Time spent grooming  
 
4.3.4.12.1 Treatment A 
 
During the treatment, 15.7% (n = 3) of cats spent more time grooming than 
before, and 2% (n = 1) of cats spent less time than before. After the treatment, 
5.9% (n = 1) of cats spent more time grooming than before, and 23.5% (n = 4) 
less than before (Figure 4.6A). 
 
4.3.4.12.2 Treatment B 
 
During the treatment, 7.8% (n = 1) of cats spent more time grooming than 
before, and 3.9% (n = 1) of cats less than before. After the treatment, 5.9% (n 
= 1) of cats spent more time grooming than before, and the same percentage 
(5.9%; n = 1) less than before (Figure 4.6A). 
 
4.3.4.13 Time spent sleeping at night 
 
4.3.4.13.1 Treatment A 
 
During the treatment, almost a quarter of the cats (21.6%; n = 4) slept more at 
night than before, and 7.8% (n = 1) slept less than before. After finishing the 
treatment, 5.9% (n = 1) of the cats slept more at night than before, and 11.8% 
(n = 2) slept less than before (Figure 4.6B). 
 
4.3.4.13.2 Treatment B 
 
During the treatment, a quarter of the cats (25.5%; n = 4) slept more at night 
than before, and 7.8% (n = 1) of cats slept less than before.  In contrast, when 
the treatment finished, 5.9% (n = 1) of cats slept more at night than before, 
and 29.5% (n = 5) less than before. In addition, cats slept more in general 
Results 
 
Chapter 4: The effects of Telmisartan (Semintra™, Boehringer Ingelheim) on the 
clinical signs of CDS in cats  235 
 
during treatment B, when compared to when it was finished (p = 0.05) (Figure 
4.6B). 
 
4.3.4.14 Time spent sleeping during the day 
 
Overall, female cats from both treatment groups slept more during the day than 
males at Q60 (p = 0.007). 
 
4.3.4.14.1 Treatment A 
 
During the treatment, almost a third of the cats (29.4%; n = 5) slept more during 
the day, and 17.6% (n = 3) less than before. After the treatment, 17.6% (n = 3) 
of cats slept more during the day, and 11.8% (n = 2) less than before (Figure 
4.6C). 
 
4.3.4.14.2 Treatment B 
 
During the treatment, 19.6% (n = 3) of cats slept more during the day than 
before, and 9.8% (n = 2) less than before. After the treatment, 11.8% (n = 2) 
of cats slept more during the day than before, and 5.9% (n = 1) less than before 
(Figure 4.6C). 
 
4.3.4.15 Vocalisation during the night 
 
Overall, female cats on both treatments cried less during the night than male 
cats (p = 0.01). Furthermore, when comparing the different time points, female 
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4.3.4.15.1 Treatment A 
 
During the treatment, almost a quarter of cats (23.5%; n = 4) cried less at night 
than before, and 9.8% (n = 5) more than before. In contrast, after the treatment, 
5.9% (n = 1) of cats cried less at night than before, and 35.3% (n = 6) more 
than before. In addition, cats cried less during the night while receiving the 
treatment, when compared to when it was finished (p = 0.02) (Figure 4.6D). 
 
4.3.4.15.2 Treatment B 
 
During the treatment, more than a third of the cats (37.2%, n = 19) cried less 
at night than before, and 17.7% (n = 9) more than before. After the treatment, 
none of the cats cried less at night than before, and 35.3% (n = 6) more than 
before. In addition, cats cried less during the night when receiving the 
treatment, when compared to when it was finished (p = 0.006) (Figure 4.6D). 
 
4.3.4.16 Vocalisation during the day 
 
4.3.4.16.1 Treatment A 
 
During the treatment, a small number of cats (15.7%; n = 8) cried less during 
the day than before, and 29.4% (n = 5) more than before. After the treatment, 
none of the cats cried less during the day than before, and 47.1% (n = 8) more 
than before. In addition, cats cried less during the day when on treatment A, 
compared to when the treatment finished (p = 0.05) (Figure 4.6E). 
 
4.3.4.16.2 Treatment B 
 
During the treatment, a quarter of cats (25.5%; n = 4) cried less during the day 
than before, and 27.5% (n = 5) more than before. In contrast, after the 
treatment, 5.9% (n = 1) of cats cried less during the day than before, and 35.3% 
(n = 6) more than before (Figure 4.6E). 
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Figure 4.6 Behavioural changes. Changes through time (mean ± SD), for both 
treatments, in A) time spent grooming; B) time spent sleeping at night; C) time spent 
sleeping during the day; D) vocalisations during the night; and E) vocalisations during 
the day. Negative scores in the y axis represent a decrease (i.e., - 1 = mild, and – 2 = 
significant), while positive scores represent an increase (i.e., 1 = mild, and 2 = 
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4.3.4.17.1 Treatment A 
 
During the treatment, almost a third of cats (29.4%; n = 5), ate more than 
before, and 9.8% (n = 2) less than before. After the treatment, the same 
percentage (29.4%; n = 5) ate more than before, and 11.8% (n = 2) of cats ate 
less than before (Figure 4.7A). 
 
4.3.4.17.2 Treatment B 
 
During the treatment, more than a third (35.3%; n = 6) of cats ate more than 
before, and 19.6% (n = 3) ate less than before. After the treatment, 17.7% (n 
= 3) ate more than before, and 29.4% (n = 5) ate less than before (Figure 
4.7A). 
 
4.3.4.18 Changes in weight 
 
4.3.4.18.1 Treatment A 
 
During the treatment, 15.7% (n = 3) of cats weighed more than before, and 
19.6% (n = 3) less than before. After the treatment, 11.8% (n = 2) weighed 
more than before, and 35.3% (n = 6) less than before (Figure 4.7B). 
 
4.3.4.18.2 Treatment B 
 
During the treatment, 15.7% (n = 3) of cats weighed more than before, and 
15.7% (n = 3) less than before. After the treatment, 11.8% (n = 2) weighed 
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4.3.4.19 Drinking  
 
4.3.4.19.1 Treatment A 
 
During the treatment, 29.4% (n = 5) of cats drank more than before, and none 
of the cats drank less than before. After the treatment, none of the cats drank 
more than before, and 5.9% (n = 1) drank less than before. Cats drank more 
water in general during treatment A, compared to when it was finished (p = 
0.04) (Figure 4.7C). 
 
4.3.4.19.2 Treatment B 
 
During the treatment, 21.5% (n = 4) of cats drank more than before, and 11.8% 
(n = 2) less than before. After the treatment, 23.5% (n = 4) of cats drank more 
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Figure 4.7 Behavioural changes. Changes through time (mean ± SD), for both 
treatments, in A) appetite; B) changes in weight; and C) drinking. Negative scores in 
the y axis represent a decrease (i.e., - 1 = mild, and – 2 = significant), while positive 
scores represent an increase (i.e., 1= mild, and 2= significant) in the behaviours; zero 





4.3.4.20.1 Treatment A 
 
During the treatment, 5.9% (n = 1) of the cats were more constipated than 
before, and 3.9% (n = 1) were less constipated than before. After the 
treatment, none of the cats were more constipated than before, and 5.9% (n = 
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4.3.4.20.2 Treatment B 
 
During the treatment, 5.9% (n = 1) of cats were more constipated than before, 
and none of them were less than before. These proportions remained the same 




4.3.4.21.1 Treatment A 
 
During the treatment, none of the cats had more diarrhoea than before, and 
5.9% (n = 1) had less than before. These percentages remained the same after 
the treatment finished (Figure 4.8B). 
 
4.3.4.21.2 Treatment B 
 
During the treatment, 7.8% (n = 1) of the cats had more diarrhoea than before, 
and none of them less than before. These percentages remained the same 
after the treatment finished (Figure 4.8B). 
 
4.3.4.22 Passing faeces outside litter box 
 
4.3.4.22.1 Treatment A 
 
During the treatment, 7.8% (n = 1) of cats showed less toileting mistakes than 
before, and 11.8% (n = 2) more than before. After the treatment, 5.9% (n = 1) 
showed less toileting mistakes than before, and 11.8% (n = 2) of cats made 
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4.3.4.22.2 Treatment B 
 
During the treatment, 2% (n = 1) of cats showed less toileting mistakes than 
before, and 5.9% (n = 1) made more. After the treatment, none of the cats 
showed less toileting mistakes than before, and 11.8% (n = 2) made more 
(Figure 4.8C).  
 
4.3.4.23 Passing urine outside litter box 
 
4.3.4.23.1 Treatment A 
 
During the treatment, 11.8% (n = 2) of the cats showed less toileting mistakes 
than before, and 7.8% (n = 1) made more. After the treatment, 5.9% (n = 1) of 
cats showed less toileting mistakes than before, and 17.6% (n = 3) made more. 
When comparing the different time points, cats had less toileting mistakes (i.e., 
urination) in Q60 than in Q120 (p = 0.05) (Figure 4.8D). 
 
4.3.4.23.2 Treatment B 
 
During the treatment, 9.8% (n = 2) of the cats showed less toileting mistakes 
than before, and 3.9% (n = 1) made more. After the treatment none of the cats 





4.3.4.24.1 Treatment A 
 
During the treatment, 7.8% (n = 1) vomited less than before, and 15.7% (n = 
3) more than before. After the treatment, none of the cats vomited less than 
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4.3.4.24.2 Treatment B 
 
During the treatment, 5.9% (n = 1) of the cats vomited less than before, and 
9.8% (n = 2) more than before. After the treatment, none of the cats vomited 
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Figure 4.8 Behavioural changes. Changes through time (mean ± SD), for both 
treatments, in A) constipation; B) diarrhoea; C) passing faeces outside the litter box; 
D) passing urine outside the litter box; and E) vomiting. Negative scores in the y axis 
represent a decrease (i.e., - 1 = mild, and – 2 = significant), while positive scores 
represent an increase (i.e., 1 = mild, and 2 = significant) in the behaviours; zero 
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4.3.4.25 Hair loss or hair thinning 
 
4.3.4.25.1 Treatment A 
 
During the treatment, 11.8% (n = 2) of cats lost less hair than before, and 3.9% 
(n = 1) more than before. After the treatment, none of the cats lost less hair 
than before, and 11.8% (n = 2) more than before. In addition, cats lost less hair 
during treatment A, than when it was finished (p = 0.03) (Figure 4.9A). 
 
4.3.4.25.2 Treatment B 
 
During the treatment, none of the cats lost less hair than before, and 7.8% (n 
= 1) more than before. After the treatment, none of the cats lost less hair than 
before, and 11.8% (n = 2) more than before (Figure 4.9A). 
 
4.3.4.26 Hearing loss  
 
4.3.4.26.1 Treatment A 
 
During the treatment, 1.9% (n = 1) of cats appeared to hear less than before, 
and 5.9% (n = 1) more than before. After the treatment, none of the cats 
appeared to hear less than before, and 5.9% (n = 1) more than before (Figure 
4.9B). 
 
4.3.4.26.2 Treatment B 
 
During the treatment, none of the cats appeared to hear less than before, and 
2% (n = 1) more than before. After the treatment, none of the cats appeared 
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4.3.4.27 Vision loss 
 
4.3.4.27.1 Treatment A 
 
No changes in vision were reported at any time in any of the cats (Figure 4.9C). 
 
4.3.4.27.2 Treatment B 
 
Only 2% (n = 1) of cats were reported to see better than before, and none of 
them less well than before. After the treatment, no changes in vision were 
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Figure 4.9 Behavioural changes. Changes through time (mean ± SD) for both 
treatments, in A) hair loss or hair thinning; B) hearing loss; and C) vision loss. Negative 
scores in the y axis represent a decrease (i.e., - 1 = mild, and – 2 = significant), while 
positive scores represent an increase (i.e., 1 = mild, and 2 = significant) in the 
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This is the first study to show that PPARγ is expressed in the cat brain; 
however, the administration of telmisartan, a PPARγ agonist, failed to reduce 
the clinical signs of CDS in affected cats. This study provides additional 
evidence about the correlation between age and certain physical and 
behavioural changes in the cat, including weight loss, house-soiling (in this 
case passing faeces outside the litter box), and repetitive and/or compulsive 
behaviours. 
 
Immunohistochemistry revealed PPARγ expression in all regions of the cat 
brain, and in all age groups. This is consistent with rat studies, where PPARs 
have been found in the cortex, the hippocampus, and the olfactory areas of 
the brain306, 307. Interestingly, the number of these receptors vary with disease 
in the human brain,  being increased in AD308. Further studies are needed to 
determine whether the number of PPARγ increases in the brains of cats with 
CDS. 
 
That correlations were found between age and certain behaviours, including 
weight loss is not surprising. Weight loss is observed frequently in elderly cats; 
in fact, aged cats tend to be underweight309-311. In a questionnaire-based study 
that assessed age-related changes in over 800 cats, owners reported that 
almost 40% of the cats had lost weight once they were over 11 years of age18. 
This weight loss can be associated with ageing itself (i.e., sarcopenia of 
ageing312), which is associated with normal physiological decline. However, it 
may be exacerbated by elderly cats having reduced senses of smell and 
taste313, and the digestion and absorption of nutrients, as well as intestinal 
motility and blood flow are considerably reduced with age314-317. The presence 
of disease may also contribute to weight loss, especially those diseases that 
may lead to hyporexia313, such as dental disease, inflammatory bowel disease, 
neoplasia, etc., or diseases that alter metabolism, such as hyperthyroidism 
and diabetes mellitus. Significant associations have been found between 
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weight loss and kidney disease, blindness, hyperthyroidism, arthritis, heart 
disease, and deafness in elderly cats18. Significant associations have also 
been found between a decreased appetite and kidney disease, blindness, 
lower urinary tract infection, hyperthyroidism, arthritis, deafness, and dental 
disease18. 
 
House-soiling (both faeces and urine) has been associated with age in cats. It 
can be caused by many different interacting factors and illnesses; however, it 
is considered to be one of the clinical signs of CDS once all other causes have 
been ruled out16. One study looking at behavioural changes in cats over 11 
years of age reported that house-soiling occurred in more than half of the cats, 
regardless of whether they had access outside or to a litterbox18. Some of the 
potential causes for house-soiling include urinary tract disorders (e.g., urinary 
tract infections, stones or neoplasia); chronic diseases that lead to polyuria 
and polydipsia (i.e., hyperthyroidism, diabetes mellitus, or chronic kidney 
disease); gastrointestinal disorders (e.g., lymphoma, or constipation); 
musculoskeletal disorders (i.e., osteoarthritis) that prevent cats from using cat-
flaps or high-sided litterboxes; or true behavioural disorders, such as stress. 
Furthermore, increased house-soiling in elderly cats has been associated with 
kidney disease, blindness, lower urinary tract infection, arthritis, and 
deafness18. 
 
Repetitive and/or compulsive behaviours were found to increase with age. 
These types of behaviour can be associated with disorientation, which is 
another major behavioural sign of CDS in cats16. Disorientation (e.g., forgetting 
if they have eaten, forgetting where the food is, or getting stuck in corners) 
may lead to confusion and an increase in stress levels, and cats experiencing 
high levels of stress may display repetitive and/or compulsive behaviours as a 
coping mechanism318. Disorientation may be associated with changes in 
activity levels (e.g., aimless wandering, restlessness, and repetitive activities), 
which have also been reported in aged cats14, 15. Disorientation is sometimes 
associated with agitation; this has also been associated with age, as more than 
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70% of the aged cats included in a questionnaire-based study, appeared to be 
agitated for no apparent reason18. Agitation in elderly cats may be caused by 
many different and often interacting factors and illnesses, including CDS, and 
it has previously been shown to be associated with blindness, and arthritis18.  
 
Despite finding no overall statistically significant differences between the 
treatment groups, nor clear behavioural improvements during the 
administration of telmisartan (Semintra™, Boehringer Ingelheim), available 
evidence suggests that this drug has a strong potential to improve the cognition 
and clinical signs of cats with CDS. Sartans, including telmisartan, have been 
shown to improve memory, cerebral blood flow, and cognition in people with 
AD290, 319 and in mice models of AD134, 298. In addition, studies in humans and 
mice demonstrated that PPAR activators, such as telmisartan, reduce the 
aggregation of amyloid-298 and promote its clearance133, as well as reducing 
the accumulation of tau deposits299 and neuronal loss320, 321. 
 
A number of limitations were identified that could have influenced the findings 




4.4.1 Dose of medication 
 
In this study, telmisartan was administered at 1 mg/kg PO q24h. However, 
telmisartan is now licenced at a dosage of up to 3 mg/kg PO q24h for the 
treatment of hypertension in cats. Telmisartan has a dose response effect in 
reducing hypertension in cats303 (i.e., higher doses of telmisartan will reduce 
high blood pressure more efficiently than lower doses). Similarly, sartans have 
also been shown to have a dose response efficacy at reducing dementia in 
people276. It is therefore possible that a higher dose of telmisartan may be more 
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4.4.2 Sample size 
 
Since this was a pilot study with limited funds, only a limited number of cases 
were recruited. Recruitment was challenging as many cats with clinical signs 
of CDS had illnesses that precluded their recruitment. Initial power calculations 
estimated that 12 to 15 cats in each group should be sufficient to show a 
statistically significant difference between the groups; however, this was not 
shown to be the case. This calculation was based on previously published 
treatment trials on dogs with CDS103, 105, 322. Furthermore, retrospective power 
analyses were performed to determine the sample size needed, for future 
studies, to show a statistically significant difference between treatment groups. 
These showed that 17 cats in each group should be sufficient to show 
statistically significant differences between the groups; since this was the 
number of cats recruited (per group) in this study, it is possible that other 
confounding factors such as dose of medication, duration of the trial, and/or 
placebo effect may have negatively affected the results of the present study. 
 
Another factor that may have reduced the ability to see a significant difference 
between the groups was the low variability between them, as the values from 
the responses for all the behaviours were very similar in both groups. In 
addition, this lack of significance could also be caused by the marked inter-
individual variability in the responses within both groups. 
 
 
4.4.3 Duration of trial 
 
This trial ran for three months. The duration of study was selected based on 
papers investigating CDS treatments in dogs which showed improvements in 
as little as two months in trials looking into the efficacy of nutraceuticals102, 103, 
105, 322. The treatment period was lengthened to three months in the current 
study because cats show more subtle behavioural changes than dogs and 
tend to hide their illness. That no positive effect was seen in this study period 
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may have resulted from cats hiding signs of CDS until more chronic damage 
had occurred than was present in the dogs; if this is true, a longer treatment 
period may be needed before improvements are seen after a positive 
intervention. Alternatively, the duration may have been sufficient, if a higher 
dose of telmisartan had been selected. Currently, there are two ongoing 
studies assessing the effect of telmisartan in human patients with AD142. These 
studies will be running for eight months and one year, respectively, which 
highlights the importance of a long duration of study. 
 
 
4.4.4 Severity of CDS 
 
Only cats with severe CDS were recruited to ensure that they were clear cases 
of CDS and reduce the risk of misdiagnosis. It is therefore possible that once 
CDS is at an advanced stage, the behavioural changes are too severe to be 
improved, minimising the efficacy of any drug intervention. If true, it is plausible 
that, if cats with mild, moderate, or early CDS had been recruited, a positive 
response to treatment may have been detected.   
 
 
4.4.5 Possibility of misdiagnosis 
 
It is possible that some of the cats did not have CDS, or that it was not the only 
cause of their behavioural changes. If any of the cats had other causes for their 
behavioural changes this could have resulted in a heterogeneous group and 
might explain why the telmisartan appeared not to work. While no cats had 
lateralising neurological signs or papilledema that might have suggested an 
intracranial mass lesion or raised intracranial pressure, these conditions could 
have been present as none of the cats were assessed by MRI. While there 
were no retinal changes suggestive of Toxoplasmosis, it is not possible to 
exclude this infection from causing behavioural changes in some of the cats, 
as Toxoplasmosis serology was not assessed. Likewise, other infectious or 
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inflammatory conditions (e.g., feline infectious peritonitis, Bartonellosis, etc.) 
could have been missed if they were causing no ocular changes, or any 
alterations in haematology or serum biochemistry. The accepted cut off for 
hypertension was reduced after the study had started, decreasing from < 180 
mmHg systolic to < 140 mmHg304. It is therefore possible that some of the cats 
had marginal hypertension. The risk of target organ damage from hypertension 
is graded as moderate at 160-180 mmHg, so it is possible that some of the 
cats had hypertensive encephalopathy304. However, if that were the case, it 
could be argued that, since telmisartan is an effective treatment for 
hypertension in the cat 301-303, this drug should have treated the cats regardless 
of whether their behavioural changes resulted from hypertension or CDS; that 
said, higher doses of telmisartan than the one used in the present study (1 
mg/kg) may be required to effectively normalise blood pressure. 
 
 
4.4.6 Placebo effect 
 
Most of the statistically significant behavioural changes were reported in cats 
from group A (placebo). Interestingly, the majority of these behaviours were 
associated with CDS, including affection with people within the house, aimless 
activity, house-soiling (i.e., urination), increased tolerance of handling, and 
vocalisation during the day. Moreover, two of the behaviours added as 
distractors were reported to change in the cats of this treatment group: 
drinking, and hair loss/hair thinning. In contrast, cats from group B (telmisartan) 
were reported to display changes in only one behaviour related to CDS (i.e., 
time spent sleeping at night) and none of the distractors. Furthermore, owners 
of cats from both treatment groups reported changes in some of the same 
behaviours, regardless of whether they are associated with CDS, including 
activity levels, time spent sleeping during the day and vocalisation at night.  
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Hypothesis guessing bias occurs during the process of answering, when 
respondents of a questionnaire think they know what the hypothesis of the 
study is and respond accordingly323. It is also possible that owners may have 
been expecting changes in certain behaviours as they had read about CDS in 
cats.  
 
Another possibility, albeit related, is that too much information may have been 
given to the owners at the time their cats were recruited. When diagnosing a 
disease, it is important that veterinarians explain the disease to the owners, its 
potential causes and clinical signs, plus the available treatments or 
management. It is particularly important to gain the clients’ trust when trying to 
recruit cases of beloved elderly cats into a long trial. However, by oversharing  
information during the recruitment process, or if owners explored the topic in 
detail after their cat has been recruited, this may lead to a respondent’s 
conscious reaction known as faking good bias (also known as social 
desirability), in which the respondents alter their answers in what they believe 
is the desired direction of the study323.  
 
Since some of the cases were recruited through the University of Edinburgh 
email server, with many being doctors and even professors, both of these 
forms of error are possible as educated people are very likely to read up about 
their cat’s disease, including looking into potential treatment options. 
 
4.4.6.1    Alternative hypothesis 
 
Alternatively, it is possible that the improvements seen in both groups of cats 
during the treatment period may have been real. Meaning that the cats in both 
groups did have reduced signs of CDS. This can be explained by the owners 
giving their cats more attention, providing them with all of their key resources, 
plus environmental enrichment, which had a very positive effect in the cats, 
reducing their signs of CDS. This makes sense, as giving cats with CDS more 
positive attention can significantly improve their health and well-being10.  
Discussion 
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4.4.6.2    Solutions 
 
For future studies, solutions to counter the placebo effects include to avoid 
oversharing information to minimise respondent bias, plus the addition of 
measurements that do not rely on owner observations and that provide more 
objective assessments, such as veterinary or behaviourist reports, GPS 
trackers to assess activity levels, video and/or audio recorders to assess the 
amount and frequency of vocalisation, cognitive assessments, etc. Some 
cognitive tests, originally created for its use in dogs, have been modified and 
used to assess learning and memory in cats, such as discrimination and 
reversal learning15 and the delayed nonmatching to position (DNMP) test that 
assesses short-term visuospatial working memory8. Reversal learning is 
tested when the cat is first trained to remember under which shaped pot food 
is hidden (discrimination learning). Once the cat has learned this, the food is 
then hidden under a different-shaped pot, challenging the cat to reverse or 
inhibit what they previously learned during the discrimination phase). Similarly, 
in the DNMP test, cats first learn to displace a pot under which food is hidden 
(there is only one pot placed in one of three possible locations). The next phase 
occurs after a delay of five seconds; in this phase, cats are then presented with 
two pots identical to the one used in the previous phase. One of the pots is 
placed in the same location as in the previous phase and does not contain any 
food; the second pot is placed in one of the remaining two positions (nonmatch) 
and contains the food. While these tests have been successfully used in cats, 
it is important to consider that testing cognition in cats is far more challenging 
than in dogs, as they are motivated by different things, with few cats being 
motivated by food the way many dogs tend to be8, 14.  
 
Besides the aforementioned solutions, other suggestions to improve future 
questionnaire-based studies include randomising the order of the responses 
to prevent learning bias in the respondents (i.e., randomly changing the order 
of the questions in each questionnaire)323. This can be particularly effective 
when owners have to respond to similar questionnaires through time; by doing 
Discussion 
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this, respondents will not learn the order of the questions being asked. 
Furthermore, other solutions include increasing the number of outcome 
measures in order to detect more subtle clinically significant changes (e.g., 
using a scale from ‘0 to 10’ instead of ‘- 2, - 1, 0, 1, 2’); and using vertical 
response formats instead of horizontal ones, as the latter are more difficult to 
read and follow (i.e., to present the answers in a listed format, where the 
answers are listed from the top to bottom of the sheet, instead of from left to 
right, as it was used in the present study), and to prevent confusion when 
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In conclusion, there is mounting evidence suggesting that telmisartan reduces 
brain inflammation, provides neuroprotection, restores cognitive function, and 
reduces the accumulation of both amyloid- and hyperphosphorylated tau in 
mammals. However, further studies are needed to determine the true potential 






































“The cat is domestic only as far as suits its own ends…” 
-Saki (H. H. Munro)
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Cognitive dysfunction syndrome (CDS) is an age-related condition that affects 
both cats and dogs8. In spite of this, research has predominantly been 
conducted in dogs, with the findings being extrapolated to cats15. While a few 
studies have assessed the clinical presentation of CDS in cats15, 90, little is 
known about the neuropathology of the disease in this species. It is important 
to try to elucidate the mechanisms behind the pathophysiology of this 
condition, and correlate this with its clinical signs in order to provide early 
diagnosis and effective treatments in each of the species. 
 
Pet cats are now living longer than ever1, 324. This is mainly due to 
improvements in veterinary medicine, nutrition, and changes in the way we 
keep our pets (e.g., indoor living)1, 324. Increased lifespans result in more 
elderly cats attending veterinary practices1, 325-327; therefore, veterinarians 
must be capable of recognising the early signs of age-related changes and 
disease in this species. Moreover, veterinarians should be able to differentiate 




5.1 Age-related changes in cats 
 
Even though advanced age is known to produce several anatomical and 
physiological changes, it is argued that ageing, in itself, is not a disease10. In 
cats, some signs of normal ageing can be easily recognised, such as the loss 
of muscle mass (i.e., sarcopenia), changes in appetite and weight loss, and 
over-grown nails, amongst others10. Some less perceptible changes may also 
occur, such as alterations in the function of the kidneys, liver, and brain10, 313, 
328. While some of these changes may not be clinically obvious, others can be 
detected by veterinarians and even cat owners. In a questionnaire-based study 
that assessed the prevalence of disease and age-related changes in more 
than 800 cats, owners were able to recognise age-related changes and signs 
of disease in their cats18. The most common diseases affecting these cats 
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were arthritis, hyperthyroidism, dental disease, and chronic kidney disease. Of 
note, the prevalence of these diseases increased significantly in the 20 year 
period from 1995 to 201518, suggesting that both veterinarians and cat owners 
are becoming more aware of these conditions and have stopped 
misinterpreting them as normal ageing.  
 
Elderly cats can display a number of age-related behavioural changes. Some 
of these include reduced grooming, reluctance to eat, and a reduced 
willingness to play, hunt, and go outside18, 90, 329. While some of these 
behaviours may result from normal ageing, others may be associated with 
underlying disease, such as increased water intake, reluctance to eat, and 
weight loss, amongst others18. In one study, these behaviours were mostly 
associated with diseases such as hyperthyroidism, arthritis, blindness, and 
kidney disease18. 
 
In addition, some of the behaviours displayed by elderly cats that can be 
caused by normal ageing, may actually be associated with CDS when they 
cannot be attributed to underlying medical illness13, 14. These include house-
soiling, increased affection, and increased vocalisation18. 
 
 
5.2 Age-related changes associated with CDS in cats 
 
Cognitive dysfunction is a common age-related syndrome that produces well-
recognised behavioural changes and, eventually, leads to cognitive decline 
and dementia13, 14. Importantly, CDS has been shown to be a highly prevalent 
condition,  with around 50% of cats over 15 years of age displaying at least 
one of these behavioural changes14, 16. This underlines the significance of 
further studies into this condition. 
 
The behavioural changes associated with CDS are summarised under the 
acronym VISHDAAL20 and include increased Vocalisation; altered Interactions 
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with their owners (e.g., increased affection); alterations in Sleep-wake cycles; 
House-soiling; spatial and/or temporal Disorientation; altered Activity levels; 
Anxiety; and impaired Learning and memory20. Some of these behaviours are 
more common than others; our most recent study shows that 60% of cats 
vocalised excessively, with 30% of them doing so mainly at night; 50% of them 
demanded more attention; and 30% of them house-soiled18. It is still unknown 
whether there is an order of appearance of these behaviours, and it is likely 
that individual variations occur. 
 
It is important to recognise that some of these behaviours may be caused by 
other conditions, rather than by CDS. For instance, increased vocalisation 
could result from pain, especially when caused by arthritis, which is a highly 
prevalent condition in elderly cats18, 330, 331. A recent study focused on trying to 
understand the cause of increased vocalisation in elderly cats with CDS, based 
on owners’ reports19. This study showed that most of the cats primarily 
vocalised due to disorientation (40%) or attention seeking (40%)19. While only 
3% of owners reported their cat’s vocalised because of pain19, most of the cats 
appeared to vocalise for a number of reasons, so pain may have been under-
recognised. 
 
It is clear that there is a fine line between what can be considered to be normal 
and abnormal age-related changes. This highlights the importance of 
efficiently recognising and differentiating between them. This represents a 
challenge for veterinary practitioners who need to conduct a careful and 
exhaustive examination of their elderly patients in order to obtain an adequate 
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5.3 Neuropathology of ageing and CDS in cats and its 
similarities to humans 
 
Besides the clinical signs and behavioural abnormalities, cats with CDS also 
develop neuropathology, including the accumulation of amyloid- (A) and 
hyperphosphorylated tau deposits52, 63-67.  
 
According to the UniProt Consortium database, the A protein has a similar 
amino acid sequence in humans, cats and wild-type mice; the A sequences 
in cats and mice are 96.8% similar to human A332. In cats and humans, the 
A sequence is only one amino acid different, versus three amino acids 
different between mice and humans52.  
 
The amino acid sequence for the tau protein is more similar between cats and 
humans (i.e., 84.4% similarity), than between wild-type mice and humans (i.e., 
74.2% similarity)332. In addition, unlike mice, that produce only three isoforms 
of tau (i.e., 4-repeats), cats produce the same six tau isoforms as humans (i.e., 
3 and 4-repeats)52. The complete amino acid sequences for both A and tau 
proteins, in humans, cats, and wild type mice can be found in Appendix 5.1. 
 
The present study assessed the presence and distribution of A and 
hyperphosphorylated tau in the cat brain. For this, immunohistochemistry of 
seven different brain regions was performed in cats of various ages, with and 
without CDS. The cats were shown to accumulate both intracytoplasmic and 
extracellular deposits of A, as well as nuclear and cytoplasmic 
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5.3.1 A pathology in cats and its similarities to Alzheimer’s 
disease (AD) 
 
Cats of all ages were shown to accumulate intracellular and extracellular A 
deposits; however, individual variations were found, as well as differences 
between the age groups.  
 
While intracytoplasmic A was found within the neurons of cats of all ages, 
younger cats were shown to have more of these aggregates than older cats. 
Most of the young cats were shown to have these intracytoplasmic A deposits 
in the cortical brain regions, whereas only a few young cats were shown to 
have them in other brain regions, such as the hippocampus, locus coeruleus, 
and cerebellum. In contrast, the proportion of cats with intracytoplasmic A in 
the hippocampus, locus coeruleus, and cerebellum, increased with age. In 
humans, intracytoplasmic A is known to start accumulating at young ages 
and to progress with age157, 158. Furthermore, as intracytoplasmic A pathology 
progresses and neurons die, A is then released into the extracellular spaces, 
leading to the formation of extracellular A deposits and plaques, promoting 
further aggregation159. The same pattern was observed in the cats in this study, 
as intracytoplasmic A deposits tended to decrease with age; in addition, those 
elderly cats with the largest extracellular deposits had very few to no 
intracytoplasmic A.   
 
The early stage of intracytoplasmic A accumulation within neurons has been 
shown to be a harmless event56; in fact, it has been suggested that intracellular 
A may confer neuroprotection as it has antioxidant properties160, 161. However, 
as A pathology progresses and intracytoplasmic A increases, it becomes 
toxic altering synapsis and promoting cytoskeleton and mitochondrial 
dysfunction56, 157, 159. In AD, intracytoplasmic A has been reported to 
accumulate in the areas that are first affected by disease, such as 
hippocampus and entorhinal cortex56, 159. A similar pattern was found in the 
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present study; as cats became older, intracytoplasmic A deposits appeared 
in the hippocampus, cerebellum, and locus coeruleus. 
 
As is the case in humans, extracellular A deposits in cats are formed from the 
A42 peptide63, 64. In contrast, A40 deposits, which are commonly found in 
the blood vessels of elderly humans (i.e., cerebral amyloid angiopathy)54, 56, 
have been only rarely described in elderly cats65.  
 
Extracellular diffuse deposits of A were also found in cats of all ages. Younger 
cats had smaller extracellular A deposits, whereas older cats had larger A 
deposits. Of note, the youngest cat shown to have extracellular A deposition 
was a 4-years-old, which contradicts previous reports showing that A 
deposits started to accumulate at the age of eight years in the cat brain52, 63, 64, 
150. This finding suggests that extracellular A in cats can start aggregating 
earlier than has been previously observed. The location of these deposits was 
found to vary between the age groups. Younger cats accumulated few 
extracellular A deposits, and they were mainly in the cortex, whereas older 
cats had larger deposits, which were mainly in the cortex, and also in the 
hippocampus. This suggests that A pathology in cats begins in the cortical 
brain regions and later progresses to the hippocampus, as it happens in 
humans with AD60. Deposits of A in humans start  aggregating in cortical 
areas of individuals as young as 20 years old, decades before developing 
signs of AD151; as the disease progresses, these deposits tend to spread to 
the hippocampus60. 
 
In accordance with previous studies52, 64, 150, extracellular A in cats was shown 
to accumulate in a diffuse pattern, occasionally forming patches. This diffuse 
pattern of deposition is also known to occur in humans, and is thought to be 
an early stage of plaque formation.53, 54 Interestingly, a 16-year-old cat in the 
current study accumulated A in a more typical plaque-like pattern, suggesting 
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that cats can potentially develop senile plaques; however, they might not 
normally live long enough for this to occur. 
 
While behavioural changes were not extensively assessed for this part of the 
present study, previous studies have shown that cats with A pathology can 
display abnormal behaviours that are associated with CDS, such as confusion, 
disorientation, and increased vocalisation63, 67; however, neither the severity or 
the prevalence of these behaviours have been correlated with the extent of A 
deposition64. The same lack of correlation has also been reported in humans 
with AD, where the severity of A pathology has not been correlated with the 
clinical signs displayed by affected people54, 60, 64, 147. 
 
 
5.3.2 Tau pathology in cats and its similarities to AD 
 
The current study found that the brains of cats of all ages strongly expressed 
the same tau isoforms that are found in humans (i.e., 3 and 4-repeat isoforms), 
as has been previously reported by others52. 
 
In the present study, some elderly cats were shown to accumulate 
intracytoplasmic deposits of hyperphosphorylated tau. Since these deposits 
occupied most of the cytoplasm and there were no changes in the shape of 
the affected neurons, these are believed to be pre-tangles, which are 
considered to be an early stage of neurofibrillary tangles (NFT)77, as previously 
reported by others52, 64, 150.  
 
In the current study, the largest number of pre-tangles were mostly found in 
the cortex of elderly cats, whereas lower numbers were found in other regions, 
such as the entorhinal cortex and the hippocampus, suggesting that tau 
pathology starts in the cortical regions and later progresses to the 
hippocampus and entorhinal cortex. If true, this differs from the initial stage of 
disease in humans, which starts in the transentorhinal cortex60, a region that 
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was not assessed in the present study. Therefore, it is impossible to say 
whether tau pathology truly begins in the cortical regions or in the 
transentorhinal cortex. Further studies are needed to determine the regions in 
which tau pathology begins in the cat brain and its progression with age. 
 
Even though tau pathology was predominantly found in the brains of elderly 
cats, two young cats, aged four and 6-years-old, were found to have 
occasional pre-tangles, which occurred within the cortical brain regions. The 
presence of pre-tangles at this young age could be the result of a non-
diagnosed neurological disorder that produces tauopathy, and/or an age 
miscalculation, with the cats being older than originally recorded. Alternatively, 
it could potentially suggest that in some cases, and similarly to A, tau 
pathology in cats might begin at a young age. In humans, early stages of NFT 
have been reported in people as young as 25 years old, and this increases 
with age, leading to more severe stages of disease77. 
 
For the first time, significant associations were found between the presence of 
pre-tangles and CDS. The present study demonstrated that cats with CDS had 
larger numbers of pre-tangles than cats without CDS. In humans, strong 
correlations have been reported between NFT and cognitive decline169. 
However, due to the small number of CDS cases, further studies are needed 
to corroborate these findings, and to determine whether there is a correlation 
between the presence of pre-tangles, and the prevalence and severity of 
behavioural changes. 
 
In addition, this was also the first time that intranuclear tau was found in both 
phosphorylated and non-phosphorylated states, within the cat brain. This was 
validated by performing a number of experiments, such as using isotype 
controls for each of the antibodies; dephosphorylating the tau protein using 
alkaline phosphatase; and performing Western blots on different cell structures 
after fractionation (e.g., nuclear fraction, cytoplasmic fraction, etc.).  
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Intranuclear tau is known to be present in the human brain and is believed to 
have a neuroprotective role181, 182, 187, 188. Tau can translocate to the nucleus to 
bind and protect DNA182, 187. Since this process is believed to be regulated by 
phosphorylation182, 187, abnormal phosphorylation of tau may alter its ability to 
translocate to the nucleus and to bind to DNA182, 189-191. 
 
The highest number of intranuclear deposits was found mainly in the cortex of 
younger cats, and the proportion of cats showing intranuclear deposits tended 
to decrease with age. In contrast, elderly cats with pre-tangles were shown to 
have few to no nuclear labelling. This suggests that intranuclear tau is 
predominantly found in younger cats and, as animals’ age, it decreases as the 
pathology progresses and pre-tangles form. The picture appears to be more 
complex in humans, where  intranuclear tau increases with age, reaching its 
most prevalent in geriatric people193; however, in people with AD, intranuclear 




5.4 Diagnosis of CDS in cats  
 
The diagnosis of CDS can only be made by exclusion;  ruling out all other 
potential causes for the behavioural changes displayed by the affected cats13, 
14. This is a challenging task for veterinary practitioners, who need to have a 
high index of suspicion to investigate the cause of the cats’ behavioural 
abnormalities and then have the ability to perform thorough and extensive 
examinations. New diagnostic tools are therefore needed to facilitate efficient 
and early diagnosis. 
 
Normal ageing alters the anatomy of the brain and its various structures. As 
individuals get older, age-related changes start to appear, such as shrinkage 
of the brain. As these changes progress, they may later lead to cognitive 
decline. Imaging techniques, such as computed tomography (CT) and 
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especially magnetic resonance imaging (MRI), have shown great potential as 
diagnostic tools for the assessment of age-related brain changes in humans.  
 
The present study assessed brain atrophy and other age-related brain 
changes in cats of various ages, with and without CDS, by using a 1.5T MRI.  
 
 
5.4.1 Age-related brain changes in cats and their similarities 
to humans 
 
As mentioned previously, imaging techniques have been widely used for the 
diagnosis of age-related brain changes in humans. They are particularly useful 
with AD, where some of the changes can be seen decades before people 
develop clinical signs91, and hence, can be considered as early diagnostic 
criteria for AD36-39, 92, 215. These changes include shrinkage of the brain213, 214, 
hippocampal atrophy36-38, and enlargement of the ventricles35.  
 
In the present study, brain changes were mostly detected in elderly cats, as 
expected. In accordance with previous reports, elderly cats in this study were 
shown to develop total brain atrophy226 and enlargement of the lateral 
ventricles40, plus age-related changes in other brain structures, such as the 
occipital lobe and the hippocampus. Elderly cats were also shown to have 
larger lateral ventricles than younger cats, which correlates with age. In 
agreement with this, in humans, enlargement of the ventricles occurs with 
increasing age as the brain shrinks and the size of the cerebrospinal fluid 
(CSF) spaces increases32. It has been proposed that enlargement of the 
ventricles, in addition to the reducing size of the interthalamic adhesion (a 
structure that has shown to become smaller with age224, 226), could be 
diagnostic criteria for brain atrophy and ageing in pets225. However, in the 
current study, the enlargement of the ventricles was not correlated to the size 
of the interthalamic adhesion. 
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Age-related changes were also found in regions of the brain not reported 
previously. For instance, atrophy of the occipital lobe was found in cats with 
CDS, suggesting that this structure could be affected earliest in this condition.  
However, in humans, the occipital lobe is the least affected region31. This may 
represent a difference in the onset and progression of disease between 
species, or be an error, related to the small number of cats with CDS.  
 
Sex-related differences are also of interest. Male cats were found to have 
larger brains than females, which can be explained because male cats are 
physically bigger than female cats. Similarly, male humans have larger total 
brain volumes and hippocampi than females32. In the cats, both the frontal and 
occipital lobes tended to decrease more abruptly with age in female cats. In 
humans, differences in the rate of atrophy have also been reported. Atrophy of 
frontal and temporal lobes is more prominent in men144, 212, whereas atrophy 
of the hippocampi and parietal lobes is more prominent in women144, 212. 
 
Even though cats and humans have been shown to develop similar age-
related brain changes, further studies are needed to assess similarities in the 
progression of these changes and the regions that are mostly affected in both 
species. Since there were only a small number of cats with CDS in this study, 
it is possible that these findings were not a true representation of CDS-related 
brain changes. Furthermore, some of the brains were assessed post-mortem; 
hence, the fixation process may have altered their structure, especially as 
there was no set fixation period. Further longitudinal studies are needed to 
determine the onset and progression of the age-related brain changes that 
could lead to CDS in cats. Moreover, simultaneous assessments of 
behavioural and/or cognitive changes are needed to help elucidate the 
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5.5 Treatment for CDS in cats 
 
To date, there is no treatment available for CDS in cats13, 14; however, 
interventions including environmental enrichment, dietary supplementation, 
specific diets, and potentially, non-licenced drugs, can be offered to try to 
reduce the clinical signs of CDS in cats. 
 
Studies in humans and rodents have shown that drugs that block certain renin-
angiotensin receptors (i.e., AT1) have a positive effect on cognition and 
memory131, 251. Telmisartan is a potent AT1 receptor blocker, plus an activator 
of the peroxisome proliferator activated receptors gamma (PPARγ)134, 282. It 
has been shown to reduce neuroinflammation133, provide neuroprotection, and 
to improve cognition in humans290, 319 and rodents140, 297. Telmisartan has also 
been shown to reduce the accumulation of A and phosphorylated tau 
deposits, and to promote their clearance in in vitro and mice models of AD133, 
298, 299. It is therefore plausible that telmisartan could also have positive effects 
in cats with CDS.  
 
The present study assessed the effects of telmisartan (Semintra™, Boehringer 
Ingelheim) on the clinical signs of CDS in cats by conducting a double-blinded 
placebo-controlled study. To be recruited, cats had to have displayed signs of 
CDS for at least one month prior to this study, but to be otherwise healthy. 
Behavioural changes were assessed using owners’ reports conducted every 
30 days for a total of four months. During the first three months the cats 
received the treatment (i.e., telmisartan or placebo), followed by a wash-out 
period of a further month. 
 
This study demonstrated that some of the behavioural changes associated 
with CDS are also strongly associated with age, for example, weight loss, 
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Despite finding no statistically significant differences between the treatment 
groups, other available evidence suggests that telmisartan has a strong 
potential to improve cognition and to reduce the clinical signs of CDS in cats. 
Further studies are needed to prove this; however, these will need to use 
higher doses of telmisartan and/or for longer treatment periods, a larger 
sample size, and to avoid or minimise placebo effects by not oversharing 
information with the owners. Including more objective measurements, such as 
behaviourists and/or veterinarian assessments would be highly advisable. 
 
 
5.6 The cat as a model for AD  
 
Animal models have been widely used to try to understand the mechanisms 
behind AD and to develop potential therapeutic treatments. However, 
extrapolating findings from animal models to humans has been challenging 
due to natural differences between species333. 
 
Alzheimer’s disease is only one of the many different types of dementia that 
exist in people333; however, it is the most common type, causing around two 
thirds of all dementia cases333. Most cases of AD result from the sporadic form 
of the disease, with far fewer cases of the familial form333. While the 
mechanism behind the development of both types of AD remain unknown55, 
333, the neuropathology produced is very similar333; however, they differ by the 
age of onset, the progression of disease, and their cognitive symptoms55, 333. 
 
The most used animal model for the study of AD is the mouse model; however, 
mice do not naturally develop either AD or its pathology56, 333. For this reason, 
transgenic mice with genetic mutations were developed to recreate the 
neuropathology of the disease333. Of note, these mouse models mimic the 
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Mutations on the amyloid precursor protein (APP) gene that lead to abnormal 
A production are known to exist in the familial form of AD58. For this reason, 
and to reproduce it, transgenic mice that overproduce APP were initially 
created. These mice develop severe A pathology, which is very similar to that 
seen in the human brain56, 333. However, this strain of mice does not develop 
NFT333. Hence, another double transgenic mouse model had to be developed 
that overexpressed APP plus developed NFT333. These models have been 
shown to be useful in elucidating both A and tau pathologies, plus the 
interaction between them333. 
 
Genetically modified mice lacking specific genes associated with AD have also 
been created333. Even though these mice do not produce neuropathology, they 
have been used to try to elucidate the mechanisms behind the pathology, the 
progression of disease and to identify targets for potential drug treatments333.  
 
For decades, transgenic mouse models have been widely used to help 
elucidate some of the mechanisms behind AD and to identify potential 
treatments; however, there is still no cure for AD333. Some of the drugs used 
in pre-clinical trials that have been successful in mouse models, have been 
unsuccessful in clinical trials with people with AD56. For instance, in mouse 
models some drugs have been shown to reduce the production, aggregation, 
and clearance of A, plus reverse cognitive damage56; however, these positive 
changes were not seen in humans with AD56. Moreover, tau mutations in some 
transgenic mice are mostly associated with frontotemporal dementia, rather 
than with AD55. For all the aforementioned, it has been questioned whether 
mice models are a good representation of human AD and/or whether there 
could be more accurate animal models55.  
 
Recent evidence has demonstrated that there are other animals that develop 
the neuropathology seen in AD. For example, horses and dogs accumulate A 
deposits and develop senile plaques334, 335. Dogs have been proposed to be a 
good model for AD, especially as they display similar cognitive impairment, 
 
Chapter 5: Final discussion  273 
 
they develop senile plaques and cerebral amyloid angiopathy, plus they share 
the same environment as humans336; however, they do not produce NFT3. In 
contrast, there are several other animals that naturally and spontaneously 
develop both A and tau pathologies, and could potentially be accurate animal 
models, such as cheetahs337, leopards338, dolphins339, donkeys (data 
submitted) and cats64, 150, amongst others. 
 
The evidence provided by the present study suggests that the domestic cat 
has a strong potential to be a natural model for AD, especially as cats display 
several age-related behavioural changes, plus the neuropathology of ageing 
and CDS, which shares many similarities to that seen in humans. In addition, 
since the owners of cats with CDS are highly motivated to find a treatment that 
reduces their cat’s distress, many are keen to have their cat involved in 
potential treatment trials. 
 
 




The present study provides evidence of the most common age-related brain 
changes in cats with and without CDS. These changes include brain atrophy, 
atrophy of the occipital lobe and the hippocampus, plus enlargement of the 
ventricles. In addition, it proposes the use of MRI as a potential in vivo tool for 
the diagnosis of age-related brain changes and the early recognition of CDS 
in cats.  
 
This study has also shown that cats accumulate A as intracytoplasmic 
deposits within neurons and diffuse extracellular deposits, and accumulate 
hyperphosphorylated tau within neurons as intranuclear deposits and 
intracytoplasmic pre-tangles. Hence, there are several similarities between the 
neuropathologies of ageing and CDS with AD. 
 
While there is still no treatment for CDS, this study has proposed the use of 
telmisartan as a potential treatment, as this drug has been shown to have 
several beneficial effects on cognition in other species.  
 
There is mounting evidence to suggest that mice are probably not the best 
model for the study of AD. In contrast, there are many other animals that 
naturally and spontaneously produce the neuropathology of the disease and 
may be more accurate models for the study of this condition. However, it is 
important to consider the sustainability and welfare implications involved in 
using these animals as potential models. Here the role of elderly cats with CDS 
could be significant, as the owners of these cats are typically very keen for 
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Finally, all the evidence presented in the current study helps to further our 
understanding of CDS in cats. It will help owners and veterinary practitioners 
to distinguish between normal and abnormal age-related changes; it will help 
veterinarians to reach the diagnosis by facilitating them with tools that can be 
used in practice; furthermore, it may help to provide early and efficient 
interventions that will ultimately improve the quality of life and the welfare of 
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Group (n) Median Median Rank Z-value
Cerebellum
Prime (4) 24.3881 26.5 0.3
% Load Mature (23) 26.4364 25.2 0.34
Senior (8) 17.4322 20.4 -0.91
Super Senior (13) 27.2351 25.2 0.2
2.1. Positive amyloid- (A) immunolabelling in the different age groups. 
Means of the one-way ANOVA and Kruskal-Wallis for positive A labelling 
(mOC64 antibody) in all the age groups with standard deviations and 95% 
confidence interval (CI).  
 
 
   
Group (n) Mean St. Dev. 95% CI
Rostral
Prime (5) 4.194 2.831 (2.957, 5.431)
% Load Mature (25) 5.28 1.903 (4.726, 5.833)
Senior (9) 4.809 1.913 (3.887, 5.732)
Super Senior (14) 5.183 1.775 (4.444, 5.922)
Prime (5) 9.65 6.06 (4.58, 17.71)
Burden Mature (25) 19.89 8.76 (17.62, 22.15)
Senior (9) 17.18 8.2 (13.41, 20.96)
Super Senior (14) 17.58 7.25 (14.55, 20.61)
Parietal
Prime (5) 4.291 3.067 (2.892, 5.690)
% Load Mature (25) 5.158 2.137 (4.533, 5.784)
Senior (9) 4.665 2.21 (3.622, 5.707)
Super Senior (14) 5.093 2.071 (4.257, 5.929)
Prime (5) 4.268 1.91 (2.884, 5.652)
Burden Mature (25) 6.23 2.475 (5.611, 6.849)
Senior (9) 5.76 2.266 (4.719, 6.792)
Super Senior (14) 6.056 1.682 (5.229, 6.884)
Occipital
Prime (5) 5.353 1.681 (4.188, 6.518)
% Load Mature (25) 5.473 1.894 (4.952, 5.994)
Senior (9) 4.665 2.052 (3.796, 5.533)
Super Senior (12) 4.995 1.679 (4.243, 5.747)
Prime (5) 15.19 6.46 (10.07, 20.31)
Burden Mature (25) 19 8.6 (16.71, 21.29)
Senior (9) 16.2 9.41 (12.38, 20.01)
Super Senior (12) 17.23 6.66 (13.92, 20.53)
Hippocampus
Prime (4) 28.81 16.65 (6.98, 50.64)
% Load Mature (24) 35.99 20.54 (27.08, 44.90)
Senior (7) 37.43 23.92 (20.93, 53.93)
Super Senior (11) 38.11 23.85 (24.95, 51.28)
Prime (4) 13.75 3.13 (5.41, 22.09)
Burden Mature (24) 18.13 8.63 (14.72, 21.53)
Senior (7) 18.63 11.17 (12.33, 24.94)
Super Senior (11) 20.02 6.17 (14.99, 25.05)
 
 
N Mean StDev SE Mean N Mean StDev SE Mean
% Load 53 6 1.87 0.26 53 4.15 1.61 0.22
Burden 53 21.75 8.41 1.2 53 13.96 6.58 0.9
% Load 53 5.76 2.21 0.3 53 4.19 1.94 0.27
Burden 53 6.73 2.13 0.29 53 5.11 2.07 0.28
% Load 51 5.99 1.77 0.25 51 4.42 1.61 0.23





2.2. Positive amyloid- (A) immunolabelling in grey matter (GM) and 
white matter (WM), and in cats with and without cognitive dysfunction 
syndrome (CDS). Means of the two-sample t-tests for the positive A labelling 
(mOC64 antibody) in all the age groups with standard deviations and standard 
errors of the means for GM and WM; and for cats with and without CDS.   
 
 














N Mean StDev SE Mean N Mean StDev SE Mean
% Load 9 5.08 1.47 0.35 14 5.01 2.04 0.38
Burden 9 18.23 5.15 1.2 14 16.91 8.8 1.7
% Load 9 4.62 1.74 0.41 14 5.12 2.33 0.44
Burden 9 15.26 5.42 1.3 14 16.29 8.22 1.6
% Load 7 4.77 1.41 0.38 14 4.9 2.03 0.38
Burden 7 18.43 5.45 1.5 14 15.96 8.81 1.7
% Load 5 22.22 3.25 1.5 13 43.9 24.8 6.9
Burden 5 295 141 63 13 499 367 102
% Load 8 23.2 21 7.4 13 23.4 19.3 5.3









2.3. Intranuclear immunolabelling of hyperphosphorylated tau (AT8 
antibody) in the different age groups. Means of the one-way ANOVA for the 
intranuclear immunolabelling of hyperphosphorylated tau (AT8 antibody) in all 
age groups with standard deviations and 95% confidence interval (CI). 
 
  
Group (n) Mean St. Dev. 95% CI
Rostral
Prime (6) 21.42 16.71 (11.58, 31.27)
Mature (24) 15.92 17.7 (11.00, 20.84)
Senior (9) 19.99 15.73 (11.95, 28.03)
Super Senior (13) 18.15 17.4 (11.46, 24.84)
Parietal
Prime (6) 1.951 0.472 (1.659, 2.244)
Mature (25) 1.7879 0.5702 (1.6447, 1.9310)
Senior (9) 2.006 0.473 (1.768, 2.245)
Super Senior (13) 1.8336 0.4435 (1.6351, 2.0321)
Occipital
Prime (6) 2.494 0.892 (1.826, 3.161)
Mature (26) 2.156 1.299 (1.835, 2.476)
Senior (9) 2.592 0.953 (2.047, 3.137)
Super Senior (12) 2.277 1.11 (1.805, 2.749)
Hippocampus
Prime (5) 1.753 0.388 (1.226, 2.280)
Mature (24) 2.006 0.589 (1.765, 2.246)
Senior (9) 2.374 0.519 (1.981, 2.766)
Super Senior (13) 2.117 0.669 (1.791, 2.444)
 
 
2.4. Intranuclear immunolabelling of hyperphosphorylated tau (AT100 
antibody) in the different age groups. Means of the one-way ANOVA and 
Kruskal-Wallis for the intranuclear immunolabelling of hyperphosphorylated 
tau (AT100 antibody) in all age groups with standard deviations and 95% 
confidence interval (CI). 
 
Group (n) Mean St. Dev. 95% CI
Rostral
Prime (6) 4.867 2.011 (3.732, 6.001)
Mature (22) 4.475 1.999 (3.883, 5.068)
Senior (9) 4.297 2.068 (3.371, 5.224)
Super Senior (13) 4.916 1.869 (4.146, 5.687)
Parietal
Prime (6) 2.251 0.507 (1.949, 2.554)
Mature (22) 2.1062 0.5483 (1.9519, 2.2605)
Senior (9) 2.146 0.535 (1.900, 2.393)
Super Senior (13) 2.1694 0.4917 (1.9641, 2.3747)
Occipital
Prime (6) 32.88 26.1 (21.05, 44.71)
Mature (25) 23.29 18.44 (17.50, 29.09)
Senior (9) 24.14 22.72 (14.49, 33.80)
Super Senior (12) 27.31 20.55 (18.95, 35.67)
Hippocampus
Prime (6) 47.14 13.74 (27.73, 66.54)
Mature (22) 44.47 22.02 (34.34, 54.61)
Senior (7) 46.7 28.9 (28.7, 64.6)
Super Senior (12) 47.36 26.54 (33.64, 61.09)
 
 
2.5. Positive immunolabelling of hyperphosphorylated tau (AT8 
antibody) in the different age groups. Means of the one-way ANOVA and 
Kruskal-Wallis for the positive immunolabelling for hyperphosphorylated tau 




Group (n) Mean St. Dev. 95% CI
Rostral
Prime (5) -0.088 0.506 (-0.711, 0.535)
% Load Mature (25) -0.048 1.077 (-0.327, 0.230)
Senior (9) 0.29 1.009 (-0.175, 0.754)
Super Senior (13) -0.03 0.94 (-0.416, 0.356)
Prime (5) -0.1256 0.3051 (-0.3438, 0.0927)
Burden Mature (25) 0.047 0.967 (-0.227, 0.322)
Senior (9) 0.292 1.054 (-0.232, 0.816)
Super Senior (13) -0.153 0.99 (-0.553, 0.247)
Parietal
Prime (5) -0.208 0.431 (-0.516, 0.100)
% Load Mature (25) 0.009 0.996 (-0.274, 0.292)
Senior (9) 0.006 0.874 (-0.428, 0.441)
Super Senior (14) -0.261 1.118 (-0.695, 0.173)
Prime (5) -0.26 0.464 (-0.839, 0.320)
Burden Mature (25) 0.185 0.863 (-0.075, 0.444)
Senior (9) 0.137 1.021 (-0.295, 0.569)
Super Senior (14) -0.24 1.071 (-0.586, 0.107)
Occipital
Prime (5) 2.458 2.478 (-3.344, 8.259)
% Load Mature (26) 7.26 9.81 (4.71, 9.80)
Senior (9) 9.21 10.61 (4.88, 13.53)
Super Senior (13) 5.62 8.59 (2.02, 9.22)
Prime (5) 0.7674 0.0789 (0.6735, 0.8612)
Burden Mature (26) 0.6873 0.1517 (0.6462, 0.7285)
Senior (9) 0.6566 0.1695 (0.5866, 0.7265)
Super Senior (13) 0.6951 0.1505 (0.6368, 0.7533)
Hippocampus
Prime (4) 1.203 1.062 (-10.865, 13.271)
% Load Mature (25) 7.78 9.02 (2.95, 12.60)
Senior (9) 9.12 6 (1.07, 17.16)
Super Senior (14) 9.13 18.96 (2.68, 15.58)
Prime (4) 0.7939 0.0439 (0.6227, 0.9651)
Burden Mature (25) 0.5677 0.1644 (0.4992, 0.6362)
Senior (9) 0.5101 0.1682 (0.3960, 0.6243)
Super Senior (14) 0.6382 0.1983 (0.5467, 0.7297)
Cerebellum
Prime (4) 2.58 2.72 (-6.44, 11.59)
% Load Mature (23) 8.67 10.58 (4.91, 12.43)
Senior (7) 7.19 8.06 (0.37, 14.00)
Super Senior (13) 3.73 6.84 (-1.27, 8.73)
Group (n) Median Median Rank Z-value
Cerebellum
Prime (4) 13.5352 21.8 -0.34
Burden Mature (23) 37.3083 26.2 1.09
Senior (7) 69.8205 24.9 0.18
Super Senior (13) 5.6716 20.3 -1.14
 
 
Group (n) Median Median Rank Z-value
Cerebellum
Prime (5) 35.541 18.4 -0.97
Burden Mature (22) 153.8 28.1 1.92
Senior (8) 60.695 22.5 -0.34
Super Senior (12) 43.738 19.8 -1.22
2.6. Positive immunolabelling of hyperphosphorylated tau (AT100 
antibody) in the different age groups. Means of the one-way ANOVA and 
Kruskal-Wallis for the positive immunolabelling of hyperphosphorylated tau 
(AT100 antibody) in all age groups with standard deviations and 95% 





Group (n) Mean St. Dev. 95% CI
Rostral
Prime (6) 1.476 0.758 (0.771, 2.182)
% Load Mature (22) 1.331 1.241 (0.963, 1.699)
Senior (8) 1.103 1.427 (0.492, 1.714)
Super Senior (13) 1.291 1.252 (0.812, 1.770)
Prime (6) 0.6184 0.0834 (0.5466, 0.6903)
Burden Mature (22) 0.6053 0.1229 (0.5678, 0.6428)
Senior (8) 0.6291 0.154 (0.5669, 0.6914)
Super Senior (13) 0.636 0.1259 (0.5872, 0.6848)
Parietal
Prime (6) 0.953 1.006 (0.195, 1.711)
% Load Mature (24) 1.089 1.314 (0.710, 1.468)
Senior (9) 1.086 1.57 (0.467, 1.705)
Super Senior (13) 1.052 1.281 (0.537, 1.567)
Prime (6) 2.614 1.144 (1.887, 3.341)
Burden Mature (24) 3.195 1.673 (2.709, 3.681)
Senior (9) 3.062 2.452 (1.843, 4.282)
Super Senior (13) 2.968 1.516 (2.356, 3.581)
Occipital
Prime (6) 1.2257 0.1737 (1.0850, 1.3664)
% Load Mature (25) 1.2222 0.245 (1.1532, 1.2911)
Senior (9) 1.2025 0.301 (1.0876, 1.3174)
Super Senior (12) 1.2353 0.2306 (1.1358, 1.3348)
Prime (6) 2.948 0.913 (2.368, 3.528)
Burden Mature (25) 3.414 1.593 (2.961, 3.867)
Senior (9) 3.361 2.148 (2.293, 4.430)
Super Senior (12) 3.362 1.298 (2.814, 3.910)
Hippocampus
Prime (5) 1.193 0.255 (0.781, 1.606)
% Load Mature (24) 1.4478 0.3911 (1.2595, 1.6362)
Senior (7) 1.307 0.532 (0.958, 1.656)
Super Senior (12) 1.497 0.583 (1.230, 1.763)
Prime (5) 1.408 0.283 (1.022, 1.793)
Burden Mature (24) 1.63 0.3776 (1.4540, 1.8060)
Senior (7) 1.539 0.546 (1.213, 1.864)
Super Senior (12) 1.599 0.492 (1.350, 1.848)
Cerebellum
Prime (5) 1.51 0.322 (1.050, 1.970)
% Load Mature (22) 1.67 0.539 (1.450, 1.889)
Senior (8) 1.379 0.414 (1.015, 1.743)
Super Senior (12) 1.365 0.562 (1.068, 1.662)
 
 
N Mean StDev SE Mean N Mean StDev SE Mean
Rostral 52 25.5 19.7 2.7 52 10.13 8.83 1.2
Parietal 53 2.025 0.485 0.067 53 1.685 0.481 0.066
Occipital 53 2.77 1.07 0.15 53 1.83 1.07 0.15
Hippocampus - - - - - - - -
GM WM
N Mean StDev SE Mean N Mean StDev SE Mean
Rostral 50 4.78 2.04 0.29 50 4.43 1.89 0.27
Parietal 51 2.385 0.501 0.07 51 1.908 0.428 0.06
Occipital 52 35.6 22 3 52 15.4 12.8 1.8
Hippocampus - - - - - - - -
GM WM
2.7. Intranuclear immunolabelling of hyperphosphorylated tau in grey 
matter (GM) and white matter (WM). Means of the two-sample t-tests for the 
intranuclear immunolabelling of hyperphosphorylated tau with both AT8 and 














2.8. Positive immunolabelling of hyperphosphorylated tau in grey matter 
(GM) and white matter (WM). Means of the two-sample t-tests for the positive 
immunolabelling of hyperphosphorylated tau deposits with both AT8 and 















N Mean StDev SE Mean N Mean StDev SE Mean
% Load 49 1.467 0.961 0.14 49 1.13 1.42 0.2
Burden 49 0.617 0.109 0.016 49 0.62 0.139 0.02
% Load 52 1.39 1.09 0.15 52 0.74 1.43 0.2
Burden 52 3.12 1.68 0.23 52 2.98 1.79 0.25
% Load 52 1.285 0.207 0.029 52 1.159 0.26 0.036







2.9. Intranuclear immunolabelling of hyperphosphorylated tau in cats 
with and without cognitive dysfunction syndrome (CDS). Means of the 
two-sample t-tests for the intranuclear immunolabelling of 
hyperphosphorylated tau with both AT8 and AT100 antibodies with standard 









N Mean StDev SE Mean N Mean StDev SE Mean
Rostral 9 16.3 15.5 3.6 13 20.7 17.4 3.4
Parietal 9 17.300 18.1 4.3 13 17.4 12.5 2.5
Occipital 8 16.4 17 4.3 13 18.8 17 3.3
Hippocampus 9 32.7 28.9 9.6 13 26.5 16.6 4.6
CDS Intact
N Mean StDev SE Mean N Mean StDev SE Mean
Rostral 9 25.1 18.8 4.4 13 25.7 20.1 4
Parietal 9 23.4 18.9 4.4 13 23.1 18.8 3.7
Occipital 8 25.7 21.8 5.4 13 26.1 21.4 4.2




2.10. Positive immunolabelling of hyperphosphorylated tau in cats with 
and without cognitive dysfunction syndrome (CDS). Means of the two-
sample t-tests for the positive immunolabelling of hyperphosphorylated tau 
with both AT8 and AT100 antibodies with standard deviations and standard 







N Mean StDev SE Mean N Mean StDev SE Mean
% Load 8 0.92 1.61 0.4 14 1.18 1.58 0.3
Burden 8 -0.08 1.05 0.26 14 0.1 1.04 0.2
% Load 9 0.69 1.53 0.36 14 0.81 1.5 0.28
Burden 9 0.048 0.843 0.2 14 0.038 0.876 0.17
% Load 8 0.81 1.4 0.35 14 1.1 1.61 0.3
Burden 8 91 202 50 14 303 621 117
% Load 9 1.5 1.6 0.53 14 1.18 1.32 0.35
Burden 9 0.551 0.214 0.071 14 0.57 0.2 0.053
% Load 8 -0.27 1.25 0.44 12 -0.003 0.866 0.25







N Mean StDev SE Mean N Mean StDev SE Mean
% Load 8 1.2 1.06 0.27 13 1.23 1.46 0.29
Burden 8 0.471 0.111 0.028 13 0.448 0.19 0.037
% Load 9 0.95 1.16 0.27 13 1.14 1.54 0.3
Burden 9 3 1.22 0.29 13 3.01 2.32 0.46
% Load 8 1.04 1.19 0.3 13 1.16 1.48 0.29
Burden 8 3.16 1.08 0.27 13 3.49 1.98 0.39
% Load 7 1.838 0.671 0.25 12 1.353 0.629 0.18
Burden 7 1.964 0.609 0.23 12 1.626 0.661 0.19
% Load 7 1.1 1.57 0.59 13 1.01 1.64 0.45









Structure Group (n) Mean St. Dev. 95% CI
Junior (12) 355.3 109.1 (305.9, 404.6)
Prime (13) 280.9 92.6 (233.5, 328.4)
ITAr Mature (21) 313.9 77.7 (276.5, 351.2)
Senior (15) 333.6 69.8 (289.4, 377.7)
Super Senior (9) 287.2 82.4 (230.1, 344.2)
Junior (11) 1.4766 0.3144 (1.1923, 1.7609)
Prime (11) 1.714 0.524 (1.430, 1.999)
LVr Mature (19) 1.508 0.532 (1.297, 1.718)
Senior (12) 1.402 0.508 (1.130, 1.675)
Super Senior (8) 1.277 0.312 (0.943, 1.610)
Junior (11) 13.57 6.58 (9.15, 17.99)
Prime (11) 14.99 5.09 (11.57, 18.41)
TEMr Mature (19) 14.265 3.976 (12.349, 16.182)
Senior (12) 13.776 2.156 (12.406, 15.146)
Super Senior (8) 14.89 3.09 (12.31, 17.48)
Junior (11) -0.318 0.552 (-0.868, 0.232)
Prime (11) -0.119 0.996 (-0.669, 0.431)
Total transversal area Mature (21) 0.247 1.033 (-0.151, 0.645)
Senior (12) -0.111 0.873 (-0.637, 0.416)
Super Senior (8) 0.071 0.884 (-0.574, 0.716)
Junior (11) 33.371 2.247 (31.861, 34.880)
Prime (12) 34.694 2.808 (32.910, 36.478)
HEMr Mature (21) 35.692 2.64 (34.490, 36.893)
Senior (11) 35.836 2.159 (34.386, 37.287)
Super Senior (9) 36.756 1.819 (35.350, 38.161)
Junior (11) 13.659 1.577 (12.715, 14.604)
Prime (12) 14.033 1.081 (13.129, 14.937)
Total dorsal area Mature (21) 14.181 1.666 (13.498, 14.865)
Senior (12) 13.477 1.678 (12.573, 14.381)
Super Senior (9) 14.017 1.693 (12.973, 15.061)
Junior (11) 12.503 0.945 (11.868, 13.138)
Prime (12) 10.702 1.662 (9.645, 11.758)
OCCr Mature (21) 10.911 2.263 (9.881, 11.941)
Senior (15) 11.934 1.19 (11.275, 12.593)
Super Senior (11) 10.265 1.948 (8.956, 11.574)
Junior (11) 0.08387 0.01092 (0.07467, 0.09307)
Prime (12) 0.0779 0.01147 (0.06909, 0.08671)
FROr Mature (21) 0.08239 0.01914 (0.07574, 0.08905)
Senior (15) 0.08396 0.01237 (0.07608, 0.09184)
Super Senior (11) 0.08178 0.01751 (0.07258, 0.09099)
Junior (11) 11.874 1.103 (11.177, 12.571)
Prime (12) 11.348 1.118 (10.680, 12.015)
Total sagittal area Mature (21) 11.154 1.24 (10.649, 11.658)
Senior (15) 11.232 1.149 (10.635, 11.829)
Super Senior (11) 10.866 1.095 (10.169, 11.563)
Structure Group (n) Median Mean Rank Z-Value
Junior (11) 18.4517 40.6 1.72
Prime (11) 17.7237 32.1 0.02
HIPr Mature (21) 11.8367 28 -1.21
Senior (12) 17.3137 36.3 0.91
Super Senior (8) 11.1698 23.9 -1.34
3.1. Differences in the size of the structures in the different age groups. 
Means of the one-way ANOVA and Kruskal-Wallis for all structures and age 
groups with standard deviations and 95% confidence interval (CI) for live cats 




Structure Group (n) Mean St. Dev. 95% CI
Junior (12) 18.654 2.817 (17.220, 20.088)
Prime (10) 15.767 2.926 (14.196, 17.338)
ITAr Mature (9) 17.843 1.078 (16.187, 19.499)
Senior (12) 17.885 2.043 (16.451, 19.319)
Super Senior (3) 16.56 3.77 (13.69, 19.43)
Junior (11) 0.2666 0.1406 (0.1649, 0.3682)
Prime (7) 0.1581 0.0606 (0.0307, 0.2855)
LVr Mature (8) 0.4942 0.1595 (0.3751, 0.6134)
Senior (9) 0.4398 0.2479 (0.3275, 0.5522)
Super Senior (3) 0.5154 0.0906 (0.3208, 0.7100)
Junior (11) 6.784 3.292 (5.259, 8.310)
Prime (8) 7.32 3 (5.53, 9.11)
TEMr Mature (8) 5.609 1.787 (3.820, 7.398)
Senior (9) 6.753 1.191 (5.067, 8.440)
Super Senior (3) 6.637 1.685 (3.716, 9.559)
Junior (11) 9.414 1.348 (8.539, 10.289)
Prime (8) 9.625 0.978 (8.599, 10.651)
HIPr Mature (9) 10.635 1.767 (9.667, 11.602)
Senior (9) 9.732 1.63 (8.764, 10.699)
Super Senior (3) 9.377 0.464 (7.702, 11.053)
Junior (11) 0.01138 0.00185 (0.010057, 0.012703)
Prime (8) 0.01148 0.00216 (0.009935, 0.013037)
Total transversal area Mature (9) 0.01184 0.00223 (0.010384, 0.013309)
Senior (9) 0.01175 0.00218 (0.010297, 0.013222)
Super Senior (3) 0.01232 0.00304 (0.00979, 0.01486)
Junior (11) 33.371 2.247 (31.955, 34.787)
Prime (9) 33.721 2.508 (32.155, 35.287)
HEMr Mature (9) 33.469 2.498 (31.903, 35.034)
Senior (8) 35.128 2.065 (33.468, 36.789)
Super Senior (3) 34.87 1.84 (32.16, 37.58)
Junior (11) 13.659 1.577 (12.685, 14.634)
Prime (9) 13.901 1.233 (12.824, 14.978)
Total dorsal area Mature (9) 13.639 1.504 (12.562, 14.716)
Senior (9) 13.17 1.734 (12.093, 14.247)
Super Senior (3) 13.24 2.47 (11.37, 15.10)
Junior (11) 12.503 0.945 (11.629, 13.377)
Prime (9) 11.167 1.608 (10.202, 12.133)
OCCr Mature (9) 12.095 1.997 (11.130, 13.061)
Senior (11) 12.195 1.127 (11.321, 13.068)
Super Senior (3) 12.36 1.349 (10.687, 14.032)
Junior (11) 12.108 1.597 (11.284, 12.931)
Prime (9) 12.36 1.093 (11.450, 13.271)
FROr Mature (9) 11.505 1.326 (10.594, 12.416)
Senior (11) 11.545 1.12 (10.721, 12.369)
Super Senior (3) 11.37 1.94 (9.79, 12.94)
Junior (11) 11.874 1.103 (11.305, 12.443)
Prime (9) 11.882 0.528 (11.254, 12.511)
Total sagittal area Mature (9) 12.091 0.941 (11.462, 12.719)
Senior (11) 11.63 0.954 (11.062, 12.199)
Super Senior (3) 11.776 1.104 (10.687, 12.866)
3.2. Differences in the size of the structures in the different age groups 
of live cats. Means of the one-way ANOVA for all structures and age groups 







3.3. Differences in the size of the structures in the different age groups 
of fixed brains. Means of the one-way ANOVA for all structures and age 





Structure Group (n) Mean St. Dev. 95% CI
Prime (3) 19.025 1.257 (16.050, 21.999)
ITAr Mature (12) 17.381 2.879 (15.894, 18.868)
Senior (3) 19.286 1.312 (16.312, 22.260)
Super Senior (6) 16.878 2.202 (14.775, 18.981)
Prime (3) 6.6 2.08 (3.76, 9.44)
LVr Mature (12) 6.509 2.666 (5.088, 7.930)
Senior (3) 7.4 2.25 (4.56, 10.25)
Super Senior (5) 4.302 1.428 (2.101, 6.504)
Prime (3) 7.967 0.633 (6.504, 9.429)
TEMr Mature (11) 8.241 1.292 (7.477, 9.004)
Senior (3) 7.292 0.623 (5.829, 8.754)
Super Senior (5) 7.933 1.403 (6.800, 9.065)
Prime (3) 4.292 0.416 (3.374, 5.210)
HIPr Mature (12) 5.22 0.914 (4.761, 5.679)
Senior (3) 5.799 0.753 (4.881, 6.717)
Super Senior (5) 5.307 0.273 (4.596, 6.018)
Prime (3) -0.02 0.539 (-1.310, 1.269)
Total transversal area Mature (12) 0.126 1.329 (-0.518, 0.771)
Senior (3) 0.336 0.506 (-0.924, 1.655)
Super Senior (5) -0.703 0.522 (-1.701, 0.296)
Prime (3) 37.614 1.07 (36.410, 38.818)
HEMr Mature (12) 37.359 1.03 (36.757, 37.961)
Senior (3) 37.724 1.014 (36.520, 38.928)
Super Senior (6) 37.699 0.892 (36.848, 38.551)
Prime (3) 14.428 0.1671 (12.634, 16.222)
Total dorsal area Mature (12) 14.588 1.726 (13.691, 15.484)
Senior (3) 14.398 1.325 (12.604, 16.192)
Super Senior (6) 14.407 1.266 (13.138, 15.675)
Prime (3) 9.304 0.978 (7.207, 11.401)
OCCr Mature (12) 10.022 2.098 (8.974, 11.071)
Senior (4) 11.216 1.2 (9.400, 13.032)
Super Senior (8) 9.48 1.523 (8.196, 10.764)
Prime (3) 15.5 3.84 (11.23, 19.78)
FROr Mature (12) 13.85 4.06 (11.71, 15.99)
Senior (4) 13.91 2.92 (10.21, 17.61)
Super Senior (8) 13.26 2.88 (10.65, 15.88)
Prime (3) 9.744 0.788 (8.630, 10.858)
Total sagittal area Mature (12) 10.451 0.945 (9.894, 11.008)
Senior (4) 10.135 0.969 (9.170, 11.100)
Super Senior (8) 10.524 0.936 (9.842, 11.207)
 
 
3.4. Sex-related differences in the size of the structures. Means of the two-
sample t-tests and medians of Mann-Whitney tests for all structures and sex 







Group (n) Mean St. Dev. SE Mean Group (n) Mean St. Dev. SE Mean
ITAr Female (22) 314.1 65.8 14 Male (43) 321.3 92.5 14
LVr Male (37) 1.412 0.484 0.08 Female (20) 1.536 0.46 0.1
TEMr Male (37) 14.08 4.41 0.73 Female (20) 14.22 4.46 1
HIPr Male (38) 16.62 4.69 0.76 Female (20) 16.76 5.82 1.3
Total transversal area Female (20) -0.23 1.01 0.23 Male (38) 0.039 0.869 0.14
HEMr Male (39) 34.61 2.52 0.4 Female (20) 35.96 2.48 0.56
Total dorsal area Female (21) 13.13 1.5 0.33 Male (39) 14.3 1.45 0.23
OCCr Female (24) 11.18 1.7 0.35 Male (41) 11.57 1.83 0.29
FROr Male (41) 12.53 2.42 0.38 Female (24) 12.67 2.57 0.52




Structure Group (n) Median Difference CI difference Achieved confidence




3.5. Sex-related differences in the size of the structures of live cats. 
Means of the two-sample t-tests for all structures and sex with standard 




















Group (n) Mean St. Dev. SE Mean Group (n) Mean St. Dev. SE Mean
ITAr Female (13) 17.52 1.78 0.49 Male (33) 17.54 2.86 0.5
LVr Male (27) -1.167 0.68 0.13 Female (12) -1.134 0.827 0.24
TEMr Female (12) 6.54 2.68 0.77 Male (27) 6.68 2.35 0.45
HIPr Male (28) 9.51 1.33 0.25 Female (12) 10.48 1.5 0.43
Total transversal area Female (12) 8.843 0.555 0.16 Male (28) 9.6 0.894 0.17
HEMr Male (29) 33.79 2.38 0.44 Female (11) 34.42 2.15 0.65
Total dorsal area Female (12) 12.25 1.11 0.32 Male (29) 14.11 1.36 0.25
OCCr Female (12) 12.05 1.18 0.34 Male (31) 12.05 1.55 0.28
FROr Male (31) 11.82 1.33 0.24 Female (12) 11.88 1.41 0.41






3.6. Sex-related differences in the size of the structures of fixed brains. 
Means of the two-sample t-tests for all structures and sex with standard 



















Group (n) Mean St. Dev. SE Mean Group (n) Mean St. Dev. SE Mean
ITAr Female (9) 17.78 2.24 0.75 Male (10) 18.37 1.84 0.58
LVr Male (10) 5.06 2.53 0.8 Female (8) 6.97 2.26 0.8
TEMr Female (8) 7.975 0.881 0.31 Male (10) 8.03 1.42 0.45
HIPr Male (10) 4.962 0.667 0.21 Female (8) 5.236 0.791 0.28
Total transversal area Female (8) 11.37 0.614 0.22 Male (10) 11.49 1.19 0.37
HEMr Male (10) 36.99 0.841 0.27 Female (9) 37.96 0.804 0.27
Total dorsal area Female (9) 14.29 1.14 0.38 Male (10) 14.83 1.66 0.52
OCCr Male (10) 10.08 1.87 0.59 Female (12) 10.3 1.73 0.5
FROr Female (12) 13.47 3.23 0.93 Male (10) 14.74 3.61 1.1






3.7. Differences in the size of the structures in cats with and without 
cognitive dysfunction syndrome (CDS). Means of the two-sample t-tests for 
all structures and cognitive status with standard deviations and standard error 






Group (n) Mean St. Dev. SE Mean Group (n) Mean St. Dev. SE Mean
ITAr Intact (20) 17.62 2.19 0.49 CDS (4) 17.76 2.97 1.5
LVr CDS (2) 0.283 0.237 0.17 Intact (18) 0.372 0.22 0.052
TEMr CDS (2) 6.741 0.543 0.38 Intact (18) 7.15 1.34 0.32
HIPr Intact (18) 7.97 2.45 0.58 CDS (2) 8.11 2.1 1.5
Total transversal area Intact (18) 9.93 1.27 0.3 CDS (2) 11.26 0.811 0.57
HEMr Intact (18) 35.96 1.91 0.45 CDS (2) 38.9 0.334 0.24
Total dorsal area Intact (19) 13.47 1.56 0.36 CDS (2) 15.97 0.547 0.39
OCCr CDS (4) 9.43 2.45 1.2 Intact (22) 11.56 1.42 0.3
FROr Intact (23) 12.24 2.29 0.48 CDS (3) 13.79 2.02 1.2






3.8. Differences in the size of the structures in cats with and without 
cognitive dysfunction syndrome (CDS) in the fixed brains. Means of the 
one-way ANOVA for all structures and cognitive status with standard 
deviations and 95% confidence interval (CI); and the means of the two-sample 
t-tests for all structures and cognitive status with standard deviations and 





















Group (n) Mean St. Dev. 95% CI Group (n) Mean St. Dev. 95% CI
ITAr Intact (8) 17.55 2.33 (15.600, 19.497) CDS (1) 18.74 * (13.23, 24.25)
LVr Intact (7) 0.216 0.1254 (0.0998, 0.3317) CDS (1) 0.2507 * (-0.0561, 0.5575)
TEMr Intact (7) 7.632 1.24 (6.486, 8.779) CDS (1) 8.113 * (5.079, 11.146)
HIPr Intact (7) 5.525 0.551 (5.015, 6.035) CDS (1) 5.256 * (3.907, 6.604)
Total transversal area Intact (7) 11.19 0.697 (10.541, 11.829) CDS (1) 11.36 * (9.65, 13.06)
Structure
Lowest mean Highest mean
Group (n) Mean St. Dev. SE Mean Group (n) Mean St. Dev. SE Mean
HEMr Intact (7) 37.45 0.798 0.3 CDS (2) 38.618 0.297 0.21
Total dorsal area Intact (7) 13.96 0.907 0.34 CDS (2) 15.97 0.547 0.39
OCCr CDS (4) 9.43 2.45 1.2 Intact (8) 10.37 1.08 0.38
FROr CDS (4) 11.71 1.814 0.92 Intact (8) 14.36 2.83 1
Total sagittal area Intact (8) 10.23 0.754 0.27 CDS (4) 10.73 1.25 0.63
Structure
Lowest mean Highest mean
 
 
3.9. Differences in the size of the structures in live cats and fixed brains. 
Means of the two-sample t-tests for all structures with standard deviations and 
standard error (SE) of the means for the comparison of live cats and fixed 
brains scans. 
 
Group (n) Mean St. Dev. SE Mean Group (n) Mean St. Dev. SE Mean
ITAr Live (34) 17.13 2.41 0.41 Fixed (24) 17.7 2.47 0.5
LVr Live (28) 1.815 0.692 0.13 Fixed (23) 2.426 0.536 0.11
TEMr Live (28) 6.58 2.06 0.39 Fixed (22) 8 1.161 0.25
HIPr Fixed (23) 5.193 0.814 0.17 Live (29) 9.95 1.46 0.27
Total transversal area Live (29) 9.337 0.897 0.17 Fixed (23) 11.317 0.975 0.2
HEMr Live (29) 34.15 2.33 0.43 Fixed (24) 37.522 0.948 0.19
Total dorsal area Live (30) 13.54 1.55 0.28 Fixed (24) 14.5 1.39 0.28
OCCr Fixed (27) 9.96 1.76 0.34 Live (32) 11.89 1.56 0.28
FROr Fixed (27) 13.87 3.43 0.66 Live (32) 11.75 1.25 0.22
Total sagittal area Fixed (27) 10.347 0.913 0.18 Live (32) 11.844 0.841 0.15
Structure
Lowest mean Highest mean
 
 









Cat’s Name ………………………………………………... 
Breed …………………………………………………..…...   
Age …….…years ……….months 
How long has this cat been living with you? ..…years  
….months 
Gender: Male □     Male neutered □     
        Female □ Female neutered □ 
 
1) Does your cat have outdoor access?   Yes □ No  
2) Does your cat have a litter tray indoors? Yes □ No □ 
3) Has your cat been diagnosed with any new medical conditions? Yes □ No □ 
 If yes, please state what: ………………………………………………………………………………………………………………… 
4) Is your cat currently on any medication? Yes □ No □ 
 If yes, please state what: ………………………………………………………………………………………………………………… 
 (Include all food supplements, herbal remedies, over-the-counter medications, and any medications prescribed by your vet) 
5) Would you be willing to answer several questionnaires, every 3 months, for no more than a year, as part of a study into senility (cognitive decline) in 




Please answer the questions below by placing a tick in the appropriate column. For each question, think about how your cat used 
to be (perhaps a few years ago) and compare this with how he/she is now. If you have noticed a change please indicate how 









Change in weight      
Appetite      
Drinking      
Time spent grooming      
Time spent sleeping at night      
Time spent sleeping during the day      
Vocalisation at night      
Vocalisation during the day      
Affection with people in the house      
Tolerance of handling      
Aggression towards animals or people      
Wanting to spend time outdoors      
Activity levels/time spent playing      
Tolerance of being left alone      
 (Please read and complete the next page) 
 
 
How long ago did you first notice any changes listed above?...……...………………………………………………………………………... 
 Are there any other problems you think it may be useful for us to know?…………………………………………………………………..… 
 









Tolerance of other animals in the house      
Willingness to jump up or down 
(including climbing stairs) 
     
Aimless activity  
(e.g. pacing, staring into space) 
     
Repetitive or compulsive behaviour  
(e.g. grooming, licking inanimate objects) 
     
Agitation and restlessness      
Passing faeces in the house outside litter tray      
Passing urine in the house outside litter tray      
Vomiting  (including fur balls)      
Diarrhoea      
Constipation      
Vision loss      
Hearing loss      
Hair loss or hair thinning      
 
 
4.2. Cognitive decline inclusion criteria 
 
 Weighting Case Number 
Change in weight 2  
Appetite 2  
Drinking 3  
Time spent grooming 1  
Time spent sleeping at night 1  
Time spent sleeping during the day 1  
Vocalisation at night 1*  
Vocalisation during the day 1  
Affection with people in the house 1*  
Tolerance of handling 2  
Aggression towards animals or people 2  
Wanting to spend time outdoors 2  
Activity levels/time spent playing 2  
Tolerance of being left alone 1*  
Tolerance of other animals in the house 2  
Willingness to jump up or down 
(including climbing stairs) 
3  
Aimless activity (eg pacing, staring into space) 1  
Repetitive or compulsive behaviour  
(eg grooming, licking inanimate objects) 
1  
Agitation and restlessness 2  
Passing faeces in house outside litter tray 2  
Passing urine in house outside litter tray 2  
Vomiting (including fur-balls) 2  
Diarrhoea 3  
Constipation 3  
Vision loss 3  
Hearing loss 3  
Hair loss or hair thinning 3  
 
TOTAL of each number FOR THIS CAT: See below: 
 
 1* = 1                
1 = 3  
2 = 5 
3 = 3              
 
To be included in the trial a cat must score a minimum of: 
• one x1* or 
• two x 1 or 




4.3. Medication information  
 
 




Dose: 1 mg/kg Telmisartan 
Bottle concentration: placebo or 4 mg/ml Telmisartan → 0.25 ml/kg PO SID 
Bottle volume: 30 mL in each 









Weight Number of Bottles 
2.6 kg or less 2 
2.7 kg – 4.0 kg 3 
4.1 kg – 5.3 kg 4 
5.4 kg – 6.6 kg 5 
6.7 kg or more 6 
 
 
4.4. Correlation between age and behaviours. Ordinal logistic regression for 
the correlation between age and the different behaviours; statistically 
significant behaviours are shown in bold 
 
Ordinal logistic regression 
Behaviour Coef. p value 
Activity levels 0.043 0.71 
Affection with people in the house -0.014 0.91 
Agitation and restlessness 0.151 0.25 
Aggression 0.061 0.75 
Aimless activity 0.057 0.65 
Appetite 0.111 0.33 
Diarrhoea 0.021 0.91 
Drinking -0.131 0.26 
Grooming 0.194 0.13 
Hair loss 0.048 0.72 
Hearing loss 0.060 0.70 
Passing faeces outside litter box -0.421 0.05 
Passing urine outside litter box -0.262 0.22 
Repetitive/compulsive behaviour 0.590 0.01 
Sleep during the day 0.068 0.55 
Sleep during the night -0.045 0.70 
Time spent outside 0.064 0.61 
Tolerance of being handled 0.063 0.59 
Tolerance of being left alone -0.156 0.20 
Tolerance of other animals -0.151 0.37 
Vision loss 0.204 0.25 
Vocalisations during the night -0.011 0.94 
Vocalisations during the day -0.115 0.33 
Vomiting -0.137 0.29 
Weight 0.323 0.01 






4.5. Differences in the behaviours for treatment A. Table with the least 
squares means, standard error and p value of the general linear model for 
repeated measures, for all the behaviours at the different time points for 
treatment A 
 
Behaviour Least Squares Means Standard Error p  value Behaviour Least Squares Means Standard Error p  value
Activity levels Sleeping during the day
30 days 0.066 0.121 0.587 30 days 0.166 0.168 0.329
60 days 0.289 0.152 0.066 60 days 0.032 0.172 0.852
90 days 0.117 0.170 0.496 90 days 0.148 0.174 0.404
120 days -0.276 0.142 0.062 120 days 0.159 0.193 0.417
Affection Sleeping during the night
30 days 0.221 0.157 0.168 30 days 0.110 0.187 0.562
60 days 0.641 0.182 0.001 60 days 0.288 0.208 0.175
90 days 0.513 0.162 0.003 90 days 0.265 0.172 0.133
120 days 0.035 0.181 0.849 120 days -0.135 0.169 0.432
Agitation/restlessness Time spent outside
30 days -0.096 0.181 0.597 30 days 0.475 0.192 0.020
60 days 0.045 0.213 0.834 60 days 0.038 0.220 0.864
90 days -0.071 0.196 0.718 90 days -0.187 0.208 0.378
120 days 0.631 0.202 0.004 120 days -0.011 0.186 0.954
Aimless activity Tolerance of being handled
30 days -0.150 0.193 0.446 30 days -0.034 0.150 0.821
60 days -0.282 0.227 0.225 60 days 0.012 0.186 0.949
90 days -0.131 0.176 0.462 90 days 0.266 0.184 0.157
120 days 0.324 0.186 0.093 120 days -0.264 0.161 0.113
Appetite Tolerance of being left alone
30 days 0.310 0.214 0.159 30 days -0.131 0.123 0.294
60 days 0.132 0.228 0.566 60 days -0.054 0.091 0.559
90 days 0.309 0.245 0.218 90 days -0.088 0.129 0.502
120 days 0.137 0.222 0.543 120 days -0.177 0.148 0.241
Drinking Tolerance of other animals
30 days 0.363 0.183 0.056 30 days 0.002 0.103 0.983
60 days 0.392 0.157 0.018 60 days -0.095 0.081 0.255
90 days 0.395 0.174 0.030 90 days -0.103 0.058 0.086
120 days -0.044 0.162 0.787 120 days -0.228 0.173 0.200
Grooming Vocalisations during night
30 days 0.166 0.907 0.076 30 days -0.287 0.217 0.196
60 days 0.195 0.087 0.032 60 days 0.053 0.254 0.837
90 days 0.048 0.138 0.729 90 days -0.202 0.221 0.370
120 days -0.087 0.164 0.599 120 days 0.564 0.219 0.015
Hair loss Vocalisations during day
30 days -0.149 0.088 0.102 30 days 0.096 0.218 0.663
60 days -0.078 0.153 0.615 60 days 0.178 0.216 0.415
90 days -0.065 0.105 0.539 90 days 0.170 0.199 0.399
120 days 0.265 0.143 0.075 120 days 0.685 0.221 0.004
Passing faeces outside litter box Vomiting
30 days 0.001 0.130 0.997 30 days -0.016 0.121 0.897
60 days 0.101 0.103 0.335 60 days 0.335 0.151 0.035
90 days 0.236 0.158 0.147 90 days 0.115 0.165 0.492
120 days 0.231 0.136 0.100 120 days 0.216 0.152 0.166
Passing urine outside litter box Weight
30 days -0.081 0.124 0.518 30 days -0.158 0.140 0.270
60 days -0.214 0.191 0.273 60 days -0.067 0.154 0.666
90 days 0.158 0.192 0.418 90 days -0.150 0.212 0.485
120 days 0.315 0.176 0.085 120 days -0.382 0.198 0.063
Repetitive/compulsive behaviour Willingness to jump
30 days 0.141 0.086 0.113 30 days 0.058 0.097 0.551
60 days 0.101 0.157 0.523 60 days 0.006 0.139 0.968
90 days 0.055 0.142 0.701 90 days -0.113 0.140 0.425
120 days -0.245 0.193 0.215 120 days 0.060 0.093 0.520
Treatment A Treatment A
 
 
4.6. Differences in the behaviours for treatment B. Table with the least 
squares means, standard error and p value of the general linear model for 









Behaviour Least Squares Means Standard Error p  value Behaviour Least Squares Means Standard Error p  value
Activity levels Sleeping during the day
30 days -0.276 0.142 0.122 30 days 0.104 0.178 0.564
60 days 0.020 0.160 0.903 60 days -0.036 0.181 0.842
90 days -0.007 0.176 0.967 90 days 0.064 0.182 0.729
120 days -0.228 0.145 0.127 120 days 0.126 0.207 0.548
Affection Sleeping during the night
30 days 0.283 0.166 0.099 30 days 0.358 0.198 0.080
60 days 0.487 0.192 0.017 60 days 0.386 0.219 0.089
90 days 0.492 0.166 0.006 90 days 0.137 0.176 0.444
120 days 0.530 0.185 0.008 120 days -0.330 0.174 0.068
Agitation/restlessness Time spent outside
30 days -0.146 0.192 0.451 30 days 0.152 0.198 0.449
60 days 0.059 0.219 0.791 60 days -0.165 0.215 0.448
90 days 0.045 0.196 0.821 90 days 0.156 0.204 0.450
120 days 0.549 0.202 0.011 120 days 0.109 0.180 0.548
Aimless activity Tolerance of being handled
30 days -0.029 0.198 0.887 30 days 0.115 0.159 0.477
60 days -0.079 0.241 0.747 60 days 0.280 0.195 0.162
90 days -0.062 0.184 0.738 90 days 0.148 0.184 0.428
120 days 0.204 0.187 0.284 120 days -0.070 0.166 0.678
Appetite Tolerance of being left alone
30 days 0.158 0.227 0.493 30 days -0.029 0.130 0.824
60 days 0.203 0.240 0.405 60 days 0.067 0.096 0.490
90 days 0.035 0.254 0.890 90 days -0.097 0.132 0.468
120 days -0.247 0.227 0.285 120 days -0.350 0.152 0.028
Drinking Tolerance of other animals
30 days -0.042 0.194 0.831 30 days -0.069 0.100 0.498
60 days 0.131 0.165 0.433 60 days 0.070 0.076 0.364
90 days 0.299 0.176 0.099 90 days -0.016 0.051 0.753
120 days 0.279 0.165 0.102 120 days -0.169 0.161 0.305
Grooming Vocalisations during night
30 days 0.104 0.096 0.289 30 days -0.297 0.230 0.206
60 days 0.075 0.091 0.412 60 days 0.098 0.267 0.715
90 days 0.066 0.137 0.633 90 days -0.350 0.219 0.121
120 days -0.008 0.168 0.961 120 days 0.725 0.224 0.003
Hair loss Vocalisations during day
30 days 0.063 0.091 0.498 30 days -0.018 0.227 0.937
60 days 0.055 0.158 0.729 60 days 0.097 0.227 0.671
90 days 0.070 0.103 0.501 90 days 0.187 0.195 0.346
120 days 0.134 0.132 0.321 120 days 0.547 0.237 0.028
Passing faeces outside litter box Vomiting
30 days -0.078 0.131 0.556 30 days -0.074 0.123 0.549
60 days 0.085 0.102 0.411 60 days 0.103 0.154 0.509
90 days 0.040 0.159 0.803 90 days 0.103 0.157 0.515
120 days 0.186 0.130 0.164 120 days 0.235 0.146 0.119
Passing urine outside litter box Weight
30 days -0.187 0.128 0.155 30 days 0.165 0.149 0.276
60 days 0.004 0.197 0.983 60 days -0.009 0.162 0.955
90 days 0.005 0.196 0.988 90 days -0.089 0.213 0.679
120 days 0.139 0.164 0.404 120 days -0.207 0.204 0.318
Repetitive/compulsive behaviour Willingness to jump
30 days -0.094 0.090 0.303 30 days 0.124 0.103 0.235
60 days 0.120 0.164 0.469 60 days -0.059 0.146 0.687
90 days 0.110 0.147 0.460 90 days -0.036 0.141 0.799
120 days 0.275 0.185 0.149 120 days -0.064 0.095 0.502
Treatment B Treatment B
 
 
4.7. Changes in the behaviours through time. Changes in the different 
behaviours (in alphabetical order) as reported by the owners and 
demonstrated by the percentage of cats displaying an increase, decrease, or 



















































































Comparison of the amino acid sequences for tau between humans and mice. 
 
 
 
 
 
 
